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Abstract
The future looks bright for a clinical practice that tailors the therapy with the best efficacy
and highest safety to a patient. Substantial amounts of funding have resulted in technolog-
ical advances regarding patient-centered data acquisition — particularly genetic data. Yet,
the challenge of translating this data into clinical practice remains open.
To support drug target characterization, we developed a global maximum entropy-
based method that predicts protein-protein complexes including the three-dimensional
structure of their interface from sequence data. To further speed up the drug development
process, we present methods to reposition drugs with established safety profiles to new
indications leveraging paths in cellular interaction networks. We validated both methods
on known data, demonstrating their ability to recapitulate known protein complexes and
drug-indication pairs, respectively.
After studying the extent and characteristics of genetic variation with a predicted
impact on protein function across 60,607 individuals, we showed that most patients carry
variants in drug-related genes. However, for the majority of variants, their impact on drug
efficacy remains unknown. To inform personalized treatment decisions, it is thus crucial
to first collate knowledge from open data sources about known variant effects and to then
close the knowledge gaps for variants whose effect on drug binding is still not characterized.
Here, we built an automated annotation pipeline for patient-specific variants whose value
we illustrate for a set of patients with hepatocellular carcinoma. We further developed a
molecular modeling protocol to predict changes in binding affinity in proteins with genetic
variants which we evaluated for several clinically relevant protein kinases.
Overall, we expect that each presented method has the potential to advance personalized
medicine by closing knowledge gaps about protein interactions and genetic variation in
drug-related genes. To reach clinical applicability, challenges with data availability need to
be overcome and prediction performance should be validated experimentally.
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Zusammenfassung
Therapien mit der besten Wirksamkeit und höchsten Sicherheit werden in Zukunft auf den
Patienten zugeschnitten werden. Hier haben erhebliche finanzielle Mittel zu technologischen
Fortschritten bei der patientenzentrierten Datenerfassung geführt, aber diese Daten in die
klinische Praxis zu übertragen, bleibt aktuell noch eine Herausforderung.
Um die Wirkstoffforschung in der Charakterisierung therapeutischer Zielproteine zu un-
terstützen, haben wir eine Maximum-Entropie-Methode entwickelt, die Protein-Interaktionen
und ihre dreidimensionalen Struktur aus Sequenzdaten vorhersagt. Darüber hinaus, stellen
wir Methoden zur Repositionierung von etablierten Arzneimitteln auf neue Indikationen
vor, die Pfade in zellulären Interaktionsnetze nutzen. Diese Methoden haben wir anhand
bekannter Daten validiert und ihre Fähigkeit demonstriert, bekannte Proteinkomplexe bzw.
Wirkstoff-Indikations-Paare zu rekapitulieren.
Unsere Analyse genetischer Variation mit einem Einfluss auf die Proteinfunktion in
60.607 Individuen konnte zeigen, dass nahezu jeder Patient funktionsverändernde Varianten
in Medikamenten-assoziierten Genen trägt. Der direkte Einfluss der meisten beobachteten
Varianten auf die Medikamenten-Wirksamkeit ist jedoch noch unbekannt. Um dennoch
personalisierte Behandlungsentscheidungen treffen zu können, präsentieren wir eine Anno-
tationspipeline für genetische Varianten, deren Wert wir für Patienten mit hepatozellulärem
Karzinom illustrieren konnten. Darüber hinaus haben wir ein molekulares Modellierungs-
protokoll entwickelt, um die Veränderungen in der Bindungsaffinität von Proteinen mit
genetischen Varianten voraussagen.
Insgesamt sind wir davon überzeugt, dass jede der vorgestellten Methoden das Po-
tential hat, Wissenslücken über Proteininteraktionen und genetische Variationen in medi-
kamentenbezogenen Genen zu schließen und somit das Feld der personalisierten Medizin
voranzubringen. Um klinische Anwendbarkeit zu erreichen, gilt es in der Zukunft, verblei-
bende Herausforderungen bei der Datenverfügbarkeit zu bewältigen und unsere Vorhersagen
experimentell zu validieren.
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Chapter 1
Introduction
Motivation
The sequencing of the first full human genome in the Human Genome Project took more
than ten years to complete and cost a little less than three billion US dollars. The
sequencing cost not only dropped by a 100-fold over the course of the project226, but has
recently reached its all time low: a complete whole personal genome is now available for less
than $1,000 including its analysis118 and within a few days125. The massive technological
progress that came with the hunt for ever cheaper availability of human genomes has also
led to advances in other biological fields as it transformed gene sequencing and related
methods, suitable for regular use in a research lab.
The broad availability of full genome sequences for a wide range of organisms has
advanced our understanding of the evolutionary history within individual species and across
all domains of life76. Through genetic material only, it is also possible to characterize long-
extinct species, such as the woolly mammoth or the Neanderthal at a precision never
seen before129,285,310,343. However, one of the main promises that came with the thorough
understanding of the human genome — that of helping to cure diseases — has not been
fulfilled yet126.
Among the unexpected complexity of the human genome126, scientific and technical
challenges include data processing and storage as well as suitable data analysis and mining
algorithms405. The genetic and epigenetic markup of a patient, the exact status of expressed
proteins in the affected cells and other features of their disease may in the future be used to
improve 1) therapy decisions and 2) drug action and metabolism in the patient, based on
a better understanding of disease etiology. These goals can only be reached by integrating
computational analysis through novel algorithms, pipelines and user interfaces into the
process of disease research, drug discovery and medical decision making.
1
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The increasingly obvious lack of a thorough understanding of many cellular processes
has further complicated the translation of sequencing-based insights into clinical practice.
It turns out that many genes previously linked to disease etiology may very well be unre-
lated236, and even newly designed drugs can be rendered useless when the cell activates
alternative pathways to evade drug action158. We still do not know the complete mechanism
of action for many drugs, let alone the three-dimensional structure or dynamic behavior of
many disease- and drug-associated proteins. In addition to the interpretation of personal
genomes, it is thus essential to shed light on these unknowns — a process that can leverage
computational methods.
Only in the recent past it has become possible to infer higher order knowledge about
a protein’s molecular structure, fitness and involvement in interactions using the data
produced by the genomic revolution. One example for such a method is the inference of
residue interactions (“contacts”) in the three-dimensional structure of a protein based on
the protein’s evolutionary record. This allowed to predict the protein structure de novo for
a wide set of proteins, including many pharmacologically relevant proteins159,267.
In this thesis, we present several approaches to translating the wealth of genetic data
into a thorough understanding of disease with the ultimate goal of improving patient care.
Our contributions are distributed along the personalized health value chain and range from
predicting residue-level protein-protein interaction interfaces to developing a pipeline that
could support the medical community in interpreting a patient’s genome.
Part I: Phenotype discovery based on the evolutionary record of proteins
Protein-protein interactions (PPI) are of pivotal importance for the pathogenesis of var-
ious diseases due to their involvement in many cellular processes270,362, but often elude
experimental characterization. Predicting which proteins interact and how genetic variants
affect that state can thus serve as an entry point for the identification of new therapeutic
targets362.
In the first part of the thesis, we developed a method using the evolutionary record of
proteins, determined by gene sequencing, to gain phenotypic insights of protein complexes.
Building on co-evolution approaches for monomer structure prediction we developed a
method capable of predicting protein interactions at residue-resolution as well as identifying
specific interacting protein pairs in larger proteins complexes.
Part II: Genetic variation in drug-related genes
Affordable genotyping methods can be used to profile patients for genetic determinants of
drug efficacy or toxicity (pharmacogenetics/pharmacogenomics, short PGx)260 in population-
stratified282,311,468 or individualized settings258,341. Even though early PGx studies mainly
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focused on genes of particular interest for pharmacodynamics (PD) or -kinetics (PK), larger
genome-wide association studies (GWAS) have recently been able to identify variants asso-
ciated with drug efficacy or toxicity in a less biased manner70,296. So far, these approaches
have led to the identification of more than 10,000 associations between genetic variants and
alteration in drug response (collated in PharmGKB453). In addition to that, drug labels
for 202 medical compounds now include PGx data with some requiring genetic testing prior
to prescription (including 36 drugs with PGx testing required by the U.S. Food and Drug
Administration, short FDA)340.
Recent advances in the creation of large reference sets of human variation63,236,427
now allow combining knowledge of drug mechanism with the prevalence of non-functional
alleles in drug-related genes. In the second part of the thesis, we use such data sets to
take a complementary approach to classic PGx research by including existing biological
information about drug action and disease etiology to study the prevalence of functional
variation in drug-related genes. The results of our survey can be used to identify potential
genetic variants for targeted PGx studies and the extension of PGx screening panels even
though our knowledge of the pharmacological action of drugs and understanding of genetic
interaction in a cellular or tissue-specific context remains incomplete279.
Part III: Drug repurposing
The complete depletion of a drug target may result in non-rescuable resistance to that drug
in a patient. Here, alternative therapy strategies need to be explored using either drugs
that treat the disease through a different mechanism of action or, possibly, through drugs
repurposed from other indications.
Inspired by success stories of compounds serendipitously repositioned for another in-
dication, a plethora of systematic drug repurposing methods have been developed over
the last decade using for example guilt-by-association (GBA) approaches of chemical and
protein similarity203,369 or knowledge about cellular protein interaction networks249,272,435.
In the third part of the thesis, we have built on our insights of the previous two chapters
and present a heterogeneous information network (HIN) that incorporates different objects
and relations to connect drugs, diseases and genetic variants through genes. The goal of
this project was to use this network to identify drugs whose target genes are in the genetic
neighborhood of the genes involved in the disease (“neighborhood targets”). By defining
meta-paths in the HIN, we developed two approaches for predicting novel indications for
existing drugs — in an unsupervised and supervised manner.
3
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Part IV: Clinical reporting and in silico treatment stratification
From a patient perspective, identifying variants affecting drug efficacy is only the first step
towards better treatment decisions. The true values lies in utilizing the molecular profile of
their personal disease to guide therapy decisions51,213,380. While newly identified variants
need characterization, validation and ultimately representation in dosing and treatment
guidelines, quickly providing a comprehensive overview over existing clinical knowledge to
the treating physician can already improve the treatment decision process202.
In the last part of the thesis, we developed a pipeline that annotates genetic variation
found in a patient with existing knowledge to support physicians in their clinical decision
making. To include previously unknown variants in drug-related genes, we further devised a
molecular modeling workflow that predicts the effect of such variants on the pharmacological
phenotype of a protein.
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Chapter 2
Background
2.1 Genetic Variation in Humans
2.1.1 The Human Genome
The instructions needed to build and direct activities of an organism are mostly stored in its
genome - a set of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA, only in the case of
some viruses) molecules, often grouped into chromosomes77. The DNA molecule contains
regions that code for functional units called protein-coding genes which are translated to
proteins, intermixed with large regions that are not translated and fulfill other (regulatory)
functions332. Proteins then perform specific actions in a cell of the organism, including
transport of molecules, catalysis of chemical reactions, and housekeeping functionalities.
The human genome is with 3.2 billion base pairs (3.2 Gb) among the larger genomes
currently known and is estimated to contain approximately 20,500 genes332, which take
up only about 1% of the total genome304. In its most recent versions the reference as-
semblies, GRCH37 and GRCh38, of the human genome covers now close to 90% of the
full genome180, with more than 300 gaps remaining between scaffolds in the most recent
release, GRCh38.p12 (as of August 2018).
To understand how this low number of genes can result in the complex structure of
the human organism that grows from 1 zygote to 37 trillion cells26 of more than 200
different cell types351 one needs to take a closer look at the genome and protein-coding
gene structure:
Each gene in the genome consists of an open reading frame (ORF) with exons, elements
that are transcribed and translated into a protein, and introns, elements that are transcribed,
but then removed prior to translation. The untranslated regions (UTRs) at the 5’ and 3’
ends contain ribosome binding sites and the start/stop codons. For a gene to be expressed,
a promoter region at it’s 5’ terminus binds transcription factors (proteins regulating the
rate of transcription) and RNA polymerase which is responsible for the transcription of
5
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the gene into messenger RNA, mRNA. Through alternative splicing of the same mRNA a
multitude of protein isoforms with different functionality can be encoded in a single gene.
Multiple promoter regions further increase the combinatorial space arising from different
transcription alternatives293. Through these mechanisms, up to 95% of the genes in the
human genome with more than one exon give rise to multiple, different protein products321.
The human genome is organized into 23 chromosomes, which are compact structures
consisting of DNA wrapped around histones that package the DNA tightly enough to fit
into the cell’s nucleus while also structuring it for later expression. Except from germ cells,
human cells contain two sets of chromosomes, one from each parent. These cells are called
diploid — compared to haploid germ cells that only contain one set of chromosomes and
give rise to gametes used in sexual reproduction.
2.1.2 Evolution and Population Genetics
In the course of the past 3.8 billion years, life on earth has been able to survive in differ-
ent living circumstances through the gradual introduction of random smaller and larger
changes into the genome that have helped the offspring adapt to and survive in a particular
habitat289. Our understanding of this evolutionary process driven by natural selection on
variation in a population produced by genetic mutation and recombination171 can be traced
back to major contributions from Charles Darwin, Alfred Wallace and Gregor Mendel, syn-
thesized by Roland Fisher in his book “The Genetical Theory of Natural Selection“ in
193094,108.
The theory of natural selection and adaptation was formulated independently by Alfred
Wallace and Charles Darwin after they made (at that time curious) observations about
slight variations of related species in different environmental niches. To explain these
observations they formulated a hypothesis that can be broken down in three pillars:
1. Phenotypic variation: traits among individuals in a population can vary in respect
to physiology, morphology, and behaviors contains one allele for a gene
2. Differential fitness: different traits confer different rates of survival into adulthood
and following from this into reproduction
3. Heritability of fitness: traits can be passed onto a child generation
They also concluded that different environments might affect the fitness of an organism
resulting in selection of distinct traits in disparate niches 237.
While Darwin had no precise explanation for how exactly new species arise, in 1865/66
the Austrian monk Gregor Mendel was the first to devise the modern theory of genetics
following a series of breeding experiments with purple and white flower pea plants. From
6
Genetic Variation in Humans
his observations, he formulated the idea of hereditary units, now known as genes, that may
occur in different forms, now known as alleles, and result in a particular phenotypic trait
of the organism. In this case the gene for pea flower color exists in two alleles, one for each
color. An organism then obtains (inherits) an allele from each of its parents and thus may
carry two identical (homozygous) or two different alleles (heterozygous) for a specific trait.
This theory can be formulated as the three laws of inheritance:
1. Law of segregation: during gamete formation in sexual reproduction, each gamete
only contains one allele for a gene
2. Law of independent assortment: the alleles of different genes segregate independently
3. Law of dominance: some alleles can dominate the phenotype as soon as they occur in
the organism, while others are recessive and need to occur in the homozygous state
to show their effect.
The analysis of how the genetic markup (genotype) changes the organism’s observable
properties (phenotype) are still active research areas.
Natural Selection and Fitness
One fundamental concept of the modern theory of evolution is natural selection, which
describes the phenomenon that some individuals in a population are more likely to survive
and produce offspring than others under certain conditions. This is due to the advantages
their genotype provides in the current environment. While this appears simple at first
sight, its nuances are not as trivial to understand and have been discussed elsewhere171.
One particular phenotype often used in this context is the organism’s fitness which
corresponds to its survival potential and its success at reproduction.
Fitness, as other traits, is significantly determined by the organism’s genotype. Genetic
variation randomly arising in the population is thus one essential driving force of natural
selection by introducing novel alleles into the population that may prove to be advantageous
in the environment: Individuals with certain alleles may show traits that allow them to
survive under certain harsh conditions or reproduce more than others, thus spreading their
particular alleles to their offspring. These variants get fixed in the population, which, as a
consequence, evolves to show these traits at a larger frequency171.
Genetic Variation
Genetic variation in an organism is introduced through random mutations of the genome
during gamete formation in the parents (germline variation) or in the tissue during the
7
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organism’s lifetime (somatic variation). Especially larger structural changes can be in-
troduced through sexual reproduction by equal or unequal recombination of the genetic
material of the parents including the crossover of parental chromosomes.
Genetic variation comes in multiple forms: from substitutions of single bases (single
nucleotide variant, SNV), insertions or deletions of genomic segments (indels), up to the
inversion, duplication or deletion of full genes (copy number variants, CNV)103 (Figure
2.1). These events can occur at any place in the genome, such as protein-coding segments,
transcription-modulating regulatory elements, splice sites, and regions with currently un-
known direct connections to protein function46. The phenotype can then be affected
through direct alterations of the protein transcript as well as modulation of gene expression.
Larger structural changes mainly influence the transcription of a gene similar to variants
outside coding regions that modulate regulatory elements. Duplication and deletion events
result either in amplification or reductions of transcription levels of the affected genes31.
Genetic changes can affect the function of the gene’s protein product in multiple ways
and thereby alter the offspring’s phenotype: it can reduce a protein’s ability to fulfill its
cellular function (non-functional), inactivate the protein completely (loss-of-function, LoF),
or confer a new molecular function (gain-of-function, GoF). If one of the two copies of a
gene in the diploid genome is entirely lost, the second copy on the homologous chromosome
has to fulfill the its function — in the case that this copy also harbors a variant, a disease
phenotype can arise103.
2.1.3 Genetic Variation in Disease
While each human genome is different, most variants observed in an individual are common
in the population showing allele frequencies (AF) > 5% in the reference population with
only a small percentage (1-4%) being seen in fewer than 0.5% of the total population63.
While many of the variants may be of neutral effect under our current living conditions,
some of them can be associated with beneficial or deleterious effects on health, causing or
altering susceptibility to a disease263,286.
While rare diseases with a strong inheritance pattern are usually characterized by
targeted sequencing efforts involving one or more affected families, many common disorders
are not amenable to this approach. Here, GWAS have become a popular tool to screen
larger cohorts of patients in a genome location-agnostic manner for statistical association
between the trait of interest and any locus. The idea behind this approach is, that many
common diseases have a different underlying genetic architecture than rare Mendelian
disorders. While rare diseases are often caused by single rare variants, common disorders are
hypothesized to being influenced by multiple common variants in the population (common
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ATCGGCCTGTAAC
ATCGGCCAGTAAC ATCGGCCCTGTAAC ATCGGCC-GTAAC ATCGGCCCTTAAC
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Figure 2.1: Genetic changes can be either on the nucleotide level through nucleotide
substitution, insertion, or deletion (or a combination thereof) (top row) or as large
scale structured variation of the genome (bottom row). In that case the structure of
the genome may be modified through the deletion, duplication, fusion or inversion of
larger chromosomal segments. Figure inspired by Cardoso et al.46
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disease-common variant hypothesis)43. Such patterns can then be found by testing for
statistical associations between a patient cohort and variant.
However, there are problems with genome-wide approaches432, such as very small effect
sizes, and failure to explain the full extent of heritability of the trait122,482. Enthusiasm
was further damped by the high proportion of association signal being found not within
but between gene coding regions, complicating their immediate interpretation263.
2.2 Drug Discovery
Deregulation of cellular processes caused by genetic variation, infection with a pathogen or
other factors can result in the dysfunction of parts or all of an organism, associated with a
decline of the well-being (i.e., pathology or disease). The aim of pharmaceutical treatment
of a diseased individual (patient) is to restore their well-being by either alleviating disease-
associated symptoms such as pain or to correct the deregulation and stop the dysfunction
altogether. Depending on the causal background (etiology) of the disease, this can be done
by a variety of measures, including surgical procedures or administration of medicines.
The protocol for disease treatment has undergone significant changes over the past
centuries from praying, bleeding a patient with leeches, and administering herbal tinctures
to the using high-purity therapeutic molecules often targeted specifically at the molecular
pathways that are involved in disease etiology. Nowadays, two main classes of drug molecules
can be distinguished: 1) small organic or non-organic molecules (small molecules) and 2)
larger biomolecules such as antibodies (biologics or large molecules). The discovery process
with which therapeutics are found has evolved in parallel with the changes in medical
practice, from the serendipitous discovery of pharmacological effects of herbal remedies
elicited through one or more unknown compounds therein to a process of systematic search
for such molecules.
2.2.1 Drug Pharmacology
Usually, therapeutics act on the organism in one of two ways: 1) etiology-specific, i.e.,
targeting the underlying cause of a disorder, or 2) palliative, i.e., alleviating symptoms,
but not targeting disease-mechanism246,470. A drug’s effect is further determined by the
molecule’s effect on the target organism (pharmacodynamics, PD) and the organism’s effect
on the drug molecule (pharmacokinetics, PK).
Pharmacodynamics
The PD profile of a drug molecule describes what the molecule does to the organism. It
relates to the mechanism of action (MoA) of a compound and includes its molecular effects
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on the body (including biochemical and physiological effects such as receptor binding and
chemical interactions). Usually, the effect of a drug is dependent on its dose ranging from
ineffective if given in too small quantities to toxic if given in too high a dose258. The
relationship between a compound’s dose and the body’s response is determined during
the drug’s development and is required to anticipate later dosing regimens and off-target
effects. This dose-response relationship can be described by several parameters, including
affinity, potency, and efficacy. While the first describes the ability of a compound to bind
to a cellular target, the second describes how much of a compound is needed to provoke a
effect and the last the maximal response that can be achieved by a compound.
A therapeutic elicits its MoA through interaction with biomolecules in the cell, such as
receptors, enzymes or ion channels. In the past, a multitude of different mechanisms have
been discovered412, including
• Stimulation or depression of a receptor (receptor agonism)
• Blocking of a receptor (receptor antagonism)
• Stabilization of receptor activation
• Inhibition of the activity of an enzyme
• Direct chemical reaction
The way in which this result can be obtained varies by drug, either through competitive
interaction with a target, i.e., the drug competes with the natural substrate, or through
non-competitive or allosteric effects412.
Pharmacokinetics
The PK profile of a drug molecule describes what the organism does to a therapeutic
molecule. This includes the molecule’s passage through the body, from its liberation,
absorption, and distribution to its metabolism and excretion (ADME). This scheme is
often extended to include a drug’s toxicological effects (ADMET) as these are often caused
by a compound’s metabolites.
Before a compound can reach its target in the cell, it is usually taken up by the
bloodstream. From there it gets distributed through the different compartments of the
body, if not hindered by natural barriers (e.g., the blood-brain barrier). Once in the cell,
the drug’s response is determined by its PD profile. Near-instantly after entering the body,
the molecule also starts being broken down — primarily in the liver. Prior to excretion
(for example through the kidneys), therapeutics and their degradation intermediates can
interact with enzymes and thus affect the normal metabolism, cause adverse events, and
alter the breakdown pathways of other therapeutics.
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A variety of proteins is involved in handling therapeutic compounds in the body (some-
times referred to as pharmacogenes). These include transporters and carriers responsible
for shuttling the therapeutic in and out of the cell and metabolic enzymes involved in its
breakdown218. The most prominent class of enzymes, involved in the metabolism of up to
80% of all currently available drugs, is the cytrochome P450 family (CYP450)114.
Pharmacokinetics further influences the drug’s bioavailability, i.e., the proportion of
the drug that reaches the site of action in the cell. Together with a drug’s PD profile
it also influences a drug’s dose-response relationship and plays a crucial role in finding a
therapeutic’s optimal formulation, route of administration and dosing. Nowadays, modeling
of the PD and PK characteristics of a molecule belongs to the standard procedure in the
drug discovery process347,426.
2.2.2 The Drug Discovery Pipeline
Even today, the discovery process of new therapeutics is a complicated endeavor that does
not fit a single cookie-cutter recipe. Nevertheless, we can distinguish some general steps
in modern drug discovery and development412: the discovery pipeline usually starts with
research into the mechanism of the disorder to identify molecular key players that could
be modified to alleviate the disorder (target identification).
A target can be a protein, gene, or RNA and has to fulfill a catalog of criteria to be
considered suitable. In particular, it has to be druggable, meaning that it is accessible
to putative drug molecules and elicits a measurable biological response upon binding168.
Then follows the search for suitable molecules (small-molecules or biologics) (hit and
lead identification) and their optimization to improve their pharmacological and safety
profile (lead optimization). Afterwards, one or two final candidates are selected for clinical
development in which the candidates are vigorously tested for efficacy and safety in vivo. If
they succeed in the clinical trials, the developing instance (often a pharmaceutical company)
can apply for marketing approval.
2.2.3 Hurdles in the Drug Development Process
Developing new drugs is a time and cost expensive process which has - despite all techno-
logical advances - experienced a decline in productivity over the previous years284,370. For
example, the widely established estimate of development cost per new molecular entity by
Paul et al.326 of $1.8B has been recently updated to $2.8B79. Due to increasing constraints
imposed by legislators on proving efficacy and safety of drugs, only few chemical compounds
in the pipeline make it to the market370 and many drug candidates fail in the late steps
of development or post-marketing65,214,284,441: only one in 24 drug candidates entering
clinical development, will pass all clinical trial phases41.
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There are multiple reasons why a drug may not work or cause unexpected adverse events
in a patient, including 1) mechanistic problems, such as a wrong or insufficiently established
target41,284, 2) cross-reactivity of compounds with off-targets (proteins and tissues)361 and
3) pharmacogenomic effects, meaning that the drug targets or pharmacokinetic genes
contain genetic alterations that alter the drugs PD/PK profile144 (see also Section 2.2.4).
The failure of a single-target based therapeutic can in many cases be backtracked to the
intrinsic robustness of the target system, as organisms evolved to maintain functionality and
handle perturbations in their environment through chemicals, toxins and genetic mutations.
Sometimes, a diseased system also remains robust against drug-induced perturbations
through shifts in the cellular network flow which results in lack of drug efficacy. At the
same time, a drug may interfere with other components of the cellular network, leading to
side effects210. Especially when there is a high level of genetic diversity, as found in cancer
cells and pathogens, chances are high that some cells evade the drug action and lead to
resistant subclones210.
Failures in the late stages of the development cycle are particularly expensive because
they require the repetition of most earlier phases to find a new suitable candidate. One of
the outspoken goals of the pharmaceutical companies is thus the reduction of late-stage
attrition by addressing and solving all potential risks early in the process or kill a project
if necessary (“fail early, fail cheap”)223,326. Developing teams try to incorporate as much
high-quality information about the disease, targets, compounds and target organism early
on into the drug discovery pipeline55,65.
The payoffs of recent changes in the development process and ongoing massive invest-
ment in the establishment of in vitro methods for toxicology screening441, inclusion of big
data55 and systems-medicine approaches162, the movement away from the single-target
paradigm277, and towards open innovation284 remain to be seen in the future.
2.2.4 Influence of Genetic Variation on Drug Efficacy
Even after approval of a drug, patients respond differently to drugs374 — some suffer from
serious adverse events, and others do not experience any effect at all52. A multitude of
factors can affect the response of a patient to a drug, including the complexity of the disease,
drug-drug interactions, environmental factors, age, sex, and also the genetic mutations in
drug-related genes in the patient2,63. Gaining a thorough understanding of the impact of
genetic variations in pharmacogenes on a drug’s efficacy has been of scientific interest in the
past. PGx aspects now have found their way into the drug development144 and approval
process481.
The two most important aspects in which genetic variation can affect a therapeutic are:
i) modulation of the drug’s efficacy and PD properties, if they occur in the therapeutic
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target or associated pathways. The breast cancer drug herceptin, for example, is now
prescribed to patients whose tumors overexpress its drug target ERBB2 as this renders
them more susceptible to said compound358. ii) Modulation of the metabolism of a drug
through variants in ADMET genes, giving rise to poor, intermediate, extensive and ultra-
rapid metabolizers144. Another breast cancer medication, tamoxifen, requires activation
through cytochrome P450 enzymes and can be affected by genetic variants in these enzymes
that result in their overly slow or quick metabolic activation that can be associated with
over-/under-dosing393.
PGx can be included early in the discovery pipeline358, and also to guide treatment
decisions after marketing approval453. Through large-scale sequencing efforts in the past
years, there have been efforts from different groups — including us — to quantify and
characterize the extent of variants in drug-related genes44,114,218,302,459.
2.3 Molecular Modeling Methods
Molecular modeling algorithms are commonly used in the in silico drug discovery process
for modeling, representing and manipulating structures and reactions of molecules (e.g.,
drug targets, target-ligand complexes, ...). They can be used to characterize a molecule
by predicting properties dependent on its three-dimensional structure and to simulate the
behavior of molecules.
2.3.1 Molecular Mechanics (MM)
Molecular mechanics refers to the use of classical mechanics (Newtonian mechanics) to
describe the energetic properties of the molecule. Atoms, as the smallest individual units
considered here, are described as point charges with masses and linked by covalent interac-
tions (bonds) and noncovalent interactions. A potential energy function can then be used
on this system of N particles (atoms) to calculate the potential energy V(rN ) for the given
coordinates r in space. This function describes the potential energy of the system as a sum
of covalent (Ecov) and non-covalent (Enon_cov, i.e., electrostatic and van der Waals forces)
energy terms.
The parameterized form of a potential energy function is called a force field in which
parameters for equilibrium bond, angle, and dihedral values, van der Waals multipliers
and other constants are usually determined empirically. Based on equilibrium constants
and the observed terms in the structural conformation at hand, the overall energy of the
system’s given conformation can be calculated.
Two commonly used force field families for the simulation of biomolecules are Optimized
Potentials for Liquid Simulations (OPLS)17,194,454 and Assisted Model Building with Energy
Refinement (AMBER)30,66,215,244,446,447. The functional form of both force field families
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is very similar and builds on previous work by Lifson and Warshel241, but differs in the
details of its parameterization. For example, while the authors of AMBER used quantum
mechanical calculations to derive the electrostatic potential, the OPLS authors derived
charges empirically. Different to the first AMBER force field, the OPLS force field also
focused on modeling systems in the presence of an explicit solvent.
The general form of the second generation AMBER force field, was defined by Cornell
et al.66 as
V(rN ) =
∑
bonds
kl(li − li,eq)2+∑
angles
kθ(θi − θi,eq)2+
∑
dihedrals
Vn
2
[1 + cos(nω − γ)]+
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i<j
(
4ij
[(
σij
rij
)12
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Here, the first term sums over the bonds in the molecule, interpreted as ideal spring
forces and defined as harmonic potential centered around equilibrium bond-length val-
ues (li,eq). The bond-stretching constant kl controls the stiffness of the bond spring.
Parametrization of this term in the force field consists of determining values for kl and li,eq.
The second term similarly sums over the bond angles centered around equilibrium angles
(θi,eq).
The third term sums over torsion angles and represents how the energy changes as a
bond rotates using a Fourier series over multiple terms. A bond twist can occur for different
reasons, including bond order (e.g., double bonds), neighboring bonds or lone electrons.
Here, Vn is the barrier to free rotation, n the periodicity of rotation, ω the observed torsion
angle and γ the angle at which the potential energy achieves its minimum. Each of these
first three terms thus represents the energy difference between an ideal geometry for bond
lengths, bond angles and dihedral angels compared to the actual geometry446.
The non-bonded energy between all atom pairs is covered by the fourth term of the
force field, including van der Waals and electrostatic energies. The van der Waals term is
computed as the Lennard-Jones potential in which attractive forces fall off with distance
r between two atoms with r−6 while repulsive forces fall off with r−12. The electrostatic
term, on the other hand, is described using Coulomb’s law of atom-centered point charges,
falling off with r−1 for the atom point charges qi and qj .
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The AMBER force field — like all others — makes several simplifications. Electrostatic
and van der Waals interactions for example are only calculated between atoms separated
by at least three bonds and between molecules66.
2.3.2 Molecular Dynamics (MD)
To model the movements of a molecule (often together with water molecules and ions),
MD simulations can be used. Here, Newton’s laws of motion are employed to generate a
trajectory by propagating the potential energy of the system over time. The position and
velocity of each atom are updated by solving the differential equation embodied in Newton’s
second law of motion, F = ma, where F is the force acting on the atom calculated from
its mass m and its acceleration a. The velocity of an atom describes how fast it changes
with time, v = dr/dt. Acceleration is the derivative of velocity, defined as a = dv/dt, the
motion of the atom along the coordinates r can thus be written as
d2r
dt2
=
F
m
= a (2.1)
F can be derived from the inter-atomic potentials as described in the potential energy
function F (r) = −∇V(r)
From the trajectory one can then sample the conformation distribution by taking
discrete snapshots and calculate time averages of properties.
2.3.3 Molecular Docking
The structure of an inter-molecular complex of two molecules (e.g., a protein receptor and a
small molecule ligand) can be predicted using molecular docking 29. Most molecular docking
algorithms consist of two steps: 1) generation of potential receptor-ligand conformations
through sampling of translational and rotational conformations of the molecules relative
to each other (often also including the conformational freedom within each molecule),
and 2) scoring the solutions towards their likelihood of representing the “true” complex
conformation. This second step typically uses a knowlegde-based or empirical scoring
function. Particularly when evaluating a large set of ligands for their ability to bind to a
protein, the scoring step further has to be able to rank the ligands relative to each other.
Most scoring functions try to achieve this task by estimating the free energy of binding
∆Gbind.
While scoring methods have become very good at predicting the true complex conforma-
tion with near atomic resolutions, they still have problems at predicting accurate binding
affinities363.
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2.3.4 Molecular Mechanics Combined with Continuum Models
To improve the accuracy of predicted binding free energies of a ligand-receptor complex,
the electrostatic contribution of the solvation free energy can be added to the MM terms
of the energy function. Common approaches in this context are MM combined with
Poisson-Boltzmann (PB) or generalized Born (GB) and surface area (SA) approaches (MM-
PBSA and MM-GBSA) which have been shown to be more accurate than purely empirical
scoring functions, particularly when also averaging interaction energies over MD or Monte
Carlo simulations337. In this method, the standard force field terms are combined with a
polar solvation energy obtained from PB or GB continuum-solvation methods, a non-polar
continuum solvation energy estimated as linear relation to the solvent-accessible surface
area (SASA) and the entropy calculated at the MM level. For MM-PBSA, for example,
the overall free energy of a system is then computed as G = EMM +GPBSA−TSMM with
EMM = Ecov + Eelectrostatic + EvdW and Ecov = Ebond + Eangle + Etorsion. The solvation
free energy GPBSA = Gpolar +Gnon_polar can be calculated from the PB equation and an
estimate for the non-polar free energy. The solute entropy TSMM can be estimated from
the MD trajectory by quasi-harmonic analysis.
The binding affinity is then calculated from the energies of the receptor-ligand (RL)
complex as well as structures of ligand (L) and receptor (R) that are obtained by removing
the respective partner338:
∆Gbind =
〈
GRL −GR −GL
〉
RL
(2.2)
2.4 Protein Interactions
Proteins often interact with other biomolecules to fulfill their function21: cellular processes
such as signal transduction, cell-to-cell communication, membrane transport as well as
transcription and replication are orchestrated by a multitude of interacting proteins that
form binary or higher-order complexes 270.
2.4.1 Identification of Protein-Protein Interactions
The process of identifying interacting partners in the cellular protein-protein interaction
(PPI) network and their binding sites faces several inherent challenges: the multitude of
genes, proteins with their isoforms, and modification states in a cell, low protein abundance
and problems with the purification of many proteins therein172. PPIs are dynamic and
the lifetime of many protein complexes is limited, i.e., transient, to the duration of a
particular process which complicates their detection using conventional approaches205.
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Such interactions are usually not stable in experimental conditions, thus complicating co-
purification of the interacting partners. Similarly, some interactions occur only in certain
tissues and may be missed by experimental approaches using the wrong tissue or cell line130.
Experimental Methods for PPI Determination
A multitude of experimental methods have been developed to characterize PPIs. Yeast two-
hybrid (Y2H) has been shown capable of identifying binary interactions between proteins
at reasonable accuracy355. In such studies yeast cells are transfected with a bait and a
prey plasmid. The bait is the protein of interest fused with a DNA-binding domain of
a transcription factor, while the prey confers a potential interacting protein fused to an
activation domain of the transcription factor. If bait and prey interact, the transcription
of reporter genes occurs, so that the presence of gene products resultant of the reporter
gene expression serves as indicator of the interaction456. Other biochemical and mass
spectrometry (MS) approaches in which the protein complexes are first purified through
immunoprecipitation (IP-MS)148 or affinity purification based on epitope-tagged baits
(AP-MS)172,403 have been used for proteome-wide experimental elucidation of the PPI
network. However, none of these methods give the three-dimensional structure of the
protein complex. To yield these information experimentally, more complex experiments,
such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, or high-
resolution cryo-electron microscopy (cryo-EM) are required309.
PPI Prediction
Due to the difficulty of experimental PPI elucidation, computational methods have been
developed that can be used to characterize different aspects of protein interactions (re-
cently reviewed by Keskin et al.205). These methods have previously demonstrated their
utility for coarse-grained interaction prediction, while residue-level prediction was less
successful136. Methods utilizing global criteria of genome structure make use of data in
genomic databases and can be grouped into gene neighborhood-based, fusion-based, interac-
tion homolog search-based, phylogenetic similarity-based, coexpression-based and network
topology-based approaches205.
Particularly in bacteria, interacting proteins tend to be close on the genome, which led
to the development of methods that search for co-localized genes (e.g., on the same operon
in bacteria71,116). Furthermore, some interacting proteins can be found in a fused form in
some organisms. Some computational approaches search for such examples and use these
to identify potentially interacting proteins in other organisms (“Rosetta Stone”)264,265.
Similarly, proteins that are known to interact in one species are likely to also have a
conserved interaction in their homologs in other species giving rise to methods that mine
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databases for such interaction homologs. Due to the assumption of interaction conservation,
such methods work primarily for protein complexes that are obligate205. Similarities
between the expression profile of genes418 or their evolutionary record, e.g., based on the
structure of their phylogenetic trees196,328, have also successfully been employed to identify
PPIs. These coarse-grained methods can be combined with additional approaches for
prediction of binding surface patches at residue-level and docking205. Methods that use
the full amino-acid sequence of proteins could also be used to predict protein interactions
at a high resolution. Here, co-evolution based methods using mutual information (MI)
between residues of two proteins have been proposed in the early 1990s119. However, due to
limitations of the employed statistical method and the large number of sequences required
for their successful use, they have only recently seen further development and application.
2.4.2 The Human Interactome
The set of all protein interactions in an organism is called interactome. For humans,
the interactome is estimated to consist of up to 650,000 binary interactions (0.2% of the
minimally ∼ 20, 000× 20, 000 possible pairwise interactions if each gene only coded for one
protein)408 with a variety of interface types5. However, we still know only a small fraction
of the interacting pairs and types5,279.
While many anecdotal reports of PPIs can be found in the literature, so far only small
sections have been charted systematically in larger projects. These include the probing
of 13,000 genes using Y2H355 and the MS-based probing of 7,668 genes172. These studies
found that each protein node in the interaction network is on average connected to three
other proteins172,355. Sub-networks exist, however, in which nodes are more connected to
each other (modules) and a relatively small number of genes have many more connections
to other genes than the rest (hubs)18. Still incomplete, such reference maps of the human
interactome have already been used to study disease mechanisms18,431, find novel drug
targets277 and analyze the effects of gene mutations130,153.
To facilitate the use of these reference maps for computational analyses, database
resources exist. The molecular interaction (MINT) database, for example, collates ex-
perimentally verified PPIs from literature240 and covers 25,000 interactors across 650
species including 8,000 human proteins and the Database of Interacting Proteins (DIP)364
comprises 29,000 proteins across 850 species including 9,100 interactions of 5,000 human
proteins (as of July 2018). Consortia have further compiled meta-databases from such
primary databases, integrating experimental and literature sources. Widely used examples
include STRING182,183, IMEx315, and GeneMania440. Some resources further incorpo-
rate knowledge about functional PPI modules (i.e., pathways) including KEGG198 and
PathwayCommons50.
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2.4.3 The Role of the Human Interactome in Disease
The dysfunction of cellular processes due to the disruption of PPIs is often implicated in
the emergence of disease. The understanding of protein interactions in healthy and diseased
cells can thus give valuable, molecular-level information about the links between proteins,
genetic variants and diseases205.
One of the first studies that explored the human disease network was published 2007 by
Goh et al.121 where the authors conclude that complex diseases can be caused by different
mutations in a common functional module that perturbs cellular function as “genes that
contribute to a common disorder (i) show an increased tendency for their products to
interact with each other through protein-protein interactions, (ii) have a tendency to be
expressed together in specific tissues, (iii) tend to display high co-expression levels, (iv)
exhibit synchronized expression as a group, and (v) tend to share Gene Ontology (GO)
terms” 121.
Disease Modules in the Interactome
Genes connected to the same disease tend to cluster in the PPI network121,279. This
clustering is coupled to an increase in biological similarity of the disease genes according
to the GO terms for biological processes, molecular function, and cellular localization and
could be used in the target identification step of the drug discovery process279.
The small fraction of diseases that have overlapping disease neighborhoods, however,
show a statistically higher GO annotation similarity, coexpression correlation, symptom
similarity (from medical records) and relative risk of comorbidity (from disease history
of 30 million individuals)235,323. This implies that the network-based distance between
diseases correlates with pathobiological and clinical similarity and distances between disease
modules have predictive power for identifying overlapping disease pairs that also share high
levels of comorbidity and biological mechanism (shared pathways etc.)279.
2.4.4 Network Connection Between Drug Targets and Disease Genes
Only a small proportion of validated disease genes also act as targets for approved drugs470.
Retrospective studies have, however, shown that compounds that are effective against a
protein whose involvement in the disease has been established, have a higher likelihood
of gaining FDA approval292. The minimum shortest path in the PPI network for disease-
drug pairs can be associated with their palliative or etiology-based use: compounds whose
shortest path to the disease gene are shorter than expected at random are more likely to treat
disease-causation rather than symptoms470. This was explained through one or more of the
following factors: 1) direct druggability of disease genes (e.g., because they are aberrant
membrane-bound receptors that can be targeted by substrate-mimicking molecules), 2)
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a rather thorough understanding of etiology or 3) targeted design of therapeutics (e.g.,
inhibitors of hyperactive oncogenes in cancer)470.
2.5 Drug Repurposing
Approximately 10-14% of the human proteome is estimated to be druggable and between
1,500 and 3,500 proteins are estimated to be directly involved in disease163,314. Given that
roughly the same number of genes are already used as drug targets314,318, novel strategies
for finding new drugs targeting previously untreated diseases have to be devised. As stated
by Nobel laureate Sir James Black, “The most fruitful basis of the discovery of a new drug
is to start with an old drug” 348. Recycling existing compounds for novel indications appears
attractive because their pharmacological profile and safety in humans are already estab-
lished257. These compounds can be the starting point for the conventional drug discovery
pipeline with additional efforts to optimize their side activities using experimental451,452
and computational24 methods. While this approach may circumvent the need for the
initial steps in the pharmaceutical discovery process (Figure 2.2), relatively few system-
atic repurposing programs exist so far in practice, and the area remains of high research
interest325.
2.5.1 Repurposing Using Classical Drug Discovery Methods
A straightforward approach for finding additional therapeutic indications for approved
drugs — and late-stage candidates that may have failed for their primary indication — is
to use them as libraries in chemical screens, either in vitro or in silico:
Compounds with a high similarity with respect to their chemical structure are often
also similar in their properties (similar property principle), including activity190. Searching
a molecule library for compounds similar to those showing initial activity against a target
is thus a common strategy in drug discovery. By using only existing drug molecules as the
search library, the same ligand-based computational chemistry strategies can be applied in
repurposing203,204,242,322.
Protein structure-based drug discovery approaches such as molecular docking can simi-
larly be used with only known drugs as the virtual screening libraries146,207,451,452,473. This
method was applied, for example, for the identification and experimental validation of
synapsin-I as a target for staurosporine73. The major disadvantage of protein structure-
based approaches is the dependence on structural data either of the protein-ligand complex
or at least of the target. Furthermore, one has to acknowledge that even though molecular
docking can adequately reproduce the binding pose of a ligand in the binding site, docking
scores often do not correlate with measured binding affinities336,342,399,400.
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Figure 2.2: Drug discovery pipeline with repurposing. By using repurposing and
phenotypic screening, the average development cycle of a new drug can be shortened
from 10-12 years through conventional targeted or phenotypic approaches (a, b) to a
few years. (c) Using established compounds in phenotypic repurposing screens, the
clinical development phase for showing the drug’s efficacy for the novel indication can
be drastically shortened. (d) Repurposing screens can further be used to identify novel
disease targets. Here, the activity of a compound with known molecular target on a
disease phenotype can point towards novel disease targets. Reprinted from Zheng et
al.479, with permission from Elsevier.
Phenotypic screening is one of the main drivers for experimentally identifying new
lead compounds91,412. Especially phenotypic animal models provide useful model systems
for the disease and results are clinically translatable367,479. Using such an experimental
approach with approved drugs minimizes the need for further validation after screening,
saving development time and cost (Figure 2.2).
2.5.2 Genetic Variation- and Gene Expression-Based Repurposing
The involvement of a gene/protein in the disease etiology is crucial (but not sufficient)
to be considered a potential drug target163 and modern genomic technologies have been
widely used for target identification254. If the genetic basis of the disease is known, this
knowledge can also be used to find existing drugs that act on these proteins: for a genetic
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disease caused by the LoF (or GoF) mutation of a gene, the treatment with an agonistic
(or antagonistic) drug may be a potential strategy39,349,365,439.
There are some pitfalls with the approach, requiring further development. The main
point to consider in predictions is the directionality of a mutation effect (LoF vs. GoF)
and drug action (agonist or antagonist) — both often not recorded in the literature439.
Other problems arise from the quality of the included data: in GWAS many variants
associated with a phenotype do not fall in a protein-coding region complicating their
interpretation63,243,349,365. Even when using curated databases such as OMIM, the data
can be polluted by non-causal gene-disease links236, stemming from the era before whole
genome sequencing (WGS) when the genetic characterization of a disease was expensive,
and often only a small set of genes was explored286.
Compared to full genetic profiles of patients, it is much easier and cheaper to obtain
data on gene expression changes in diseases and on cellular effects of drug perturbation
through microarrays and RNA sequencing. By comparing the gene expression profile (GEP)
induced by drug treatment with that of the diseased tissue, one can search for matching
pairs of cellular perturbation169.
The most famous example of this approach is the Connectivity Map (CMap) — a
compendium of drug perturbation GEPs in a set of cell lines224,225 which has been used
for the development of several repurposing approaches175–177,184,206,273,394. Several of the
strongest predictions could later be validated including topiramate for inflammatory bowel
disease88, ursolic acid in muscle atrophy221 and the HDAC inhibitor vorinostat for gastric
cancer61.
While disease GEP signatures are shown to be robust across tissues87, this does not
necessarily transfer to the cell lines used in the main public databases81. Additionally,
while many FDA-approved drugs now have established GEPs, such profiles often exist
only for a single drug dose. Predictive power despite those drawbacks could, however, be
overcome by the creation of cell type-specific drug perturbation profiles222 and the inclusion
of background gene expression networks417.
2.5.3 Network-Based Repurposing
The guilt-by-association (GBA) approaches is based on the hypothesis that if two diseases
can be modulated by the same drugs, then their underlying mechanisms may be similar.
Thus, if two diseases share a large number of drugs, those drugs that are currently only
used in one of the two indications, may be repurposed to the other59.
This approach has inspired the development of a multitude of different networks contain-
ing various node and edge types166,238,249,271,272,344,435,466 where paths through the network
are used to identify new drug-disease associations (see Figure 2.3 for an example). Some
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of these methods are built on heterogeneous information networks154, while others follow
a semantics-based approach67.
An alternative approach is leveraging the modularity of the protein-protein network (see
also Chapter 2.4.3) in a pathway-agnostic manner to identify drug-disease pairs through
drug-gene-disease co-modules. In this case, modules are identified in the gene network
through partition methods on gene closeness data137,477.
Methods for drug-target or disease-gene predictions based on network knowledge can
also be used in repurposing studies, as they can be easily integrated with the missing
disease-gene or drug-target links if the molecular target is established56,78,99,300,463.
Network-based approaches have the advantage that they allow the prediction of drug
MoA on top of the repositioning. Once created, the networks can also easily be extended
for a disease or drug of interest with a known target gene. However, the construction
of a reliable network is complicated by a plethora of data sources with partially overlap-
ping entries and little quantitative information about the interaction strength. For the
protein-protein interactome, only a small proportion is currently known279, but noise is
introduced by predicted connections or by those obtained in high-throughput setups. Thus
each additional integrated data source may add false associations, resulting in different
performances of the same method depending on the integrated database166.
2.5.4 Hybrid and Machine Learning-Based Repurposing
While some of the network-based methods are de facto machine learning (ML)-based, using
the network or structures derived from it as features, there are also other methods that
combine multiple types of data and prior knowledge for supervised learning approaches. The
problem is then usually formulated as a binary classification problem to predict associated
drug-disease pairs. The two gold standard methods are PREDICT127 and PreDR438. While
PREDICT uses a logistic regression classifier that employs multiple similarity measures for
drug-drug and disease-disease relationships as features127, PreDR employs a kernel-based
approach on the same dataset438.
Two approaches treating the problem of drug-disease association prediction as super-
vised network inference have been shown to outperform PREDICT and PreDR45,179,369.
Here, the features for drugs contain chemical fingerprints or a phenotypic profile while dis-
eases are encoded using molecular features (disease genes, diagnostic biomarkers, pathways
and environmental factors). Then either logistic regression179,369, template matching369 or
a Random Forest (RF) are employed for classification45.
Many of the proposed ML methods require prior knowledge encoded as feature vectors
and result in a black-box model. Another limitation of these approaches is that they often
require at least some information about the included feature types for a drug and the
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diseases45. Furthermore, the data in the training sets are often unbalanced, and even
though many groups try to reduce redundancy between training and test data, the included
data sources are frequently not independent.
In their performance, the ML-based methods tend to outperform all other proposed
repurposing approaches45,179,369. Approaches that infer edges in the drug-gene-disease net-
work, on the other hand, result in predictions with higher interpretability, than regression-
based predictions369, but fail to reach comparable prediction performance.
2.6 Phenotype Inference using Evolutionary Sequence Records
Genome sequencing has become a popular method to study the effects elicited by specific
genetic variants on the phenotype. Apart from identifying statistical associations between
a variant and a particular phenotype in GWAS, computational approaches have been
developed to utilize the data from such projects. Here, the availability of genetic information
of a protein of interest across multiple species was shown to be predictive of several
phenotypes including the 3D structure of proteins33,268,419,475 and RNA448, as well as the
overall fitness of the organism161.
2.6.1 Computational Methods to Predict Protein 3D Structure
Consideration of a protein’s 3D structure has been shown to be helpful in the analysis of
its functionality. As discussed in previous sections, knowledge of the 3D structure of a
protein can then be used to study effects of genetic variation, design new drugs (Chapter
2.2.2), and study protein interactions (Chapter 2.4). Many proteins do not have a resolved
structure yet333, thus computational methods that either rely on a template for modeling
the structure (comparative modeling) or predict the structure de novo have been developed.
Comparative modeling of 3D structures is based on the fact that protein structure
is more conserved then amino acid sequence with proteins sharing the same fold despite
only approximately 30% pairwise sequence identity60. If a solved homologous structure is
available, spatial coordinates can be transferred from this template structure to the target
protein using the aligned sequences of target and template13.
If no template structure exists, a 3D model of the protein can be created ab initio. For
smaller proteins (less than 100 amino acids) the simulation of the in vivo folding process
based on MD simulations and a force field yield reasonable 3D models given the appropriate
compute power245,386. For larger proteins, a starting structure is assembled from fragments
with known 3D structure that have been identified through a coarse-grained search of the
conformational space. This 3D model is then refined33,36,475.
Several ML-based approaches have further aimed at learning structural features of
sequences based on the solved structure space and utilize those for novel predictions283,462.
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To constrain the conformational search space explored by de novo prediction methods, or-
thogonal data from experiments, such as constraints identified by MS or NMR experiments,
can be included in the prediction.
A breakthrough in de novo modeling was obtained using correlated mutations in a
protein family to infer interacting residues from sequence data alone (Figure 2.4). Compen-
satory mutations in proteins have been observed early on in the field of sequence analysis
and occur if a second residue is required to change after an initial point mutation to rescue
the protein’s structure or function6,313. From this, the idea of using correlated mutations
to predict contacts in a protein arose in the mid-1990s119,301,390,413,414. However, while
observing correlated mutations at sites known to be close in the structural context is rela-
tively trivial, the inverse of inferring actual contacts from a multiple sequence alignment is
a challenging problem.
2.6.2 Co-Evolution-Based Prediction of Protein Structure
The concept of correlated mutation can be modeled, statistically, as the dependency of
amino acids between columns in a multiple sequence alignment (MSA). Initially, primarily
pair-independent measures were used to infer co-varying residues, including MI between
the distributions of amino acids occurring in pairs of columns i, j in the MSA (Figure 2.4).
The counts of each letter in the alphabet of Σ = {1, ..., q} with q = 21 (representing the 20
proteinogenic amino acids plus the gap character) can be converted to a frequency vector
fi for position i in the alignment. Observations of pairs of amino acids at positions i, j can
be similarly represented as a frequency matrix fi,j with each cell in the matrix representing
a particular combination of characters σi ∈ Σ.
For a multiple sequence alignment with B sequences of a protein σ = (σ1, ..., σN ) of
length N , this can be formally described as
fi(k) =
1
B
B∑
b=1
δ(σbi , k),
fi,j(k, l) =
1
B
B∑
b=1
δ(σbi , k)δ(σ
b
j , l)
(2.3)
The MSA in this case is defined as an integer array {σb}Bb=1 with a column per position
in the protein sequence and a row for each sequence in the alignment. The Kronecker
symbol δ(a, b) takes value 1 if a = b and 0 otherwise.
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The MI of two sites in the alignment can be calculated from the frequencies of single
sites and pairs of sites as
MIij =
21∑
k,l=1
fi,j(k, l) ln
fi,j(k, l)
fi(k)fj(l)
(2.4)
Those pairs (i, j) with high MI are then predicted as contacts in the 3D structure.
Many of the early papers in this field found, however, that only few of the identified pairs
were indeed close in the three-dimensional structure of the protein. This can be attributed
to confounding factors such as uneven representation of protein family members, inadequate
numbers of sequences in the MSA, phylogenetic effects and indirect and transitive signals
obfuscating direct co-evolving signals42,229,269.
Global maximum-entropy models
Inspired by statistical physics approaches dealing with similar problems in coupled spin
systems, global probability models have been recently employed to identify co-evolving
residues while removing transitive effects. These models treat pairs of residues as dependent
on each other while also including the single-position conservation of each residue269.
Several such global methods have been proposed in the past years: either based on
Bayesian network modeling42 or entropy maximization under data constraints known as
Potts models (or pairwise graphical models). The latter is often also referred to as direct
coupling analysis (DCA)96,269,291.
The Potts model is the least biased probabilistic model capable of reproducing the ob-
served frequencies fi(k) and fi,j(k, l) as defined in equation 2.3, while explaining underlying
patterns in the data through hidden constraints95,181,229,
P (σi = k) =
∑
σ,σi=k
P (σ) = fi(k),
P (σi = k, σj = l) =
∑
σ,σi=k,σj=l
P (σ) = fi,j(k, l),
(2.5)
Under the Potts model, the probability of sequence σ is defined as
P (σ|h,J) = 1
Z(h,J)
exp(H(σ))
H(σ) =
N∑
i=1
hi(σi)︸ ︷︷ ︸
conservation
+
N−1∑
i=1
N∑
j=i+1
Jij(σi, σj)︸ ︷︷ ︸
co-conservation
(2.6)
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Where the partition function Z normalizes distribution and H(σ) describes the sta-
tistical energy of the system — defined as the sum of all its single-site constraints h and
pairwise coupling constraints Jij .
The approach of inferring the parameters {h,J} based on the constraints defined in
equation 2.5 from a set of independent equilibrium configurations {σb}Bb=1 of the model
observed in reality is called the inverse Potts problem. It would usually be solved by
maximum likelihood estimation, optimizing the likelihood function
L(h,J) =
∏
σ∈B
P (σ|h,J)
=
∏
σ∈B
1
Z(h,J)
exp
(
N∑
i=1
hi(σi) +
N−1∑
i=1
N∑
j=i+1
Jij(σi, σj)
) (2.7)
so that the probability of observing the sequence σ in the alignment B is maximized.
This process requires the calculation of the partition function Z
Z(h,J) =
21∑
σ1=1
...
21∑
σN
P (σ1, ..., σN |h,J)
=
21∑
σ1=1
...
21∑
σN
exp
(
N∑
i=1
hi(σi)
N−1∑
i=1
N∑
j=i+1
Jij(σi, σj)
) (2.8)
for any configuration {h,J}. This partition function sums over all system configurations,
i.e., possible sequences, and ensures that P (σ) is a valid probability distribution in which
the probabilities of all sequences that could be generated sum up to one. This corresponds
to the calculation of 21N possibilities for a sequence of length N and 21 possible states at
each position before summing them up. Solving systems of the size usually encountered in
protein structure determination is thus computationally intractable.
Therefore mathematical approaches have been devised that can approximate the param-
eters in the inverse Potts problem at faster compute times. Some of these have been success-
fully implemented for protein contact prediction, including Monte Carlo optimization229,
naive mean-field inversion (NMFI)268,291, and pseudo-likelihood maximization (PLM) which
has shown to further improve accuracy of the inferred contacts16,95,96.
The general concept of the DCA approach to obtain interaction scores from a multiple
sequence alignment is illustrated in Figure 2.5.
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Sequence re-weighting
One of the main assumptions used in maximum likelihood inference of Potts models is that
the B sample configurations (i.e., sequences) are independent and identically distributed
(i.i.d). Sequences in an MSA do not fulfill these assumptions due to sampling bias and
phylogeny. The information content of each sample does therefore not match that of a
truly independent sample. One way to mitigate this sample bias is through re-weighting
of the B configurations used in parameter estimation to penalize samples with very high
similarity. A weight wb can be added to each sequence σb that depends on its similarity to
the others.
In DCA the similarity measure is based on the fraction of identical amino acids in two
sequences σa and σb. Using a predefined similarity threshold x, one can compute the
number of similar sequences mb to sequence σb. The weight wb of σb is then defined as
wb =
1
mb
.
This weighting procedure further allows to estimate the number of “effective” samples as
Neff =
∑B
b=1wb which is a better estimator of the amount of available sample information.
Regularization
Since the number of parameters of the model outnumbers the amount of available sequences
for most protein families for model inference, measures such as regularization help to avoid
overfitting. Here, a penality term is added to the objective function before optimizing,
arg max
h,J
(logL(h,J)−R(h,J)) (2.9)
where the optimization now consists of a trade-off between maximizing the probability
of the data (log of the pseudo-likelihood L(h,J)) and minimizing the complexity of the
model, as described by the regularisation term R(h,J).
Both l1 15,192 and l2 regularization have been employed in protein structure prediction,
with l2 being more commonly used95,197,268,419,448,
Rl2(h,J) = λh
N∑
i=1
||hi||22 + λJ
N−1∑
i=1
N∑
j=i+1
||Jij ||22 (2.10)
Here, the regularization parameters λh and λJ determine the strength of regularization
for each parameter type.
Co-evolution-based interaction scores
Scalar scores for the coupling strength of residue pairs in the protein can be calculated by
summarizing the Jij matrices. The cell values inferred for each pair-matrix Jij correspond
29
2. Background
to the preferences for observing a particular amino acid combination σk, σl with k, l ∈ q.
If the cells in Jij show very strong differences in values, this indicates that this pair of
residues in the sequence is evolutionarily constrained.
In PLM-based DCA (plmDCA), the coupling scores are calculated as the Frobenius
norm (FN) of the transformed Jij matrices. By shifting the coupling matrix in the so-called
zero-sum gauge, their rows and columns means are centered around zero, as
J′ij(k, l) = Jij(k, l)− Jij(·, l)− Jij(k, ·) + Jij(·, ·) (2.11)
where · denotes the average across the matrix row/column entries. J′ij is then summa-
rized by calculating the FN
SFNij = ||Jij ||2 =
√√√√ q∑
k
q∑
l
J′ij(k, l)2 (2.12)
which sums across all 21× 21 combinations of amino acids k, l in positions i and j.
Due to confounding factors such as phylogeny and insufficient sampling, residue pairs
with high FN scores still suffer from low accuracy despite sample re-weighting and regu-
larization. This problem can partially be mitigated by an additional correction applied
to the matrix of all FN scores for the protein called average product correction (APC)89.
Based on the assumption that each individual site should only be sparsely coupled, APC
approximates the coupling background and removes it from the score. The final coupling
score (evolutionary coupling (EC) score) SCNij of a site pair (i, j) is thus calculated as
SCNij = SFNij −
SFNi· SFN·j
SFN··
(2.13)
where · denotes the row/column average so that SFNi· , for example, represents the
average FN score of all site pairs involving sequence position i.
An N ×N EC matrix can then be constructed from the SCNij scores and the cells with
the highest scores correspond to the site pairs that are strongly coupled in the evolutionary
record.
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A
B
Figure 2.3: Schematic setup of CauseNet. A) The causal inference chain passes
through several layers of distinct node types: drug (d) → target gene (t) → path-
way (p) → downstream gene (g) → disease (s). Transition weights w between the
different nodes are learned from a set of “treatment enriched chains” of known disease
treatments. B) examples of drug-disease predictions and the causal chain supporting
said predictions. Reprinted from Li et al.238, available under Creative Commons
Attribution 2.0 license.
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Figure 2.4: Compensatory mutations in proteins can be observed for residue pairs
whose interaction is relevant for protein structure or function. Co-conservation can
thus be used to infer strongly coupled residue pairs and use this to predict the structure
of a protein de novo. Figure adapted from Marks et al.267, available under Creative
Commons Attribution 2.0 license.
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Figure 2.5: Predicting coupling scores from sequence alignments starting from
sequence alignments. From the sequence alignment for a sequence σ, a global maximum
entropy model is inferred, constrained by the observed conservation of amino acids
at single sites and co-conservation at pair-sites for σ. Coupling scores for all pairs of
residues l and k (EC scores) are obtained by summarizing the Jij matrix for site-pairs
using the Frobenius norm, followed by a correction for confounding bias (using average
product correction, APC). Figure inspired by Hopf et al.161.
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Chapter 3
Predicting Protein Interactions using
Co-evolution
Parts of this chapter have also been published in the following article:
Sequence co-evolution gives 3D contacts and structures of protein complexes.160
3.1 Introduction
The cell is a crowded place in which proteins constantly interact with each other270. For
most proteins this interaction is essential to fulfill their cellular functions, and while some
form stable long-lived complexes, short-lived transient interactions are not rare, especially
in cellular signaling cascades335,416. The detection of protein interactions has seen un-
precedented progress in recent years through the development and improvement of several
high throughput approaches, e.g., AP-MS, a method combining affinity purification of
epitope-tagged proteins with MS172, but particularly transient interactions remain difficult
to observe experimentally.
Especially the determination of the 3D structure of protein complexes remains challeng-
ing, despite recent advances in structural biology12,58,165,478. We thus still have little or
no 3D information for 80% of the currently known protein interactions in bacteria, yeast
and mammals. This amounts to a total of ∼30,000/∼6,000 incompletely characterized in-
teractions in Homo sapiens (H. sapiens) and Escherichia coli (E. coli), respectively294,346.
While 3D information is not required to analyze global properties of cellular systems, it is
necessary for residue-level studies for drug development and the study of phenotype-altering
mutations.
To address this knowledge gap between PPIs and their 3D structure, all types of
available structural information of the complex subunits (including low resolution and
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homology models) can be combined with force-field driven (RosettaDock), data-driven,
and cross-linking approaches54,82,200,216,217,219,354,373,409,430,443 (see Chapter 2.4 for a more
detailed review of the methodology) to obtain 3D models of the complexes.
In addition to structural data, the use of sequence data has been explored in the past.
Particularly, mutations in one protein partner could result in compensatory mutations in the
other partner to rescue residue interactions across the PPI interface. MI methods to identify
such correlated mutations in the sequence alignments of interacting proteins were proposed
for the first time two decades ago119,328–330. These models could not discriminate between
transitive (indirect) and direct contacts, resulting in reduced prediction accuracy268. Data
about compensatory mutations were also incorporated into machine learning-based scoring
functions for interface residues9,10,101, but suffered from the same problem of identifying
transitive interaction pairs. Recently, this problem was overcome for protein contact
prediction within proteins using direct coupling analysis. Employing a global maximum
entropy model, it was possible to 1) accurately infer residue contacts, and 2) predict protein
3D structures de novo 159,268,291.
We thus hypothesized that such a generalized global statistical model employed for
monomer prediction would also be capable of inferring direct co-evolving residues in PPIs
to: 1) identify the interaction interface at residue-level resolutions, 2) predict the protein
partners in large protein complexes or even across a whole genome.
Goals of the Project
The goal of this project was to develop a method that infers residues interacting across a
protein-protein interface based on global maximum entropy methods for direct coupling
analysis. It was further the goal to show that the method is capable of identifying the
physically interacting subunits in large protein complexes, and that inferred residue pairs
can be used to produce 3D structures of protein complexes.
We evaluated the approach on a catalog of known PPis in bacteria as well as large
protein complexes, to show that it is possible to use the evolutionary record of proteins to
infer interactions.
3.2 Materials and Methods
The proposed method, EVcomplex, identifies interacting residues between two proteins
based on a statistical model similar to DCA for structure prediction of protein monomers.
The approach consists of several steps (summarized in Figure 3.1):
Creation of a joint sequence alignment. First, the evolutionary record of both
proteins is retrieved by creating multiple sequence alignments of the proteins. Putatively
36
Materials and Methods
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Figure 3.1: Contact prediction using evolutionary couplings. The evolutionary
record of both proteins is retrieved from a large sequence database by creating multiple
sequence alignments. Puatatively interacting pairs of sequences have to be identified
and concatenated before inferring the co-evolution model using pseudo-likelihood
maximisation. The model is summarized to infer particularly strong couplings. These
can then be used as constraints for docking protocols.
interacting pairs of sequences are then concatenated so that an overall sequence σ is
obtained from the two monomer sequences σm and σn.
Inference of co-evolution model. We employ a Potts model as the global probability
model from which interaction strengths between residues are inferred (the details of model
and parameter inference using pseudo-likelihood estimation are explained in depth in
Chapter 2.6)
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Mapping and scoring. After model inference, a re-mapping step then translates the
residue indices in the concatenated sequence back to the corresponding indices in σm and
σn. Given the global approach, not only co-evolving residues between the two proteins
(inter-contacts) are inferred, but also within each monomer (intra-contacts). Raw coupling
scores depend on the alignment length and depth and are further transformed to scale-free
EVcomplex scores using the method described below to facilitate comparison of predictions
between proteins. Based on a benchmark set, it was possible to determine a universal
threshold for separating high-confidence scores from noise. Strong inter-protein couplings
can then be used as constraints in docking tools such as HADDOCK to predict the 3D
structure of the complexes.
3.2.1 Method Details
Monomer sequence search
The first step in the EVcomplex method is the creation of MSAs for the two interacting
proteins. A key challenge here is to create sufficiently diverse alignments (evolutionary
depth) to facilitate statistical inference while not including proteins that have diverged too
far and thus have changed structure or are not involved in the same conserved interaction.
Iterative hidden Markov model (HMM)-based homology search methods, in which position-
specific residue and transition probabilities are determined from seed alignments, have
been shown to be more successful in identifying even distant homologs of a protein, both
in respect to accuracy and sensitivity, than other standard sequence search tools93,353,
including BLAST7,8, the de facto standard in sequence search.
jackhmmer allows creating accurate MSAs by searching for homologs using iteratively
extended profile HMMs189. The tool allows to modulate the evolutionary depth of the
created alignment using domain specific inclusion thresholds based on 1) bit score and 2)
E-value. The first is solely dependent on the profile HMM and the aligned sequence σ and
is computed as the log-odds ratio of the probability of σ given the profile HMM and the
probability of observing σ under a null model:
S = log2
P (σ|HMM)
P (σ|null) . (3.1)
In the case of jackhmmer two null models are used, first a one-state HMM describing
random sequences as i.i.d. with a pre-defined amino acid composition and secondly an ad
hoc model to correct for biased composition regions in the target sequence. The bit score
thus describes how well the particular sequence matches the HMM compared to the null
model: if the score is positive, the sequence hit is better described by the HMM than the
random distribution92.
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Based on the bit score, the E-value describes the statistical significance of obtaining a
match for a sequence of a particular length and with the specific bit score by calculating
the number of matches expected to obtain the particular bit score in a database of random,
non-homologous sequences of the same size105.
While previous studies of co-evolution in proteins usually used E-value thresholds to
determine inclusion of a protein sequence in the alignment120,159, we employ bit score-
based membership determination in this project based on the assumption that using the
same average sequence similarity per residue (bits/residue) for each protein will result in
alignments with comparable evolutionary depth (which is typically not the case for the
same E-value). For a protein with sequence length L, we define the inclusion threshold for
the domain-specific bit score (–incdomT in jackhmmer) as x×L with x being the expected
similarity in bits/residue. While the optimal coverage of the full domain length is reached
at different thresholds depending on the protein, we found that x = 0.5 serves as a good
starting point. For the high-throughput evaluation of our method, we refrained from a
protein-specific threshold optimization, choosing a bit score of 0.5×L as the protein specific
inclusion threshold. We want to highlight that varying the expected similarity to obtain
wider and narrower alignments can result in improved prediction accuracy and should be
evaluated when focusing on a particular protein complex.
Sequence matching
Once the homologs of each protein across species are identified and aligned, the specific
interacting protein pairs need to be paired up before identifying co-evolved residues. This
step is crucial in the overall process because if non-interacting proteins are combined, the
inferred residue pairs will not correspond to co-evolution driven by interaction. However,
the specificity and conservation of interactions across orthologous proteins is rarely known,
i.e., for a species S we do not know which of the paralogs of protein A interacts with which
paralog of protein B. We thus need to revert to approximate approaches to construct paired
alignments with sufficient numbers of diverse sequences. In this project, we implement two
such approaches, based on different assumptions (Figure 3.2): 1) the paralogs with the
highest sequence similarity to the query interact, 2) the paralogs with the closest reciprocal
distance on the genome to each other interact.
The most obvious strategy is based on choosing the most similar homologs of both
proteins A and B to the query proteins in each species, assuming that the interaction is
conserved across orthologs. Due to its low computational cost, our approach is based on
the absolute number of identical residues shared between the query proteins as a measure
for sequence similarity of the orthologs in each species. Then only the paralogs A* and
B* that show the highest percentage of sequence identity to the query proteins A and B
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Figure 3.2: Approaches to sequence concatenation. We implemented two different
methods for identifying possible pairs of sequences: (Left) among all paralogs in one
species, the one with the highest sequence identity is selected as putative ortholog to
the query sequence for both proteins A and B; (right) by choosing those proteins that
are located with the smallest reciprocal distance on the genome (e.g., on the same
operon in bacteria).
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are concatenated into a single record of the matched MSA. All other paralogs of A and B
are discarded as the optimal way of pairing these further cannot be determined without
any other information. The advantage of this method is that it is not restricted to any
particular kingdom and can thus theoretically be applied to any protein complex. Since
only one pair of sequences is concatenated in each species, the resulting alignment used for
parameter inference of the global model may contain too few sequences. This approach
is thus not feasible if the protein interaction is only present in a small fraction of species
(e.g., only in eukaryotes).
Based on the observation that interacting proteins in bacteria are often proximal on the
genome (e.g., same operon), co-evolution studies of the histidine kinase-response regulator
complex matched sequences based on operon structure395,445. We generalized this approach
in order to match more than one paralog per species and thus improve the sample size of
sequences used in the parameter inference step. The genomic location of the genes in the
alignments are retrieved from their coding sequences (CDS) as matched through the ENA
database320. For all possible combinations of paralogs to A and B in a species, the genomic
distance is computed using their CDS coordinates. Pairs that were not present together on
an ENA contig (or whole genome sequence) were excluded. Based on the pairwise distances,
we then determine those pairs that are mutually closest to each other, i.e., A’ is closest to
B’ and B’ is closest to A’ and not another A paralog A”. If this criterion is fulfilled, the
paralogs are matched and added to the concatenated MSA. To exclude noise introduced
by pairs that only had one paralog each and thus were paired even though they do not
reside close on the genome, the alignment can be filtered for such distant pairs (e.g., pairs
with a genomic sequence distance greater than 1000 nucleotides). While this concatenation
approach is capable of including multiple paralogs of a species, which is especially useful in
protein complexes known to have multiple copies in each genome, it is unfortunately not
applicable to eukaryotic proteins due to the different genomic architecture.
Recently, several alternative algorithms have been proposed, that may help matching
multiple paralogs per species without simultaneous co-localization in the genome. These
methods are based on the assumption that correctly matched sequences also maximize the
inter-protein co-evolution signal and can thus be found through optimizing the co-evolution
score while testing all possible combinations of paralogs per species136. Especially for
proteins unique to only certain branches of the tree of life, such methods may further
increase the applicability of co-evolution in protein interaction determination, but the
computational complexity of this iterative optimization problem has so far hindered its wide
applicability136. Given that our work was mainly aimed at proving the general applicability
of co-evolution for protein complex determination, such more elaborate concatenation
strategies have not been evaluated in our work, but could be included in the future.
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After construction of the joint MSA, we employ several post-processing steps to ensure
a certain quality of the data included in model inference. These are mainly the exclusion of
positions with low sequence coverage (i.e., many gaps) and the clustering of sequences at a
certain level of sequence identity (usually in the range of 70 to 90%) to reduce redundancy.
Each sequence is then re-weighted in proportion the cluster size to reduce the individual
influence a redundant sequence has in the model inference step.
Statistical model
We built our pipeline on the previously established EVfold approach159,268,404 that is
described in detail in Chapter 2.6.
This global maximum entropy model is constrained by the observed conservation of
amino acids at single sites and co-conservation at pair-sites for a concatenated sequence σ
and is defined as
P (σ|h,J) = 1
Z(h,J)
exp(
N∑
i=1
hi(σi) +
N−1∑
i=1
N∑
j=i+1
Jij(σi, σj)) (3.2)
in which hi represents a vector containing parameters of the single site conservation and
Jij a 21× 21 parameter matrix constrained by observed pairwise amino-acid frequencies.
The h-vectors and J-matrices for all positions i, j in the sequence can then be inferred
using optimization approaches. In the context of protein co-evolution, these have mainly
been mean-field (MF) approximation268,291 and pseudo-likelihood estimation (PLM)15,95.
Due to its higher accuracy of predicted contacts95, we chose a modified implementation
of plmDCA95 for parameter estimation in the EVcomplex approach. We then obtained EC
scores for residues i and j by first shifting the Jij matrix for this pairwise site to zero-sum
gauge (J′ij), and then summarizing it using the Frobenius norm. The resulting score SFNij
was corrected for confounding bias using APC to obtain the final EC score SCNij .
SFNij = ||Jij ||2 =
√√√√ q∑
k
q∑
l
J′ij(k, l)2
SCNij = SFNij −
SFNi· SFN·j
SFN··
(3.3)
Scoring
Every pair of residues in each protein as well as each possible combination of residues
between the two interaction partners has an EC score, but given that most residues ac-
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tually do not interact within or between proteins, weakly coupled residue pairs should
be excluded from further steps. In monomer structure prediction, a rank-based approach
using an average of one to two constraints per residue combined with several biochemi-
cally motivated filtering-steps has been shown to be robust due to the large number of
constraints120,149,159,268. Reasoning that we only need a small number of inter-protein
couplings to constrain 3D complex prediction combined with the observation that the
co-evolutionary signal between proteins is usually weaker than within a protein, a stricter
inclusion approach is required for protein complex prediction.
It is further necessary to determine a score threshold at which two proteins will not
be considered interacting. While the shape of the score distribution is similar between all
proteins, the absolute value ranges are not. We thus developed the EVcomplex score Qij
to estimate the significance of the individual couplings while facilitating the comparison of
predictions between proteins.
This score is based on several observations regarding the general EC score distribution
(see Figure 3.3):
• The zero-sum gauge transformation in the EC score calculation step results in a
zero-mean distribution (yellow dashed line in Figure 3.3)
• Most couplings are weak, i.e. have a score close to zero (red dashed line in Figure
3.3)
• A one-sided tail of couplings with positive scores can be observed in the distribution
(see Figure 3.4 A)
• Couplings in the tail are more likely to be close in 3D space than those with a score
close to zero (blue line in Figure 3.3).
From these observations we reason that the large fraction of couplings in the middle
part of the distribution correspond to a symmetric Gaussian-like “background” distribution
containing non-interacting residue-pairs. Based on the assumption that the more a coupling
in the tail exceeds the boundaries of the symmetric background distribution, the more likely
it reflects true co-evolution of the residue pair, we quantify the raw EC reliability as the
ratio by which the EC score SCNij exceeds the noise level, i.e.,
Qrawij =
SCNij
|min
i,j
(SCNij )|
(3.4)
The accuracy of EC scores critically depends both on the number and diversity of
sequences in the input alignment and the size of the statistical inference problem192,267,291.
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Estimated background noise
min(EC)
Figure 3.3: EC score distribution illustrated for inter- and intra-EC pairs of the
methionine transporter complex, MetNI. Scores are zero-mean distributed (red dashed
curve estimating the Gaussian distribution fitted to the data). Couplings with a score
close to zero are less likely to be close in 3D space compared to those in the tail of
the distribution (blue line representing the proportion of couplings with a distance
less than 8 in the MetNI structure (PDB: 3tui)). This background noise is estimated
by a symmetric range around 0 with the width being estimated by the minimum EC
score.
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Figure 3.4: Evolutionary couplings capture interacting residues in protein complexes.
(A) Inter- and intra-EC pairs with high coupling scores above the background level of
the score distribution largely correspond to proximal pairs in the three dimensional
structure of the complex. For the protein complexes in the evaluation set, this distri-
bution is compared to the distance in the known 3D structure of the complex (shown
here for the methionine transporter complex, MetNI) (B) An increasing distance from
the background noise (ratio of EC score over background noise line) results in more
accurate contacts. Additionally, the larger the alignment the more reliable the in-
ferred coupling pairs are which then reduces the required distance from noise (different
shades of blue). Residue pairs with a minimum atom distance of 8 Å between the
residues are defined as true positive contacts, and precision = TP/(TP + FP). (Plot
limited to range (0,3) excluding the outlier histidine kinase-response regulator com-
plex (HK-RR) with extremely high number of sequences) (C) To compare different
protein complexes and to estimate the average inter-EC precision for a given score
threshold independent of sequence numbers, we normalized the raw couplings score for
the number of sequences in the alignment (EVcomplex score). In this work, inter-ECs
with an EVcomplex score ≥ 0.8 are used. Note: the shown plot is cut off at a score
of 2 in order to zoom in on the phase change region excluding the high sequence
coverage outlier HK-RR. (D) For complexes in the benchmark set, inter-EC pairs
with EVcomplex score ≥ 0.8 give predictions of interacting residue pairs between the
complex subunits to varying accuracy (8 Å TP distance cutoff). Reproduced from
Hopf et al. (2014)160.
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We therefore incorporate a normalization factor to make the raw reliability score comparable
across different protein pairs. This normalized EVcomplex score Qij is defined as
Qij =
Qrawij
1 +
√
Neff
L
(3.5)
where Neff is the effective number of sequences after the clustering step and L the length
of the concatenated alignment.
As can be seen from the normalization factor, this score will be close to the raw EC
score in the case of abundant training data while reducing the confidence in predictions in
cases of limited data for the model size.
Comparison of predicted and known complex 3D structure
Once the raw and normalized coupling scores are computed, the residues with the strongest
couplings within each protein can be used for structure prediction. To evaluate the pre-
diction performance, couplings can be compared to their pair distance in the 3D structure.
We calculated the precision (positive predictive value, PPV) of the couplings with a score
above or equal to a range of thresholds,
PPV =
TP
TP + FP
(3.6)
True positive (TP) couplings are here defined as those that are also close in the structure,
in respect to minimum atom distance between two residues, while couplings with a high
score, but large distance in 3D are considered false positives (FP). Following the general
consensus in the field residues with a minimum atom distance of 8 Å or less are considered
interacting between two complex subunits317.
Using top ranking couplings (with a EVcouplings score above a certain threshold),
monomer structures can be docked HADDOCK82. Residues with coupling scores above
the EVcomplex score threshold are implemented as unambiguous distance constraints on
Cα atoms in the docking protocol, with an effective distance of 5 Å (deff) and upper and
lower bounds of 2 Å.
In the HADDOCK procedure a series of models is generated (500/100/100 in each
of the following three steps: rigid-body energy minimization, semi-flexible refinement in
torsion angle space, and finally refinement in explicit solvent/water). The models are scored
by HADDOCK using a weighted sum of van der Waals and electrostatic energies (Evdw
and Eelec) together with an empirical desolvation term (Edesolv). The score would usually
also include a distance restraint energy term in the last iteration, that is excluded in our
evaluation protocol to allow comparison of scores between multiple runs.
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After obtaining the 3D model of the complex, we evaluated the agreement of the models
with experimentally determined structures. Following the CAPRI guideline for protein
complex predictions280, we focused on the binding interface for which we computed the
root mean square deviation (RMSD) of all heavy atoms in the protein backbone at the
interface,
RMSD =
√√√√ 1
N
N∑
i=1
δ2i (3.7)
The RMSD measures the average distance between a defined set of N atoms in two
superimposed structures. In protein structures comparison the Euclidean distance between
the atom coordinates is commonly used distance measure δ. While monomer structure pre-
diction is often evaluated based on backbone Cα atoms192,267,291, the CAPRI guidelines280
for the evaluation of the protein complex prediction focus on correctly modeling binding
interface between the interaction partners. Here, the interface is defined as all residues
with any heavy backbone atom (Cα, C,N,O) closer than 6 Å to any backbone atom in the
interacting protein280. The interface RMSD (iRMSD) was computed using Python and
ProFit v3.1 (available at http://www.bioinf.org.uk/software/profit).
Determination of interacting subunits in a macromolecular assembly
Co-evolution scores can also be used to predict if two proteins interact, through calculation
of the EVcomplex scores between arbitrary proteins. Based on the scores obtained in
the PPI evaluation data set, a reliability score threshold was determined to discriminate
between pairs that show co-evolution signals with high confidence and those that lack such
evidence: subunits with a maximal EVcomplex score greater or equal to 0.8 likely, those
between 0.75 and 0.8 as maybe interact, while interactions between subunits that had a
score below 0.75 could be rejected.
3.2.2 Data Sets
Validation and prediction data sets
The EVcomplex method was evaluated using a data set of known binary PPI in E. coli with
known 3D structure, compiled from yeast two-hybrid experiments and literature-curated
databases346. We further extended this data set with three additional pairs based on our
analysis of other subunits in the same macromolecular complex: ButC/BtuF, MetI/MetQ,
and ATP synthase subunits a and b. 3D structures of protein complexes in this set without
existing structural information were then predicted using the same protocol.
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As one of the two matching methods used to pair up sequences from the two protein
monomer MSA is based on genome distance, we filtered the original data set presented in
Rajagopala et al.346 to remove all pairs that are separated by more than 20 genes in the
E. coli genome (as determined by an ordered list of genes in the UniProt database64). We
then removed pseudo-homomultimeric complexes and annotated interaction homologs by
mapping the proteins in the set to protein families as defined in the Pfam database, and
then filtering those in which both partners were annotated with the same Pfam domain
as well as flagging pairs whose specific combination of Pfam domains was also observed in
other PPIs in the set.
The data set was then split into a validation subset with known structures and a
prediction set. To assign complexes to these two sets we combined the annotation of known
3D structures346 with a search for homologous structures in the PDB. First, each of the two
partners was used as a search query, then the results were intersected, keeping those where
both partners were found in the same PDB entry. We assigned those complexes whose
structures where only solved at resolutions above 5 Å to the prediction set (affecting eight
entries). This approach resulted in a final set of 93 non-redundant bacterial complexes
whose subunits are proximal in the genome for evaluation and a set of 32 complexes without
structural data.
Since the complexity of the model increases quadratically with the length of the query se-
quence, in multi-domain proteins we focused the protocol on interacting domains (informed
by the known 3D structures and assigned Pfam domains).
MSA generation
Multiple sequence alignments of the individual proteins were created by jackhmmer189 with
five iterations, a bit score domain inclusion threshold of 0.5 × L (where L is the length of
the protein) searching the UniProt database64. Genomic locations for the coding sequences
(CDS) were then retrieved for all members of the alignments from the ENA database320.
We then paired the sequences in the alignments of the two PPI partners using the matching
protocols described in Chapter 3.2.1. To compare the results to previous reports, we mainly
evaluated the performance of the distance-based matching approach. We further excluded
sequence pairs that had a genomic distance greater than 10 k nucleotides to avoid inclusion
of false-positive pairs.
We then clustered the paired sequences at 80% sequence identity and re-weighted them
according to their cluster membership. Those columns in the alignment that contained
more than 80% gaps were excluded from the prediction.
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3D structures of monomers
Three-dimensional structures of the complexes in our evaluation set were obtained from the
Protein Data Bank22. Further, out of the 22 complexes in the evaluation set that had five
or more inter-protein couplings, a diverse set of 15 was chosen for 3D complex prediction.
Where available, we selected unbound structures of the monomers in the docking step to
avoid overfitting and compared these to the 3D structure of the cognate complex. If no
unbound structures existed, we randomized side chain placement using either Schrödinger
Protein Preparation Wizard368 or SCWRL220 followed by a short optimization step in
Chimera339. We excluded domains that were reported to be highly flexible, namely the two
C-terminal helices of AtpE in the AtpE-AtpG interaction, the CA domain of histidie kinase
in the two-component signaling complex, and subunits 1 and 2 of COX 2 in ubiquinol
oxidase (here only in the docking evaluation).
Not all complexes in our prediction set had previously solved monomer structures. In
these cases, we predicted the 3D structure of the monomers using one of two strategies:
If a homologous structure existed, we created a comparative model of the structure in E.
coli using SwissModel27,34 (MetQ and IlvB). Alternatively, if no structure template for
comparative modeling was available, we built the structures de novo following the EVfold
protocols159,268 using PLM15,95 and sequence clustering at 90% sequence identity. This
was particularly the case for the subunit a of ATP synthase and UmuC.
Evaluation of interacting subunits prediction in a macromolecular assembly
We tested the usefulness of our co-evolution approach as a method to discern interacting and
non-interacting partners in larger protein complexes on the eight subunits of E. coli ATP
synthase F0 and F1 complex. For all 28 possible pairwise combinations we computed EV-
complex scores and considered the highest inter-monomer score as a proxy for the likelihood
of interaction. Predictions were then compared to observable interaction from the known
partial complex structure (PDB: 3oaa, 1ds0, 2a7u) as well as literature reports of interacting
subunits as determined by crosslinking, cryo-EM and other experiments37,75,275,379.
3.2.3 EVcomplex Webserver
We implemented the EVcomplex pipeline as a command line tool in Python that is
available through a webserver (www.evcomplex.org, source code available from https:
//github.com/debbiemarkslab/evcomplex_server). This webserver was built on top of
the pipeline using Python Flask356 as a low weight back-end following the common model-
view-controller design pattern, separating classes responsible for computations from those
delivering visualisations to the user.
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The front-end was implemented in HTML5, CSS and JavaScript, including the exten-
sions D3.js and jquery. Twitter bootstrap (http://getbootstrap.com) was used as the
main front-end framework due to its responsive and mobile first approach. The familiar
style of input elements also reduces entrance hurdle to new users. Interaction between back-
and front-end is facilitated through the Jinja templating engine357. For dynamic content
including long polling of currently active prediction runs in a constantly updating website,
we further incorporated the JavaScript framework AngularJS (https://angularjs.org/).
Past and active jobs are stored in a MySQL database. Each step in the pipeline as
described in Chapter 3.2.1, namely monomer homology search, alignment concatenation,
couplings prediction, post-processing and re-scoring, as well as comparison to known 3D
structures, if available, tracks its progress in the database and upon successful completion
the user is provided a view of the results. If the job fails in the process, the user will also
be informed of the event and the step at which the problem occurred.
We include and implement several visualizations of the data produced in the run to
support the user in his analysis, such as glyph-based sequence logos of the concatenated
alignment261 and contact maps displaying strongly coupled residue pairs within and between
the input proteins.
3.3 Results
3.3.1 Performance of the Algorithm on Known Protein Complex Struc-
tures
Of the 93 complexes in the our evaluation set, 76 had sufficient sequence data available to
allow EVcomplex predictions (minimally 0.3 non-redundant sequences per residue). For
this set we analyzed the relationship between the EVcomplex score and the precision of the
pair predictions compared to known structures. We observe that 53 out of the 76 complexes
had at least one inter-protein coupling with a score above 0.8 and that 69% of the predicted
pairs with a score above this threshold are accurate within 8 Å to the cognate complex
structure (Figure 3.4C). A small number of complexes showed more than 20 inter-protein
couplings with scores above 0.8 with precision over 80% (namely, histidine kinase and
response regulator, t-RNA synthetase, and vitamin B importer complex) (Figure 3.4D),
while 23 out of the 76 had no high-scoring coupling even though it is well known that the
subunits interact. Reasons for this are discussed in Chapter 3.4.
Contacts predicted with coupling scores below 0.8 are not necessarily false. Especially
those that cluster at the same interface as the contacts predicted with higher scores, can be
correct. In the ethanolamine ammonia-lyase complex, for example, three inter-contacts are
predicted above a threshold of 0.8 while five additional contact pairs with scores slightly
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below that threshold cluster with the contacts on the monomers, indicating their high
likelihood of being also correct.
On the other hand, as shown in Figure 3.4, not all inter-protein contacts with a
high coupling score are close in known structure models. This can be due to inaccurate
assumptions of the method in some cases, including the assumption that interaction is
conserved across paralogs and orthologs, as well as the assumption that co-evolution stems
from structural contact. It can be further the result of highly flexible assemblies that can
undergo large conformational changes of which only a subset has been captured by 3D
structures (e.g., the vitamin B12 transporter complex BtuCDF in the process of transporting
B12 across the membrane173).
Evolutionary couplings produce accurate three-dimensional complex structures
through docking
Protein-protein docking usually relies on predicted or experimental constraints that ap-
proximate the binding mode to reduce the search space of possible complex conformations
and produce meaningful results428. To evaluate the performance of ECs as constraints for
protein docking, we selected a diverse set of 15 protein complexes (Figure 3.5) with at least
five inter-protein contacts with an EVcomplex score above 0.8. We then generated 100
models per complex using ECs as distance constraints in HADDOCK82 . Additionally, we
also produced control models to assess the amount of information added to the docking
protocol by ECs (500 models per complex, no constraints except center of mass).
For 13 out of the 15 complexes, the top-ranked model obtained using ECs as HAD-
DOCK constraints had iRMDS under 6 Å when compared to their cognate structure, as did
the best-performing model in all 15 cases (Table 3.1). Overall, 74.4% of the 1500 generated
models using EC constraints are close to the experimental structures of the complexes (<
6 Å backbone iRMSD), compared to less than 2% of the 7500 controls. Not surprisingly,
complexes with a high number of true positive contacts showed the highest docking perfor-
mance, with a weak correlation between number of ECs and iRMSD (Pearson’s r=-0.28,
p=0.3) and TP rate and iRMSD (Pearson’s r=-0.48, p=0.068). For example, the 30S
ribosomal proteins RS3 and RS14 showed a precision of 0.91 for 11 ECs and an iRMSD of
1.1 Å for the top-ranked model.
In the methionine-importing transmembrane transporter complex, MetI interacts with
the ATP binding protein MetN. Overall, MetI-MetN had 14 inter-protein ECs with a
precision of 0.86 and an average iRMSD of 1.4 Å over all 100 models (1.5 Å for the top ranked
model, Figure 3.6A). The three top-ranking inter-protein ECs (K136-E108, A128-L105, and
R124-E74, MetI-MetN respectively) constitute a network coupling the ATP-binding pocket
in MetN to the open and closed conformations of the membrane transporter MetI186. Using
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Table 3.1: EVcomplex predictions and docking results for 15 protein complexes
EVcomplex
contacts
Docking quality
(iRMSD)
Complex name Subunits Seqs ECs TPrate
Top-
ranked
model
Best
model
ATP synthase  and γ subunits AtpE:AtpG 2.9 15 0.53 1.4 1.4
Vitamin B12 uptake system BtuC:BtuD 9.8 21 0.88 1.1 0.9
Vitamin B12 uptake system BtuC:BtuF 3.2 5 0.6 2.8 2.8
Carbamoyl-phosphate synthase CarB:CarA 2.3 17 0.88 1.9 1.9
Ubiquinol oxidase CyoB:CyoA 1 11 0.55 1.8 1.2
Dihydroxyacetone kinase DhaL:DhaK 1.4 12 0.42 6.7 2.4
Outer membrane usher protein/
Chaperone protein FimD:FimC 3.6 6 0.83 3.2 3
Aminomethyltransferase/
Glycine cleavage system H
protein
GcsH:GcsT 2.9 5 0.2 5.4 5.4
Histidine kinase/ response regulator
(T. maritima) KdpD:CheY 95.4 78 0.72 2.1 2
Methionine transporter complex MetN:MetI 1.9 14 0.86 1.5 1.2
Molybdopterin synthase MoaD:MoaE 3.6 8 1 4.4 4.1
IIA-IIB complex of the N,N’-
diacetylchitobiose (Chb) transporter PtqA:PtqB 3.1 5 0.2 7.2 5.5
30 S Ribosomal proteins RS10:RS14 1.2 6 1 5.3 2.5
30 S Ribosomal proteins RS3:RS14 1.4 11 0.91 1.1 1.1
Succinatequinone oxido-reductase
flavoprotein/iron-sulfur subunits SdhB:SdhA 3 8 0.62 1.4 1.4
Seqs = Number of non-redundant sequences in concatenated alignment normalized by alignment length,
ECs = inter-ECs with EVcomplex score ≥ 0.8, top-ranked model = iRMSD of model from known
structure, for docked model with best HADDOCK score, best model = lowest iRMSD observed across all
models.
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CyoA – CyoB EnvZ – OmpR
(homolog)
MoaD – MoaE
BtuC – BtuD DhaK – DhaL CarB – CarA GcsT – GcsH
Inter-EC
≤ 8Å > 8Å
FimC – FimD
RS3 – RS14
BtuC – BtuF
Blinded prediction of inter-protein contacts in complexes with known 3D structure
Figure 3.5: Blinded prediction of evolutionary couplings between complex subunits
with known 3D structure. Inter-ECs with EVcomplex score ≥ 0.8 on a selection of
benchmark complexes (monomer subunits in green and blue, inter-ECs in red, pairs
closer than 8 Å by solid red lines, dashed otherwise). The predicted inter-ECs for
these ten complexes were then used to create full 3D models of the complex using
protein-protein docking. Reproduced from Hopf et al. (2014)160
the docking protocol, this interaction network could be reproduced accurately in the 3D
structure (Figure 3.6A).
Nevertheless, the protocol also appears to be robust against a high number of false
positive constraints as both Ubiquinol oxidase (6 out of 11 constraints correct) and the ATP
synthase F1  and γ subunits (8 out of 15 correct) also resulted in top-ranked complexes
with iRMSDs of 1.8 and 1.4 Å, respectively. In ATP synthase F1, residue D82 in the 
subunit and R222 in the γ subunit together with high scoring intra-γ couplings connect
the  subunit to the core of the ATP synthase and its catalytic function which was also
reproduced in the docked models (Figure 3.6B).
Evolutionary coupling analysis thus not only identifies conserved residue networks, but
also adds significant information to the docking protocol. This results in an drastically
increased docking accuracy compared to center of mass docking (75% vs 2% correctly
docked models with and without ECs).
Strength of evolutionary couplings can help predict interacting subunits
After showing that ECs can successfully identify evolutionary interaction constraints be-
tween known interacting subunits of a complex, we asked whether it is also possible to
distinguish between interacting and non-interacting proteins based on the strength of their
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Figure 3.6: Evolutionary couplings give accurate 3D structures of complexes. EVcom-
plex predictions and comparison to crystal structure for (A) the methionine-importing
transmembrane transporter heterocomplex MetNI from E. coli (PDB: 3tui) and (B)
the gamma/epsilon subunit interaction of E. coli ATP synthase (PDB: 1fs0). Left
panels: complex contact map comparing predicted inter-ECs with EVcomplex score
≥ 0.8 (red dots, upper right quadrant) and intra-ECs (up to the last chosen inter-EC
rank; green and blue dots, top left and lower right triangles) to close pairs in the
complex crystal (dark/mid/light gray points for minimum atom distance cutoffs of
5/8/12 Å for inter-subunit contacts and dark/mid gray for 5/8 Å within the subunits).
Inter-ECs with an EVcomplex score ≥ 0.8 are also displayed on the spatially separated
subunits of the complex (red lines on green and blue cartoons, couplings closer than
8 Å in solid red lines, dashed otherwise, lower left). Right panels: superimposition
of the top ranked model from 3D docking (green/blue cartoon, left) onto the com-
plex crystal structure (gray cartoon) and close-up of the interface region with highly
coupled residues (green/blue spheres). Reproduced from Hopf et al. (2014)160.
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co-evolution signal. We chose ATP synthase as well characterized test case, even though
some aspects of its 3D structure still remain unknown (see Section 3.3.2). This macro-
molecule consists of eight subunits, of which five are located in the cytoplasm (α, β, γ, δ, )
and three are anchored in the membrane (a, b, c). ATP synthase is ubiquitous in all king-
doms of life and is essential in ATP production. To see if the EVcomplex score can be
used as a proxy for existing interaction, we calculated the EC and EVcomplex scores for
all 28 possible subunit combinations. Using the previously determined threshold of 0.8, it
was possible to correctly classify 24 out of 28 (86%) interactions. Furthermore, 80% of the
interacting residue pairs covered in the known partial crystal structure of ATP synthase
(PDB: 3oaa) were correct at 10 Å minimum atom distance.
The four interactions that are wrongly classified as not interacting at an EVcomplex
threshold of 0.8 can partially be restored at a lower threshold of 0.75, at the expense of
introducing two new false positives (correctly classified: β − b,  − c, now false positive:
β−c, δ−a). For some of the interactions in the complex, evidence diverges in the literature.
For these cases it is interesting to note that some are supported by strong ECs (e.g., α− 
and β − δ) while others lack this strong signal (β −  and γ − c, classified as false negative
in the statistics presented above). The interaction between β and  is a special case as can
be seen in the crystal structure of 3oaa that involves a highly extended conformation of the
last two helices of the  subunit into the enzyme that is not present in other structures. The
lack of a reasonably strong signal for this interaction could either result from the transience
of the interaction or a lack of conservation of this interaction across homologs (see also
Section 3.4).
Based on the high success rate of classification of interacting subunits we suggest
that EVcomplex and the EVcomplex score can be used on a larger scale for genome-wide
interaction predictions as well as identification interacting subunits in large complexes.
3.3.2 Novel Predictions of Protein Complexes
The data set of 3,449 E. coli PPI used to derive our evaluation and prediction sets346
did not contain any high-resolution structural information for 229 complexes in which the
interacting partners are close on the genome (subunits less than twenty genes apart). 82
of these complexes had sufficiently large and diverse concatenated sequence alignments
(Neff/L ≥ 0.3) and no known structure of interacting homologs. For these complexes we
predicted evolutionary couplings and after transforming the raw EC score into EVcomplex
scores for inter-protein couplings, 32 of the complexes had at least one inter-protein contact
with a score above 0.8.
Based on observations in the evaluation set that protein pairs with a high number
of contacts with a high confidence score tend to also have a higher proportion of correct
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Figure 3.7: Predicted interactions between the a-, b-, and c-subunits of ATP synthase.
(A) The a- and b- subunits of E. coli ATP synthase are known to interact, but the
monomer structures of subunits a and b and the structure of their interaction in the
complex are unknown. (B) EVcomplex prediction (right matrix) for ATP synthase
subunit interactions compared to experimental evidence (left matrix), which is either
strong (left, solid blue squares) or indicative (left, crosshatched squares). Interactions
that have experimental evidence, but are not predicted at the 0.8 threshold are
indicated as yellow dots. (C) Left panel: residue detail of predicted residue-residue
interactions (dotted lines) between subunit a and b (residue numbers at the boundaries
of transmembrane helices in gray). Right panel: proposed helix-helix interactions
between ATP synthase subunits a (green), b (blue, homodimer), and the c ring (gray).
Reproduced from Hopf et al. (2014)160
contacts in that set (Figure 3.4D), we evaluated some examples of such complexes with
several contacts above the threshold of 0.8 in the light of prior biological information. These
examples include subunits I and Q of the D-methionine transporter (MetI - MetQ), the
UmuC and UmuD complex of the E. coli stress response system, subunits a and b of ATP
synthase as well as small and large subunits of Acetolactate synthase (IlvB - IlvN) (Figure
3.8).
While the interaction between methionine permease MetI and the ATPase MetN of the
D-methionine ABC transporter has been evaluated in our benchmark set (Figure 3.6), the
interaction between MetI and the periplasmic methionine-binding protein MetQ281 is the
prediction with the highest number of strong couplings (24 contacts with score above 0.8).
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Figure 3.8: Evolutionary couplings in E. coli complexes of unknown 3D structure
(subunits: blue/green cartoons; inter-ECs with EVcomplex score ≥ 0.8: red lines). For
complex subunits which homomultimerize (light/dark green cartoon), inter-ECs are
placed arbitrarily on either of the monomers to enable the identification of multiple
interaction sites. Left to right: (1) the membrane subunit of methionine-importing
transporter heterocomplex MetI (PDB: 3tui) with its periplasmic binding protein
MetQ (Swissmodel: P28635); (2) the large and small subunits of acetolactate synthase
IlvB (Swissmodel: P08142) and IlvN (PDB: 2lvw); (3) panthotenate synthase PanC
(PDB: 1iho) and ketopantoate hydroxymethyltransferase PanB (PDB: 1m3v); (4)
subunits a and b of ATP synthase (EVfold-membrane model for subunit a, PDB:
1b9u for subunit b), and (5) UmuC (EVfold-model) with one possible conformation
of UmuD (PDB: 1i4v). Reproduced from Hopf et al. (2014)160
57
3. Predicting Protein Interactions using Co-evolution
All of the top 15 contacts between MetI and MetQ are located at the periplasmic face of
MetI and one interface of MetQ. The identified binding interfaces is thus consistent with
the known periplasmic binding of the two subunits.
As part of the bacterial stress/SOS response, UmuD is cleaved to form UmuD’2 which
then interacts with the DNA polymerase UmuC to copy damaged DNA25. Six out of
the seven ECs above the score threshold are co-located on the same face of the dimer.
Furthermore, while the location of the residues from inter-protein ECs are located in two
separate domains of UmuC, intra-UmuC ECs further support the spatial proximity of of
these residues, supporting the accuracy of the interaction interface.
Similar clustering patterns can be observed for the other predictions, thus adding
confidence to the prediction, showing that EC analysis can be capable of identifying
interaction interfaces in previously uncharacterized protein complexes.
Post hoc evaluation of predictions using recently solved complex structures
While the manuscript160 was in preparation, the previously unsolved structure of DinJ-
YafQ, a toxin/antitoxin complex was published (PDB: 4mlo239 and 4qlu359), allowing to
further quantify the accuracy of our predictions. We compared our predicted inter-protein
couplings to the 3D structure and found that 17 out of the 19 couplings with an EVcomplex
score above 0.8 have a minimum atom distance below 8 Å in the structure. When employing
our docking protocol (as described in section 3.2) to this structure, we further find that
the predicted complex agrees well with the solved structure (overall Cα RMSD of the best
model: 4.6 Å).
This post hoc analysis again demonstrates that our predicted inter-EC contacts agree
well with experimental data and the method is capable of identifying de novo interaction
patterns.
Prediction of residue details of subunit interactions in ATP synthase
While most of the 3D structure of ATP synthase is known436, some parts of this complex
remain elusive. Particularly, the interactions between the a, b and c subunits as well as
the monomer structure of a have not yet be solved experimentally. After the successful
evaluation of inter-protein EC predictions, including the correct identification of interacting
subunits in the overall ATP synthase complex, we moved on to predict details on the
interaction of the previously uncharacterized interfaces. There exists only a homology
model for the a subunit of the complex, developed in 1999 (PDB: 1c17350) based on
constraints obtained from mutation experiments. From these a model of transmembrane
helix (TMH) 2 to 5 was inferred. This topology was later supported by crosslinking data for
all possible combinations of helix pairs of TMH2 - TMH5381. To incorporate TMH1 into a
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model of the full a-subunit, we used the EVfold protocol for transmembrane proteins159.
The helix packing arrangement of the resulting model is supported by several crosslinking
data sets74,104,253 including the exact or near exact correspondence between the crosslinks
obtained by Schwem and Fillingame (2006)381 and the top-ranking intra-subunit ECs.
There is, however, only a weak coupling signal for TMH1 to the helical bundle suggesting
that this helix is not part of the bundle, again supported by studies that failed to detect
crosslinks between the first transmembrane helix and the four-helix bundle104.
We then predicted inter-protein ECs based on the previously established inter-protein
co-evolution protocol and detect ten high confidence contacts. All of these are between the
membrane helices (TMH1-3 and THM5) in a and the membrane-integral part of b. Again,
these interactions can be supported by crosslink data as they either directly correspond to
known cross-links or are in the direct neighborhood thereof74,75,253. Unfortunately, it was
not possible to construct an explicit 3D model of the a-b complex due to the conflicting
constraints between the individual helices in a to the b homo-dimer. It is thus necessary to
resolve these conflicting information in further work that may result from an intertwined
arrangement of the two subunits.
For the interaction between subunits a and c, we also analysed high confidence inter-
protein ECs and found that the top ranked inter-protein coupling is close to the known
interaction interface (aR201 - cD61)80.
While it was not possible to create a full three-dimensional model of the ATP synthase
a and b interaction at the time, our study still shows that it is feasible to add orthogonal
information to previous data. With more work on disentangling contradicting couplings it
may well be possible to reconstruct the full 3D structure of ATP synthase. This is supported
by two recent cryo-EM structures of bovine and L. pneumonia ATP synthase476,480 which
are consistent with the predicted ECs.
3.4 Discussion
In this chapter, we were able to show that it is possible to reconstruct PPI interfaces from
sequence information alone. The statistical approach presented here is based on a global
maximum entropy model that successfully detects direct co-evolution between residues
within and between two proteins. We were able to show that co-evolved residues between
two subunits are indeed close in the complex structure and can successfully be used as
constraints in protein docking to determine the correct three-dimensional structure of the
complex. We applied this approach to a set of unknown complexes for de novo interface
prediction. This work, together with an independent and parallel work by Ovchinnikov et
al.317 constitute the first generalized application of a global co-evolution model to PPIs.
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While the presented work can be seen as a proof-of-concept for several aspects of
co-evolution based predictions in the context of protein interactions, limitations remain.
Availability of sequence information
The dependence on large numbers of evolutionary related, but diverse, sequences is one
of the main limitations of the method and depends on two factors: i) the availability of
enough homologous monomer sequences in public databases and ii) the concatenation of
those to form a joint MSA. With the dramatic increase of available genome sequences, the
problem of finding sufficient numbers of homologs for each interacting subunit will likely
subside in the future. We hypothesize that once there are more than 10,000 (i.e., more
than ten times the concatenated length of proteins, on average) fully sequenced bacterial
genomes of sufficient diversity, it will become feasible to test all possible interactions in
a typical bacterial genome, and for those with strong evolutionary couplings infer the
three-dimensional structure of the complex.
For protein complexes that are unique to a single domain of life, the scenario is worse
due to the lower availability of sequence data. It is easy, though, to imagine targeted
sequencing efforts in a particular set of species to further such approaches. For PPIs with
a large number of paralogous interactions, but only present in a small number of species,
the matching of monomer sequences poses the largest limitation of our approach.
Correct matching of protein monomer sequences
As mentioned before, the accuracy of the proposed method depends on correctly matching
the found monomer sequences because each wrongly matched pair in the alignment adds
misinformation to the statistical model. It is evident from the results presented here that
sufficiently large sequence alignments result in more precise predictions of the interacting
residues. In this work we implemented two approaches to match the homologous sequences
of both subunits across multiple species: one based on the assumption that the two homologs
in a species with the highest sequence identity to the query proteins also interact with each
other; the other matching method is based on the observation that interacting proteins in
bacteria often reside on the same operon in the genome. It has been shown to be successful
in identifying multiple interaction homologs per species (e.g., multiple copies of the two-
component signaling and toxin/anti-toxin systems), but is not applicable to interactions
only found in eukaryotes due to the absence of operons in their genome architecture.
Solving the matching problem in general is not a trivial task because we usually do
not know 1) how conserved an interaction is compared to the monomer sequence, and 2)
which pairs of paralogs interact in a species. In the case of non-specific or promiscuous
interactions between multiple pairs of paralogs this task is further exacerbated as there
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exists no clear 1:1 matching. The effect of incorrect matching can be observed in the
prediction result as a strong (and correct) intra-protein co-evolution signal, while no strong
inter-ECs can be identified. This means that while co-evolution within proteins remains
detectable since it is independent of the sequence order in the alignment, the wrong pairing
of interacting sequences results in the loss of detectable couplings between the proteins.
There is still a demand for more elaborate sequence matching approaches that likely
require additional prior knowledge to optimally pair multiple paralogs even in non-bacterial
organisms. Several approaches can be envisioned that can either include further phyloge-
netic data, additional interaction predictions such as those described in Chapter 2.4.1, or
an iterative optimization approach that combines sequences matching with simultaneous
co-evolution detection. The latter has been tested recently by Gueudre et al.136. Here, the
authors hypothesize that the alignment that maximizes the inter-protein co-evolution signal
is most likely the correct one. While generally promising, this method currently has some
shortcomings. Detection of interacting proteins may be biased by initial assumptions that
the two protein families are indeed interacting as this served as the basis for maximizing the
inter-family co-evolutionary signal. The method is thus not suitable to predict if two pro-
teins interact in the first place. Secondly, the problem definition results in an exponential
search space in respect to the number of species in the alignment and a super-exponential
search space in the number of paralogs inside each species. The authors use a different
definition of the statistical model that allows determining heuristic solutions to the problem
in reasonable time, but further development is required to apply such approaches in the
EVfold and plmDCA based framework suggested here.
In other cases, such as cross-species contacts involved in pathogen-host or antibody-
antigen interactions, currently no general matching strategies exist, but the required paired
sequences may be obtained by targeted sequencing of specific specimen in a cohort of
infected individuals.
Discrimination between monomer- and homooligomeric signals
Another limitation of the proposed method is that it is not capable of detecting homo-
oligomeric interactions. In the case that a protein interacts with other copies of itself,
this poses an evolutionary constraint on the monomer sequence, which cannot be found
through our approach. Discriminating between homo-oligomeric inter-contacts and within
monomer intra-contacts has so far been mainly done based intra-contacts determined
from experimental monomer structures83,120,306,307. While this approach can be useful if
there exists structural data about the monomers, it cannot blindly discriminate between
those contact classes in the absence of any structural information. Possible strategies
in this context could include a folding strategy that simultaneously folds the monomers
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and assembles them, at the same time in- and excluding constraints to the two contact
classes based on observed clashes or energy changes of the resulting structures — similar
to approaches used to disambiguate constraints for structure reconstruction from NMR
and cross-linking data102,308. This approach may particularly be helpful in cases where the
monomer structure is not stable on its own and an intertwined assembly, such as the one
seen in many ion channels, is required to stabilize the complex.
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Chapter 4
Genetic Variation in Drug Targets
and Other Pharmacogenes
Parts of the content of this chapter have also been published in the following article:
Genetic variation in human drug-related genes 371
4.1 Introduction
About three in five Americans aged 20 and above take prescription drugs every month199
and many either encounter adverse events or reduced treatment effects230,374. In addition
to environmental factors and heterogeneity of the disease, the genetic markup of the patient
is expected to contribute substantially to the effectiveness of treatments through variants
in drug metabolizing enzymes and drug targets260 that affect the drug’s PK and PD profile
in the patient341. The identification of genetic determinants of drug efficacy and toxicity
is thus of large interest for the development of effective medicines246, to optimize dosing,
and minimize side effects for the patient.
The advent of affordable genotyping of patients has resulted in the rise of PGx studies
searching for such determinants260 in population stratified282,311,468 or individualized set-
tings258,341. Population genetics studies investigating drug-related genes have so far mainly
focused on a limited set ADME pharmacogenes44,114,218,287,459 in smaller patient cohorts
(Supplementary Table E.1). Geographic ancestry was only considered in few studies and
was mainly derived from either two different American populations or five global super-
populations in the 1,000 Genomes Project63. Overall, differences in AF between populations
could be observed in all studies that considered geographic ancestry90,114,218,459, indicat-
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ing the need to overcome annotation bias and extend study cohorts to better represent
populations of Non-European descent.
Even though early PGx studies have mainly focused on genes of particular interest for
PD or PK, larger GWAS have recently been able to identify PGx variants in a less biased
manner70,296. Much of the current knowledge on genetic variation and drug response is
summarized in PharmGKB453, but the majority of drugs are missing PGx information.
The extent to which genetic variation affects drug response can be illustrated by the
class of anti-hypertensive drugs, now taken by a quarter of all adults in the US199, where
over 200 publications have reported PGx variants in close to 250 different genes (https:
//www.pharmgkb.org/disease/PA444552, accessed 09/03/18). Most of these variants only
have a small effect256, but the analysis of drug target-associated variants in addition to
other PGx genes has shown promise to predict part of the treatment response123. Such
connections between polymorphisms in disease genes/drug targets include two common
functional variants in the β1-adrenergic receptor (ADRB1, Ser49Gly and Gly389Arg) that
are linked to different responses to channel blockage by beta-blockers187,248,401.
Translation of known PGx factors into clinical prescribing has only taken place for a
few drugs, many of which are targeting cancer and cancer-type specific somatic mutations,
such as the anti-HER2/neu antibody trastuzumab (trade name Herceptin) for breast can-
cer167,396. The dosage of few other medications is already based on genetic variants in the
patient. In the case of the commonly used anticoagulant warfarin, taken by roughly 1.5%
of the US population, the correct dosage depends on the haplotype of the metabolizing
enzyme CYP2C9 as well as variants in the drug targets VKORC1 and PROS. Roughly
40% of the variation in dosing requirements of patients can be attributed to variants in
these genes191 leading to the development of genotypic dosing regimens188 and a range of
dosing algorithms115,212,250 to avoid detrimental side effects such as major bleeding and
death.
These examples show that PGx knowledge has the potential to be translated into
treatment benefits for the patient. In this chapter we show, that most genetic variants seen
in drug-related genes remain unstudied, however, and many more studies will be required
to complete our knowledge.
Goals of the Project
The goal of this project was to create an inventory of the extent to which drugs and
drug-related genes are affected by genetic variation. We focus on genetic variation in
known drug-related genes, namely drug targets and ADME genes to 1) determine the
amount of genetic variability due to common and rare polymorphisms in pharmacogenes,
2) investigate how much an individual in the average population is at risk of containing
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functional genetic variants that may affect drug action, and 3) quantify how much this risk
may change depending on geographic ancestry and drug.
Ultimately, the effect of genetic variation in pharmacogenes is just a proxy for the
extent to which a drug’s efficacy may be affected by altered PD or PK properties. Since
the MoA for many drugs depends on the modulation of several cellular targets (Chapter
2.2), this required the development of a drug-centered summary score that combines the
risk of all molecular drug targets.
We then mined a data set collating genetic variants found in 60,706 patients236 for
those drugs that showed the highest risk for being affected by functional variation in their
drug targets either in the overall population or in particular subpopulations.
4.2 Materials and Methods
4.2.1 Data Sets and Data Preparation
To study the prevalence of genetic variation in drug targets and other pharmacogenes, we
utilized the reported genetic variants and their respective AF in ExAC236 for the total
cohort and for different ethnic subgroups. Based on the assumption that especially variants
resulting in the non-functional transcripts (including LoF) will also show an effect on drug
efficacy, we focused on the set of variants in our data set that were predicted to elicit such
an effect.
ExAC release 0.3 was downloaded as a variant call format (VCF) file from the project
website and variants were filtered for quality, only retaining those passing the QC filter.
The VCF file was annotated using Variant Effect Predictor (VEP, release 83) using the
standard annotation features including SIFT and PolyPhen annotation of coding variants.
We then selected only the canonical transcript for further consideration. A variant was
classified to affect the function of a protein (short non-functional) if it fulfilled one of the
following criteria:
• PolyPhen prediction probably damaging or possibly damaging and SIFT predic-
tion deleterious,
• ExAC provided LoF prediction: high confidence
We further excluded variants whose locus was not observed at least once in each sub-
populations (AN > 0, for all populations p with p ∈ (AFR, AMR, SAS, EAS, FIN, NFE))
and in less than half of all alleles in the population.
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4.2.2 Cumulative Allele Probability of a Gene
We then calculated the cumulative allele probability (CAP) for observing one of a set of
non-functional variants in a gene on the population scale based on the reported AF of these
variants in the ExAC data set. The AF corresponds to the probability of observing a vari-
ant allele in the population (P (allele A) = AF (A)). Using standard frequentist statistical
approaches, the overall probability of observing one of multiple independent events is com-
puted by multiplication of the probabilities of observing any of the events. The probability
of not observing any variant allele in a set of alleles A = (variant a, variant b, variant c, ...)
in gene g for an individual i can thus be calculated as
Pref(g) =
∏
v∈A
(1−AF (v))2 (4.1)
From this we computed the cumulative allele probability, that is the probability of at
least one variant allele occurring in the gene on at least one chromosome as
CAP(g) = 1− Pref(g) (4.2)
While these probabilities can be computed for arbitrary set of alleles in a gene g, we
focused our analyses on non-functional variants, if not otherwise noted.
4.2.3 Probability of Observing a Variant in a Gene Set
For some analyses we grouped genes into larger sets associated with a particular property,
e.g., all drug targets for drug d. To estimate the likelihood of an individual to carry at least
one non-functional variant in this set of genes G, we further extend the statistic approach
above to combine multiple genes, to a drug risk probability (DRP) for drug d with genetic
targets G, defined as
DRP(d) = 1−
∏
g∈G
Pref(g) (4.3)
Comparison of Non-Functional Variants Across Populations
To investigate whether there is a difference in prevalence of non-functional variants in drug
targets, we compare the probabilities for observing such variants and the resulting gene
sets per drug between the human populations included in the ExAC dataset. Comparison
is done using risk ratio (RR), and absolute risk difference (RD).
We calculate the risk ratio based on the probability of containing non-functional variants
between the population exhibiting the minimal risk (group 1) and the maximal risk (group
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2) for containing such a variant in a drug target. A RR of one means that the risk in both
groups is identical, while a value smaller than one means that members of group 1 are
RR-times less likely to have a non-functional variant in the gene or gene set that group 2.
RR =
DRP(group 1)
DRP(group 2)
(4.4)
The disadvantage of ratio-based measures is that the absolute magnitude of the risk is
not considered. To focus on genes with an overall high risk of containing functional variants
we also compute the absolute risk difference,
RD = |DRP(group 2)−DRP(group 1)|. (4.5)
4.3 Results
4.3.1 Genetic Variability of Drug-Related Genes Across 60K Individuals
Drug-related genes and non-functional variants
First, we investigated the extent of all non-synonymous genetic variants for 806 drug-related
genes collated from DrugBank232 and other sources114,218 in the 60,706 human individual
exomes from ExAC236 (Figure 4.1): the AF distribution of non-synonymous variants in
drug-related genes is almost identical to that of all genes in ExAC (n=17,758) with 97.5%
being rare (AF < 0.1%236) (Figures 4.1, 4.2). When filtered for variants with a negative
effect on protein function, 98.7% of the 61,134 non-functional variants in drug-related genes
are rare.
Nevertheless, 43% of the drug-related genes with predicted non-functional variants have
at least one non-functional variant with AF ≥ 0.1%. The drug-related genes with the most
frequent non-functional variants are membrane transporter genes related to drug eﬄux
and uptake such as ABCB5 (three LoF, six damaging), SLC22A1 (nine damaging), and
SLC22A14 (eight damaging). In the clinically highly important polymorphic cytochrome
P450 enzyme CYP2D6 also eight damaging variants have been identified. Since the ExAC
cohort contains an order of magnitude more individuals than previously available, it also
allowed us to identify genes with many different non-functional variants even though each
variant may be individually rare. The ADME genes with the most non-functional variants
per residue reflect similar findings from smaller cohort studies and include the glutathione
S-transferase sodium/bile transporter SLC10A1 (0.36 variants/residue), GSTA5 (0.31 vari-
ants/residue), and some cytochromes P450s such as CYP1A1 (0.30 variants/residue) and
CYP2C19 (0.28 variants/residue)218. Furthermore, our analysis revealed drug target genes
with comparable numbers of non-functional variants per residue including the dofetilide
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Figure 4.1: Analysis of genetic variation in drug-related genes. A) The analy-
sis pipeline was based on exome data from ExAC236, drug-gene relationships from
DrugBank232, and prescription information86, followed by filtering steps and subse-
quent computational analysis to investigate drug-specific risks of pharmacogenetic
alterations in patients. B) Comparison of the allele frequency distribution between
non-synonymous variants of all human genes covered in ExAC (n=17,758) and non-
synonymous variants in drug-related genes (n=806). C) Comparison of the allele
frequency distribution between non-functional variants as predicted by LOFTEE259,
Polyphen-24 and SIFT303 and all non-synonymous variants in the drug-related genes.
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Figure 4.2: Distribution of variant properties by gene in the non-synonymous subset
of the ExAC collection. From left to right: fraction of variants in each gene with allele
frequencies (AF) below 0.1% for all genes compared to drug-related genes; fraction of
variants in gene without corresponding entries in dbSNP, thus deemed novel; fraction
of variants that result in the complete loss of the protein product (LoF) in the full
data set; fraction of variants in gene that are predicted to be non-functional (LoF or
damaging as predicted by SIFT and PolyPhen).
target KCNJ12 (0.31 variants/residue) and the target for the rheumatoid arthritis drug
niflumic acid, PLA2GLB (0.30 variants/residue).
While both metrics described above may be useful to evaluate the extent of genetic
variation in the human population, they do not quantify the risk of an individual person
in the population to carry non-functional variants in a particular gene. Amongst the genes
with the highest probability of being affected by a non-functional variant, as computed
by the CAP score, are both, ADME genes and drug targets. The ADME genes with the
highest CAP scores include NAT2 (81%, involved in metabolizing arylamine and hydrazine
drugs), CYP2D6 (59.6%, involved in the metabolism of 20% of most prescribed drugs in
the US474) and the transporter gene SLCO1B1 (26.0%, a high risk gene for simvastatin-
related myopathy/rhabdomyolsis295). The drug target genes with comparable high CAPs
scores include tyrosinase (TYR; 62.4%, targeted by the acne drug azelaic acid), the alpha-4
subunit of the GABAA receptor GABRA4 (53%, targeted by benzodiazepines) and F5
(20.1%, targeted by drotrecogin alpha which was withdrawn from the market due to an
unacceptably high number of adverse drug reactions) (Figure 4.3). The major proportion
of the CAP score for these highest “risk” genes derives from common genetic variants many
of which have been observed previously. Nevertheless, for many genes a non-negligible
proportion of the score is contributed by rare non-functional variants, which were identified
69
4. Genetic Variation in Drug Targets and Other Pharmacogenes
through the sufficiently large cohort size (lines in light purple and light blue in Figure 4.3,
respectively). In addition, we estimate that more than 60% of the drug-related genes in
our set are putative novel candidates for pharmacogenomic research, so far missing relevant
information from clinical studies453.
Cancer drug-target genes with many germline non-functional variants
Especially in cancer therapy, genetic variation in drug targets has been recognized to play a
crucial role for treatment success178,360. While some cancer drugs do not act in the tumor
tissue, the cancer drug’s primary site of action usually is in the tumor, whose genome
contains tumor-specific somatic variants as well as a subset of patient-specific germline
variants406. Information on somatic variants from tumor samples is thus increasingly used
to enable research on drug design and to implement stratified or personalized cancer therapy.
However, the patient’s germline genome is routinely masked in these tumor sequencing
analysis protocols178,360.We thus wanted to assess whether target genes of drugs used in
cancer therapy contain germline variants in the population that may affect the drug action
and may be missed by current analysis protocols. More than 15% of the drugs in this report
(193 of the 1,236) are used in oncology (as defined by the WHO ATC code458) and between
them have 163 gene targets. Several of these targets have high probabilities of having a
non-functional variant in the germline genome. For some of these targets the germline risk
directly corresponds to potential altered treatment effects. This is the case for the kinase
KDR (also known as VEGFR2 ) (CAP=25%), which is targeted by sorafenib and sunitib to
inhibit vascularization of the tumor site3. Other drug targets for cancer therapeutics with
high CAP scores include MAP4 (60%) and TUBB1 (30%) that are targets of paclitaxel,
MAP1A (42%) a target of estramustine, CD3G (39%) a target of muromonab and PARP1
(37%) a target of olaparib (Figure 4.3). Overall, 40 cancer drug target genes, including 34
target genes with kinase domains, show CAP scores >1%. For these examples, functional
germline variants are only relevant for treatment response if the tumor genome also carries
them. While there is not a complete overlap between both germline and tumor genome due
to loss of heterozygosity and other alterations in carcinogenesis406, our analysis suggests
that a large percentage of the population may contain non-functional variants in cancer
therapeutic targets in the germline that may carry over to the cancer genome and could
be easily overlooked by current sequencing analysis protocols.
Aggregating risk for non-functional variants in targets by drug highlights drug
candidates for future pharmacogenomics research
About 70% of the FDA-approved drugs analyzed here do not have any pharmacogenomics
data associated with them in public repositories453. However, our analysis shows that there
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Figure 4.3: Drug-related genes with highest probability of having non-functional
variants. A) Protein-centered cumulative allele probability (CAP) scores for the 100
drug targets with highest scores (purple) and the contribution of CAP scores as
determined from rare variants alone (light purple). a1) Top 20 target genes with
highest CAP score, a2) Examples of target genes with lower CAP scores, B) 100
ADME-genes with highest CAP scores (blue), and the corresponding CAP score
determined from rare variants alone (light blue). b1) Top 20 ADME-genes with
highest CAP scores, b2) Examples of ADME-genes with lower CAP scores. Bubble
size corresponds to the number of non-functional variants observed for the respective
gene.
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are many non-functional variants in their target genes (Figure 4.4). To estimate how much
each drug can be affected by non-functional variants in its target genes and to highlight
possible candidates for future research, we computed the DRP for these durgs. For all
FDA-approved drugs considered here (n=1,236), 43% have a DRP greater than 1%. The
DRPs are weakly correlated to the number of targets (linear regression, r2 = 0.28), leaving
many drugs with few targets but higher than expected DRPs (determined by root mean
square errors, short RMSE, of the model). For instance, one of the two human targets of
azelaic acid, tyrosinase (TYR) is highly mutated in the population causing a DRP of 62.5%
for this drug, which results in an RMSE of 0.34.
Drugs with the top DRP scores are paclitaxel and docetaxel (82%), quinacrine (70%),
azelaic acid (63%), triazolam and other benzodiazepines (>50%). This means that any
individual in the population has a probability of more than 50% to carry a non-functional
variant that may affect the medication outcome of these drugs. Several of the drugs with
high DRPs are considered “essential medicines” by the WHO382. In addition to paclitaxel
and docetaxel, these include the opioid methadone (13.6%), the diuretic amiloride (11.7%),
and the local anesthetic lidocaine (11.4%). For instance, the drug methadone targets the
D- and M-type opioid receptors (OPRD1, OPRM1 ) and whilst some non-coding variants
and a single coding variant (rs1799971) have previously been associated with required dose
adjustments and treatment response, we observe another 132 non-functional variants in
these target genes, which could therefore be candidates for further testing. Since variants
with predicted damaging effects dominate especially the rather high DRPs, we filtered the
variants for only those resulting in LoF. Restricting to these high confidence variants, the
DRP decreases below 10% and the drugs with the highest DRP include the anti-cancer
drug marimastat (8.3%), the anti-ulcer medication sulfacrate (8.2%), the anti-flu drug
oseltamivir (6.0%) which targets human CES1 for activation, and several liptins used for
diabetes that inhibit DPP4 (5.6%).
Commonly used drugs have high probability of a non-functional variant in their
targets
We then focused our analysis on the top 100 most prescribed medications in the US (from
201386) which results in a list of 77 unique drug compounds for further investigation.
42% of these drugs have a DRP score greater than 1% of containing a non-functional
variant and the probability of an individual carrying a non-functional variant in any of the
targets for these 77 top prescribed drugs is 81%. For some of these drugs it is already well
established that there is some genetic component to drug response, even if the details are
debated28. For instance, five of the top fifteen most prescribed drugs in the US are asthma
drugs (budesonide, salbutamol, salmeterol, fluticasone, and tiotropium). Whilst each of the
72
Results
Functional-variants in targets of 1,236 FDA approved drugsA
Warfarin target: VKORC1B C Docetaxel target: TUBB1
novel
R53S
known 
D36Y
Warfarin Mutation sites
novel 
R307C
known
Q43P
novel
R359W
151
with variants in
other genes
132
with variants in their
target genes
(238 variants)
Documented association of genetic 
variation with altered response for
1,236 drugs
93
with only
non-coding variants
862
without
data
Functional-variants in drug target genes 
in 60,706 individuals
42,024
variants in drug targets
for previously undocumented
drugs
4,750 additional variants in
target genes with documented
association
14,360 variants in
target genes for drugs with
documented association
in other genes
Docetaxel Mutation sites
Figure 4.4: Knowledge gap between observed genetic variants in the population and
documented pharmacogenomics data. A) Availability of documented pharmacogenetic
associations for 1,236 FDA-approved drugs in public repositories such as the Phar-
mGKB database453 (left), is less abundant than non-functional variants observed in
the population for the drug target genes (right). B) and C) Examples of known and
novel genetic variants (green) in the target genes of warfarin and taxanes that could
affect drug efficacy due to effects on the binding site (ligand highlighted in purple).
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DPRs is not particularly high (ranging from 0.06% to 0.25%), their widespread prescription
rate (> 100 million prescriptions in 2013) still results in thousands of individuals who
may be affected by a non-functional variant. Similarly, statins (e.g., atorvastatin and
rosuvastatin) are prescribed to nearly one in five adults in the US199 and primarily target
HMGCR. Due to genetic variation in this target gene statins have a DRP of 0.18%. This
means that of the 40 million individuals who are prescribed a statin in the US, more than
80,000 individuals could be at risk of altered pharmacodynamics of statin treatment due
to a non-functional variant in the target HMGCR. This finding is underlined by previous
pharmacogenetic studies showing that HMGCR is the most important polymorphic gene
for treatment success of statins53.
Overall, the genetic-variability of drug targets of many of the top 100 prescribed drugs
has not been systematically annotated so far (Figure 4.5), including the Alzheimer’s drug
memantine (DRP=7.2%), the pain-medication acetaminophen (DRP=4.7%) and the proton-
pump inhibitor esomeprazole (DRP=3.1%) that all have high DRPs. While these drugs,
to our knowledge, do not have known associations between non-functional variants in drug
targets with drug action, clinical studies show that certain proportions of patients treated
with them do not respond to treatment. The extent of this non-response is reflected by the
number needed to treat, NNT437. For instance, for every one patient successfully treated
for Alzheimer’s diseases with memantine, between two and seven patients do not respond
to treatment251 (NNT=3 to 8). Similarly, the NNT for acetaminophen and its indication
of pain is five290 and for esomeprazole and reflux disease is 54117.
4.3.2 Human Ancestry and Drug Targets
Drug-related genes show geographic difference in genetic variability
Individuals with different geographic ancestry carry genomic variants with different fre-
quencies150. The six populations differentiated in ExAC are African, South Asian, East
Asian, Finnish, Non-Finnish European, and the Latino236). About half of all non-functional
variants in drug-related genes (M = 54%, SD = 15.2%) are unique to only one of the six
populations and only 0.1% of non-functional variants occur with an AF ≥ 0.1% across
all populations. Consequently, this results in drug-related genes that have a high risk of
non-functional variants depending on geographic ancestry. For instance, using a cutoff of
CAP > 1%, we found that 231 drug-related genes have functional variants in the cohort
of European ancestry compared to 298 genes with functional variants for the cohort of
African ancestry.
Nevertheless, 114 drug-related genes showed a CAP score above 1% in each population
indicating that there are genes with a similar world-wide pharmacogenetic relevance. Not
surprisingly, among those genes with the highest difference in CAP score between popula-
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Figure 4.5: Fractions of the top 100 most prescribed drugs in the US that have
established pharmacogenomics data documented in PharmGKB, either for genes doc-
umented to be the drug’s pharmacological target in DrugBank (purple) or other genes,
such as those related to drug ADME.
75
4. Genetic Variation in Drug Targets and Other Pharmacogenes
tions are many cytochrome P450s and phase II enzymes, as noted in previous studies of
smaller population sizes114. Similarly, we observe drug target genes with markedly different
CAP scores across populations. Among the target genes with the highest absolute CAP
score difference are VWF (which is targeted by antihemophilic factor), SIRT5 (targeted
by suramin for treating sleeping sickness), and the gastric lipase LIPF (targeted by orlistat
for obesity treatment). The latter has 65 non-functional variants and the most frequent
variants differ especially between African and East Asian cohorts (CAP 8% vs 51%). Target
genes with high subpopulation differences also include several targets for antineoplastic
agents, such as the olaparib-target PARP1, for which the CAP score ranges from 10.2%
in patients of African ancestry to 69.6% in Latino patients. While the efficacy of olaparib
depends on the tumor genome and not the germline, the risk to carry germline-originated
variants in the tumor should not be ignored. We also observed population differences in
the nucleoside transporter SLC28A1. While the CAP score is 4% in Non-Finish Europeans,
individuals with an East Asian ancestry have a risk of 60%. Interestingly, several variants
in SLC28A1 have been associated with different outcomes in non-small cell lung cancer
and breast cancer402,457 when treated with gemcitabine, suggesting that variant differences
across the populations may be involved.
Analysis of the DRP score reveals a population-specific risk for several drugs
Of the 1,236 FDA approved drugs considered, 241 have more than 10% absolute difference
in DRP scores between at least two sub-population cohorts and 24 of these have more than
30% DRP difference. Out of this subset of drugs, 11 belong to the 100 most prescribed
drugs in the US and 28 are recommended worldwide by the WHO for their therapeutic
use, including oxcarbazepine, amobarbital and dolasetron. 312 of the 1,236 drugs have a
high risk (DRP>1%) in all six sub-populations (Figure 4.6A, and the DRP top 20 drugs
stratified by population are illustrated in Figure 4.6B).
Well-known differences, such as response to disulfiram (treatment for chronic alco-
holism), are recapitulated in the data (Figure 4.6). Specifically, the genetic variant E487K
in the disulfiram target ALDH2 (rs671) is seen in the ExAC East Asian population at
similarly high frequencies as seen in previous genetic studies98.
The different responses in the asthma-medication salbutamol and the blood-thinner
warfarin have been attributed to variants in their respective drug targets, including R16G
in ADRB2 (rs1042713) for salbutamol247 and 1639G>A (rs9923231) in VKORC1 for war-
farin319. Since the well-known response altering variants were not annotated by mutation
prediction software as non-functional variants, we did not expect to see the drugs appear
high in our ranked list of risk differences across the populations (see Discussion). Never-
theless, our analysis shows that salbutamol still has a high risk ratio between populations,
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Figure 4.6: Variability of drug risk probabilities across populations. A) Number of
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caused by 29 variants with a dominant contribution from one variant separating the individ-
uals of Finnish ancestry from African ancestry (rs201257377, N69S, AFFIN=0.01). To our
knowledge this variant has not been functionally characterized or previously associated with
salbutamol response. Similarly, we observe 19 non-functional variants in the warfarin target
VKORC1 that are population-specific, including a non-functional variant observed most
frequently in individuals of Non-Finnish European or Latino ancestry, (rs61742245, D36Y,
AFNFE=0.003, AFLatino=0.001), that has been previously associated with predisposition
for warfarin resistance252. However, 16 of the non-functional variants may be novel risk
factors including a non-functional variant primarily observed in individuals of East Asian
ancestry (R53S, ENST00000394975.2:c.157C>A, AFEAS=0.001). Using a recent protein
3D model69,387 of VKORC1, we mapped the R53S variant to the putative warfarin binding
pocket (Figure 4.4). Furthermore, analysis of co-evolution in the protein using EVfold267
shows that R53 is strongly coupled to other residues in the protein and changes in this
site are predicted by EVmutation161 to affect protein fitness due to epistatic variant ef-
fects. Together, this suggests that this mutation might be negatively associated to warfarin
binding.
Trifusal, a drug for stroke re-occurrence, targets four genes (PTGS1 (also known as
Cox-1), NOS2, NFKB1, and PDE10A) that together have more non-functional variants
in the African population than in any other population (DRPAFR=37%, Figure 4.6B).
This difference between populations is mainly due to a variant in NOS2, which occurs
in the population of African ancestry with higher than average frequency (rs3730017,
AFAFR=19% vs AFglobal=4%) and while not functionally characterized, has been associated
with protection against cerebral malaria423. In PTGS1, three non-functional variants
have allele frequencies above 0.1% in the cohort of African ancestry. The most frequent
variant (rs5789, L237M, AFAFR=0.5% vs AFglobal=1.7%) lies on the dimer interface and
has previously been associated with reduced metabolic activity of the enzyme234. A
second variant is an indel, which is predicted to result in the total loss of protein function
(AFAFR=0.3% vs AFglobal=0.02%). The effects of the third non-functional variant common
in the African cohort (rs139956360, E259A, AFAFR=0.2% vs AFglobal=0.02%) on enzyme
activity or drug binding is less clear from the three-dimensional structure of the protein
and would require further exploration. Since triflusal is prescribed for prophylactic use in
the same way as aspirin for stroke prevention, it is clearly worth further investigating the
effects of these observed non-functional variants.
4.4 Discussion
In this chapter, we analyzed the extent of functional genetic variation in drug-related genes
and its implication for 1,236 FDA-approved drugs in sequencing data of 60,706 exomes.
78
Discussion
We show that not only the risk of carrying non-functional variants in ADME genes, but
also in drug targets is high for any patient. For ADME genes this observation is in line
with previous studies90,218,459, but novel for drug-target genes. We observed non-functional
variants in 98% of the drug-related genes and at least one high confidence LoF variant in
93% of the genes. The prevalence of non-functional variants in drug-related genes is thus
higher than previously shown459. When considering drug target genes for the 100 most
prescribed medications in the US the probability of carrying at least one non-functional
variant is above 80% for each patient. Together with the high risk for clinically actionable
variants in ADME genes (estimated at 98%90) these findings indicate that genetic variability
may contribute significantly to observed differences in drug response between patients.
While individualized cancer therapies often focus on the somatic variants present only in
tumor tissue, we can show that functional germline variants, which are routinely masked out
in the analysis of somatic variants, are common in many cancer drug targets. By excluding
germline variants that the tumor inherited from its progenitor cell from cancer genome
analysis in the context of therapeutic decision-making may thus result in the oversight of
important determinants for treatment response or resistance development. To what extent
the tumor genome varies from the germline genome, is dependent on patient and cancer
type. Loss of heterozygosity, where the germline allele is lost in the disease progression
and copy number alterations can indeed result in drastic changes between genetic variants
observed in the normal tissue of a patient and the cancer255,406. The presented results
should thus be seen as a motivation to include all types of variants seen in the tumor tissue
for clinical decision making. The high prevalence of variants in systemic cancer therapy
targets, such as KDR for sorafenib, further indicates, that the germline variants of target
genes in addition to ADME genes could be of interest for clinical decision making.
Geographic ancestry is a well-established confounding factor for drug response, but few
drugs have been assessed in their efficacy across global populations. Even where clinical
trials have been carried out in different populations, particularly non-European and non-
Asian individuals remain understudied. By calculating risk probabilities for drugs and
different populations, we showed that the frequency of non-functional variants in drug-
related genes varies widely across populations. Even for drugs where population differences
in response are observed, additional patient groups may be at high risk of altered PD due
to genetic variants in drug targets. Especially for drugs commonly used around the world,
such as those on the WHO Essential Medicines list, this could result in large numbers of
patients with reduced drug efficacy in some, but not all, of the populations they are applied
in.
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Confidence in drugs-gene-associations
The analysis in this study relied on external data for drug variant annotation and drug-gene
associations. Even though it was possible to estimate the burden of functional variation in
drug-related genes and quantify to which extent individual drugs may be affected, there
remain certain limitations. First of all, even manually curated drug-target associations
and pharmacogenomics data are susceptible to spurious annotations. For example, some
subunits of the GABA receptors including GABRA4 are generally thought to give rise to
receptors resistant to classic benzodiazepines such as diazepam288, but have been annotated
as targets for benzodiazepines. Comparison to a different, independently curated set of
drug-target associations366 further shows that annotation of drug-target pairs does not
always agree.
Furthermore, to quantify the real risk for a drug, drug-specific ADME-gene relations
should be incorporated into the DRP calculation. For example, optimal warfarin dosing is
known to be dependent on variants in CYP2C9 in addition to VKORC1 188 and variants
in the ADME-gene UGT1A1 are documented to contribute to different responses to the
cancer drug irinotecan around the globe262. Unfortunately, comprehensive inclusion of
ADME-genes in the DRP calculations is currently not possible because sufficient data for
ADME-genes is lacking for most FDA approved drugs including the relative contribution
of each enzyme. Our DRP estimates thus probably still underestimate the drug-specific
risk of functional variation as well as population differences.
Variant effect prediction
The vast majority of variants in drug-related genes considered in this study has not been seen
previously and thus lacks validated knowledge about their functional impact on drug efficacy.
We therefore had to rely on predictions of their impact on protein function. The probabilities
presented are based on the assumption that the functional classification is correct and
represents enzyme activity or drug efficacy. The relative risk between genes is based on the
assumption that there has not been a significant bias in assessment when genes already
have known deleterious mutations. However, as all ML-based prediction tools, the software
used in this study for variant effect prediction has several shortcomings: they are usually
trained on biased sets of disease-causing variants only and have issues with circularity in
training and evaluation data134,161. Except from LOFTEE, which is specifically developed
to predict complete loss of protein function, the tools cannot distinguish between activating
and deactivating effects of variants. When assessing variants not for their immediate
pathological impact (for which the classifiers were originally developed), but overall effect
on protein functionality, this distinction could be crucial as it may also affects downstream
response to therapy.
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The discrepancy between observed and predicted functional effects can be illustrated
on the well-studied PGx variants in the anti-asthmatics target ADRB2 (R16G/rs1042713,
Q27E/rs1042714 and T164I/rs1800888) that all are classified as benign247,316. To alleviate
this problem, one could include additional prediction algorithms, which comes at the risk
of reduced specificity (in some cases more than half of all non-synonymous variants were
classified as non-functional218) as all currently available methods have their individual
drawbacks140. Reliable computational classification methods for variant effects on drug
response remain scarce due to insufficient training data140, but may arise in the future if
efforts are increased to create such data, for example using novel high throughput methods
such as deep mutational scans110,278. For the present study we chose a conservative
approach to variant annotation that requires the complete loss of the protein product,
which should have a marked impact on the drug, or the consensus prediction of two
independent prediction tools at the expense of missing some known variants. It is thus
likely that we underestimated the effect of the non-functional variants in our study.
Quality and availability of sequencing data
The use of whole exome sequencing data comes with the intrinsic limitation that only
variants in protein coding regions can be detected, potentially missing pharmacologically
relevant non-coding variants141 or larger structural changes of the genome. Furthermore,
even at low false-positive rates many called variants can be inaccurate389 and several
pharmacologically relevant gene families - namely CYPs, HLA and UGTs - are at high risk
for variant calling errors due to the complex genetic structure of their loci85,420. While
members of the cytochrome P450 family have indeed been found to be problematic in
short-read sequencing114, this does not apply for most other drug-related genes218,459. To
reduce the false-positive variant calls in our survey, we included only variants of sufficient
locus coverage and high quality.
Furthermore, the ExAC cohort, despite being very large in total, does not cover all
populations at equal depth236. The power to detect very rare variants thus differs by an
order of magnitude between the individual populations (from 0.01% AF for the Finnish and
East Asian populations to 0.001% for Non-Finnish European). Due to legal restrictions
in the underlying exome sequencing projects, sample-specific data including haplotype
phase is also missing in ExAC. Epistatic effects of variants could thus not be investigated,
even though they are known to exist. For example, while the single variant rs12248560
(CYP2C18*17) results in increased CYP2C19 activity, the combination with another variant
(rs28399504) is associated with LoF of the protein (CYP2C19*4B)218.
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Future implications
Many major medical institutions have started implementing genotyping protocols for pre-
emptive pharmacogenetic testing1,84,352. However, these usually focus on a small number
of ADME-genes90 and often only test a subset of established actionable variants using
microarrays384. While these arrays facilitate fast and cheap screening, we show here that
the vast majority of variants in drug-related genes seen in the human population is not
covered. We further want to motivate that the number of genes with pharmacogenomic
variants should systematically include genes implicated in drug mechanism even though
only very few examples in such genes have yet been characterized well enough to be part of
a dosing guideline. Furthermore, with allele frequencies below 0.1%, many non-functional
variants in drug-related genes are so rare that they cannot be observed in clinical trial
cohorts, but may contribute to adverse events or diffuse lack of efficacy post-marketing. In
the future, this should be considered in all phases of clinical drug development and the
effects of genetic variants in genes associated with PD and PK of the drug candidate should
be systematically characterized.
In conclusion, large-scale sequencing efforts can be used to identify and quantify the
extent of genetic variation in genes relevant for drug action and metabolism. Identification
of such variants is only the first step towards better treatment decisions. Newly identified
variants of pharmacogenomic importance require validation and ultimately updated dosing
guidelines. The development of quality-controlled and patient-centered software solutions
to combine available knowledge of pharmacologically actionable variants with a patient’s
genome as well as fast and accurate approaches (experimental and computational) to func-
tionally classify novel variants will thus be of high importance for a future of personalized
medicine.
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Chapter 5
Drug Repurposing using the myDrug
Network
5.1 Introduction
From a patient perspective, the identification of variants affecting drug efficacy and safety
is only one step towards better care: their main goal is to find the right treatment for
their disease. However, the loss of the molecular target for the standard of care drug due
to a genetic variant can result in resistance to that drug in that patient. In this case,
alternative therapeutic strategies have to be explored. Such alternatives could be derived
from identifying drugs with different MoA, but also from drugs repositioned from their
approved indication (drug repurposing).
Systematic drug repurposing has seen several success stories, particularly in cancer
therapy, and relies on a multitude of computational approaches (see Chapter 2.5 for a
detailed overview). While personalized medicine is moving into the clinic90, repurpos-
ing methods include patient-specific attributes through patient-specific expression pro-
files175–177,184,206,273,394. Genetic variation, another data type associated with personalized
treatment decision, has so for mainly been considered as a tool to identify new drug
targets349,365,439.
Goals of the Project
Because proteins in a cell do not act independently, we hypothesized that targeting proteins
interacting with genes in the PPI neighborhood of a disease protein can affect the disease
state. This project was aimed at developing drug repurposing methods that are based on
exploring this neighborhood. Our approach utilizes biological networks to identify drugs in
in the network-neighborhood of mutated genes and genes associated with a disease through
prior knowledge (neighborhood targets).
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The first goal of the project was thus to build a heterogeneous information network
(called myDrug HIN) by integrating data about drug structure and mechanism with curated
knowledge about diseases, cellular processes, and genetic variation. To describe effects of
genetic variants on diseases and drugs, we explicitly modeled genetic variation.
We then aimed at developing repurposing methods, formulated as edge prediction
problem in the myDrug network. Here we explored and compared a rule-based approach
using neighborhood targets and a machine-learning approach where different meta paths
between drugs and diseases in the network are used as input features for a Random Forest
classifier.
Related Work
Due to the high popularity of drug repurposing, several methods with similar approaches
have been published while this project was ongoing. One such approach also uses a
heterogeneous information network to train a logarithmic regression classifier to predict
novel drug-disease edges in a network154. This project has similar intentions as myDrug,
but is not targeted towards personalized medicine and focused on gene expression data.
Other resources whose data structure is similar to the myDrug HIN are chemProt211
and PHAROS305 in which disease genes are linked to manually curated drug-target pairs.
While chemProt implemented several GBA drug-target prediction algorithms211, PHAROS
was mainly mined for novel insights about global properties of the drug-target space314,366
and could serve as an additional source for the myDrug HINin the future.
5.2 Materials and Methods
5.2.1 Data Sets and Data Preparation
We built the myDrug data base from multiple data sources containing data about drugs,
their target genes, PPIs, genetic variants associated with disease or altered drug response
and protein domains (Figure 5.1, Supplementary Table E.2 and Supplementary Table
E.3). Data integration was performed using KNIME23 and Jupyter notebooks334 (available
at https://github.com/kohlbacherlab/mydrug). An automation script coordinates the
initial data download and pre-processing. The user can configure this script to adjust for
changing sources and user authentication for those resources that require it. After pre-
processing (data cleaning and identifier mapping), the data was imported into a relational
database. The imported data was then used to build an instance of the myDrug HIN as
a graph object and further transferred into a graph database for easy access. Both, the
graph object as well as the graph database instance of the myDrug HIN can be filtered and
queried in R or Python for subsequent analysis.
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Figure 5.1: The myDrug construction workflow. Data about different node types
including drugs, diseases and genes, were collated from multiple sources. Entity
identifiers were then mapped to create a unique set of nodes and edges. The resulting
data was stored in a relational database and used to build an instance of the myDrug
HIN in a graph database.
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Drug Data
Data about therapeutic compounds and biologics was downloaded from DrugBank (version
4.3)232. To allow later integration of other data sources, compounds were assigned internal
identifiers (mydrug IDs). Unique SMILES were created for each small molecule compound
using RDKit227. From the SMILES three different molecular fingerprints (Morgan, RDKit
and MACCS) were computed to create pairwise similarity measures between drugs (see
Drug Relations below for more information).
Disease Data
We included multiple disease dictionaries into the myDrug database due to their comple-
mentary advantages: i) Online Mendelian Inheritance in Men (OMIM)139 for diseases with
a strong level of genetic evidence, ii) International Classification of Disease (ICD) codes48
for a broad coverage of diseases known in humans, and iii) Disease Ontology (DO)375 as a
common ontology for a range of disease vocabularies. Cross-mapping between identifiers
was done using mapping files provided by DO, Orphanet449, the Unified Medical Language
System (UMLS)32 and supplemental data from network medicine studies121,235,323.
Gene/Protein Data
The HUGO Gene Nomenclature Commitee (HGNC), as the global authority for a stan-
dardised human gene nomeclature128, provided the base set for gene and protein data.
Protein-coding genes were annotated with information from the UniProt database64 and
protein domain-information from the high confidence subset in Pfam (Pfam A)106.
Pathway names and the gene sets comprising these pathways were extracted from
KEGG pathway xml files198,312.
Variation Data
Allele frequencies and variation effect information of genetic variants in human genes was
obtained from ExAC236. Furthermore, variants from dbSNP388 with implications in disease
or pharmacogenomics were included.
Drug Relations
Several types of relations involving drug compounds were integrated in the myDrug resources:
• Molecular Similarity: drug-drug edges for small molecule drugs with RDKit-
fingerprint-based Tanimoto similarity > 0.85
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• Pharmacokinetic Interactions: drug-gene interactions implicated in drug mecha-
nism were obtained from the DrugBank232 xml file and the IUPHAR “interactions”
table385
• Drug Indications: drug-disease links from TTD465, pharmacotherapyDB154, MEDI444
• Drug-Related Variants: drug-variant links for pharmacogenomic associations from
PharmGKB anntotation files453. Only associations labeled significant by PharmGKB
were included in the myDrug HIN.
Disease Relations
Genetic information about disease etiology was added using OMIM, CTD and orphanet.
Pharmacologically relevant associations between diseases and genes were further incorpo-
rated through TTD and CTD, but these partially stem from transitive closure of drug-target
and drug-disease associations465 and may thus contain noise. Specific disease-variant edges
were extracted from ClinVar228 and the GWAS Catalog450 (with p-value < 5× 10−8 and
not classified as “benign”).
Gene and Protein Relations
Sequence similarity-based protein-protein links were included from SIMAP211 for all pairs of
proteins in the Uniprot database. In addition to that we included pairwise PPI information
from KEGG (parsing the individual pathway xml files), STRING database111, and Pathway
Commons50.
STRING contains protein associations from co-expression data, high and low throughput
protein interaction experiments, literature mining and protein homology. A connection of
two proteins/genes is associated with a confidence score, ranging from 1.0 (total confidence)
to 0.0 (no confidence). We filtered the full data set to only contain high confidence
associations (score ≥ 0.7) that showed up in at least two of the following channels: low
throughput databases, high throughput databases, text-mining and co-expression.
Variants falling into coding regions or adjacent UTRs of a gene were linked to these
genes using dbSNP identifiers and myvariant.info461.
Domain Relations
Protein domains were linked to genes using the human proteome data set from the Pfam
FTP server106. To link drugs to protein domains, we extracted ligand binding sites from
protein 3D structures in the PDB22 (minimal atom distance of protein to ligand of 4Å)
and mapped them to Pfam domains using SIFTS429.
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Identifier Mapping
Drug IDs were mapped to mydrug IDs via DrugBank IDs, where available, and otherwise
through name and synonym mapping. For MEDI, we used drug SMILES from chem-
spider455 using the Python module chemspipy411 and matched them using RDK-based
canonical SMILES. Diseases were mapped using the ICD system (for TTD and MEDI) or
DO terms (pharmacotherapyDB) using KNIME.
Variants were required to contain a dbSNP identifier (thus excluding structural variants)
and diseases were mapped to the three supported vocabularies either using the Experimental
Factor Ontology (EFO) for the GWAS catalog or using mapping files in the case of ClinVar.
Ensembl protein IDs were mapped to HGNC through the STRING alias file, my-
Gene.info460 and biomart398 queries.
5.2.2 myDrug Database
The pre-processing step converted the data after identifier-mapping into structured data
tables that were stored in a relational database implemented in MySQL. Here, we retained
meta-information about the original data sources as columns in the database tables.
We used the Python package SQLAlchemy19 to fill and query the MySQL database.
Update Protocol
The myDrug database can be updated through a complete re-population in which current
releases from all source databases are downloaded, mapped, and stored as text files. These
can then be imported into a new version of the database.
Each of the included databases has their own update schedule ranging from weekly
(ClinVar, OMIM) to sporadic (DrugBank) to never (MEDI). To balance the overhead of
extracting and unifying the data from the individual sources with the higher precision
obtained by the most up-to-date version of the underlying databases, we suggest an update
cycle that follows that of most included sources, which is at least once per year, but this
can be adjusted as needed.
5.2.3 myDrug Network Construction
A heterogeneous information network GmyDrug was defined as the directed graph GmyDrug =
(V, E) with vertex set V and edge set E . The network schema TmyDrug = (A,R) consist
of the vertex typing function τ = v → A that relates each vertex v ∈ V to a type in the
vertex type set A = (D,M,P, V,N,R) and an edge typing function φ : E → R with R, the
relation type set, containing all pairwise combinations of vertex types that have data in
the database.
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Several network instances were constructed from different subset of the data in the
MySQL database with vertices being collated from the tables for drugs (D), diseases (M),
genes/proteins (P), genetic variants (V), pathways (N) and protein domains (R). Edges
were constructed from the relation tables and typed by their source and target vertex types.
By default all edges were defined as bi-directional unless directionality information existed.
We created a default instance of the myDrug HIN, initialised using a subset of the data
included in the myDrug database. Specifically, only PPI present in KEGG were included
for protein-protein relations and DO was chosen as disease vocabulary. To query the neo4j
instance of the myDrug HIN we used the REST interface provided by the neo4j server and
the py2neo Python package397 .
Edge weights
Biologically meaningful information about edge weights only exists for edges based on sim-
ilarity (gene-gene, drug-drug). The raw data of the gene interaction networks in STRING
further contain confidence scores. However, due to the sparsity of this information, the
myDrug HIN is unweighted for subsequent analyses, unless otherwise stated.
We further implemented a topology-based edge weight based on the arithmetic mean of
the edge-type specific node degrees. For edge-type et between vertices u and v, we define
the promiscuity weight w as,
wuv =
deg+et(u) + deg
−
et(v)
2
(5.1)
with deg+et(v) denoting the outdegree and deg
−
et(v) the indegree of v when only consid-
ering edges of edge type et.
To down-weigh paths leading through promiscuous nodes, i.e., hubs, in the network, we
define the weight of a path p = v1
eet1−−→ v2 → ...
eetn−1−−−−→ vn in the graph as
wv1vn =
1∑
e∈E we
(5.2)
with E = (eet1 , ..., eetn−1) defined as the set of edges of pre-defined edge types on the
path p.
For the analyses of path-weight distributions in the rule-based predictions, we further
normalized the path weights for each predicted drug-disease pair to z-scores, i.e. subtracting
the average path weight of all predictions and dividing by the standard deviation.
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Figure 5.2: The network schema of the myDrug heterogeneous information network.
A) Visualization of the overall network schema containing six different vertex types,
corresponding to drugs (D), target genes/protein (P), genetic variants (V), protein
domains (R), cellular pathways (N), and diseases (M), as well as edges between those
nodes. B) Illustration of a populated network myDrug HIN instance using part of the
sub-network centered around the cancer drug sorafenib.
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5.2.4 Rule-Based Drug-Disease Edge Inference
We devised an unsupervised edge-prediction method that searches for drugs whose phar-
macological targets are adjacent to genes involved in a disease based on the myDrug HIN
using two meta paths in the network (Table 5.1).
Table 5.1: Meta paths and path instances used for rule-based neighborhood drug
repurposing
Rule Meta Path
Drug and Disease share target gene D - P - M
Drug target adjacent to gene involved in disease in
cellular gene network
D - P - P - M
Algorithm
We implemented the rule-based approach as an extension of the breadth-first search (BFS)
algorithm in which the user can define a meta path n and a set of query nodes s from
which the search on graph G is initiated (Algorithm 1). The edge sequence can be defined
as the successive pairing of the node types along the meta path or by edge attributes if
different types of edges exist.
To exclude results that could have been found with shorter meta path queries, these sub-
paths of the query are explored simultaneously in the BFS and nodes reached by them are
stored in each step. For example, to find all possible diseases linked to a drug’s neighborhood
target, we would define the edge sequence as [Compound-Gene,Gene-Gene,Gene-Disease].
We would further explore the supporting edge sequences [Compound-Disease] to exclude
the drug’s main indication from the result set and [Compound-Gene,Gene-Disease] for
predictions obtainable through a shorter path.
Implementation Details
We implemented the extended BFS algorithm and functions for data handling in the
Python package mydrug (available at https://github.com/kohlbacherlab/mydrug). The
class myDrug is implemented as an extension of a network-unaware base class myDrugBase
and uses the python bindings of iGraph68 to model graph objects.
All operations on the graph are implemented as class functions including the extended
BFS for meta path extraction, setter and getter methods, and functions that retrieve vertex-
and edge-properties from the myDrug database.
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Algorithm 1: Extended breadth-first search used to find novel indications for drugs
starting with a graph, a query node and a predefined meta path edge sequence.
Data: graph G, source node s, edge sequence es, supporting edge sequence ses
Result: Path: object containing information about the edge sequences and the meta path instance.
Function BFSmodified(G, s, es, ses)
level = {s: ∅}; parent = {s: None}; i = 1;
frontier = [s];
medges={}; sedges={};
while frontier 6= ∅ do
next = [];
# Initialize output edges
medges[(i-1, es[i-1])] = [];
for supp ∈ ses[i-1] do
sedges[(i-1, supp)] = [];
end
for u ∈ frontier do
# Add edges along main meta path
for e ∈ G.edges(source=u, edgetype=es[i-1]) do
v = e.target;
if v /∈ level then
level[v] = i;
parent[v] = u;
next.append(v);
medges[(i, es[i-1])] += e;
end
end
# Add edges along supporting meta path
for et ∈ ses[i-1] do
for e ∈ G.edges(source=u, edgetype=et) do
v = e.target;
if v /∈ level then
level[v] = i;
parent[v] = u;
sedges[(i, es[i-1])] += e;
end
end
end
frontier = next;
i += 1;
# End search if end of meta path is reached.
if i > |es| then
break;
end
end
end
return medges, sedeges
end
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5.2.5 Evaluation of Repurposing Predictions
The rule-based repurposing approach was first evaluated by estimating its potential to
retrieve known drug-disease associations. For each drug we computed how many original
indications could be retrieved using the two rules. For this, we did not filter out known
indications in the result set and then determined the fraction prd of known drug indications
Id in the predicted set Pd for a drug as
prd =
|{x : x ∈ Pd ∧ x ∈ Id}|
|Pd| (5.3)
In analogy to the validation method employed by Chiang and Butte59, we then quan-
tified the enrichment of drug-disease pairs in the prediction set that are established as
label or off-label use. For this we devised the confusion matrix, Table 5.2 and define the
enrichment as e = a ∗ (c+ d)/c ∗ (a+ b).
Table 5.2: Confusion matrix between drug-disease pairs in prediction set and already
used in the clinical practice
Used in clinical practice
Yes No Total
In prediction
Yes a b a+ b
No c d c+ d
Total a+ c b+ d N
If e > 1, predicted drug-disease pairs are e-times more likely to be already applied
in medical practice. We further calculated the significance of this enrichment using a
hypergeometric test employing the functions implemented in SciPy193.
External Validation Using Clinical Trials Data
To further validate our approach, we tested how many predicted drug-disease pairs are
already under clinical investigation because this indicates that sufficient medical evidence
data existed to support the possibility of a mechanistic association.
Clinical trial data was downloaded from the aact database (∼210,000 records, clinicaltrials.
org, March 2016). We then mapped intervention and condition IDs (NCT_IDs) of the
clinical trials database to medical subject headings (MeSH terms) using the MeSH the-
saurus. Intervention MeSH terms were then converted to DrugBank IDs (https://raw.
githubusercontent.com/olegursu/drugtarget/master/identifiers.tsv), followed by
the internal mapping to myDrug IDs. Condition MesH terms were mapped to Disease
Ontology IDs (DOIDs) using external identifiers provided in the Disease Ontology.
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Enrichment of predicted drug-disease pairs under clinical evaluation was calculated
analogously to that of approved drug-disease pairs, computing the confusion matrix of
drug-disease pairs in the prediction set and in the clinical trials database.
5.2.6 Machine Learning-Based Drug - Disease Edge Inference
The mechanisms in which drugs act in a cell to alleviate a disease are diverse121. We thus
extended the rule-based repurposing strategy to incorporate additional rules and learned
their respective importance from known drug-disease pairs using a Random Forest classifier.
Meta Path features
Features to be used in the RF classifier were defined from a set of biologically plausible
meta paths connecting a drug to a disease (Table 5.3) and extracted from the neo4j myDrug
instance using Cypher queries for each Compound-Disease (D-M) pair in the network.
Two types of feature vectors were implemented and used as input to training the classifer
in order to evaluate if network topology data could yield more accurate predictions: 1) a
binary vector where the bit is set to 1 if at least one instance of that meta path exists and
0 otherwise, and 2) a vector recording the absolute count of observed instances per meta
path and drug-disease pair.
Random Forest Classifiers for Drug-Disease Edge Prediction
We used Random Forests 38,157, as implemented in scikit-learn331, to classify drug-disease
pairs as new edges in the graph, due to their overall robustness against noisy data38,145.
An RF classifier consists of an ensemble of decision trees in which each tree is built from a
bootstrap sample of the full data set and a random subset of features at each split. This
combination of bootstrap aggregation and random variable selection results in classifiers
that are robust to noise in the data set, less prone to overfitting145 and are not affected by
correlated features38.
The optimal classifier for a given set of features was determined using exhaustive grid
search of included trees and maximum tree depth. The search space contained forest sizes
of 100 to 10,000 trees and unpruned trees as well as maximum tree depths between five
and nine levels. Within the grid search, 5-fold CV was employed to evaluate the models.
We then performed the assessment of RF classifier performance for different feature subsets
based on the output of the grid search, using ensembles consisting of 10,000 unpruned
decision trees. The maximum number of features to consider in each split was set to
√
n,
with n being the length of the feature vector145.
The data set used for classifier training and evaluation was built from positive drug-
disease tuples obtained through the meta path Compound-treats-Disease, and a negative
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Table 5.3: Meta paths and path instances used for feature creation of neighborhood
drug repurposing
Feature Rule Meta Path
F1 Drug resembles drug used to treat disease D - D - M
F2 Drug target is a disease gene D - P - M
F3 Drug targets a gene that is mutated in disease D - P - V - M
F4 Drug is affected by variant that also affects disease D - V - M
F5 Drug binds to domain that also binds a drug used to
treat disease
D - R - D - M
F6 Drug binds to domain that also occurs in disease gene D - R - P - M
F7 Drug resembles drug that binds gene that is also a
disease gene
D - D - P - M
F8 Drug binds to same domain as other drug used to treat
disease
D - R - D - M
F9 Drug binds to same domain as other drug that shares
a target with disease
D - R - D - P - M
F10 Drug resembles a drug that binds to domain that also
occurs in disease gene
D - D - R - P - M
F11 Drug targets gene in same pathway as disease gene D - P - N - P - M
F12 Drug binds to domain of a gene that is in the same
pathway as the disease gene
D - R - P - N - P - M
F13 Drug is affected by variant in a gene that is mutated
in disease
D - V - P - V - M
F14 Drug is affected by variant in a gene that is in the same
pathway as a gene mutated in disease
D - V - P - N - P - V - M
F15 Drug target gene is neighbor to gene involved in disease D - P - P - M
F16 Drug target gene is close to disease gene D - P - P - P - M
F17 Drug resembles drug that binds gene adjacent to disease
gene
D - D - P - P - M
F18 Drug resembles drug that binds gene close to disease
gene
D - D - P - P - P - M
F19 Drug binds to same domain as a drug that targets a
gene adjacent to a disease gene
D - R - D - P - P - M
F20 Drug targets gene that is adjacent to a gene mutated
in disease
D - P - P - V - M
F21 Drug is affected by variant in a gene that is adjacent
to a disease gene
D - V - P - P - M
F22 Drug is affected by variant in a gene that is adjacent
to a gene mutated in disease
D - V - P - P - V - M
F23 Drug resembles a drug that binds to domain that also
occurs in a gene adjacent to a disease gene
D - D - R - P - P - M
D = drug, P = gene (protein), M = disease (morbidity), R = domain (region), V = variant, N = pathway
(network).
set contained pairs that were linked in the network through non-causal edges (Compound-[treats_
not,treats_symptoms]-Disease). The resulting data set is highly imbalanced with 6,047
positive drug-disease pairs and only 631 negative pairs. Assuming that the majority of all
possible drug-disease pairs is in reality not connected, we enriched the negative set with
14,974 randomly chosen unconnected compound-disease pairs, resulting in a total set of
21,652 pairs. This set was then split in half, resulting in a training set and a validation set
for performance evaluation and all data points in which none of the meta paths existed in
the myDrug HIN (i.e., all features were zero) were excluded.
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We evaluated the classifiers for drug-disease edge prediction using different combinations
of the features defined in Table 5.3 as feature vectors:
1. gene-gene edges of different data sources treated separately
2. gene-gene edges of different data sources and interaction sub-types
(e.g. interacts_with,subsequent-catalysis, ...) treated separately
Cross-Validation
All classifiers were evaluated using 10-fold cross-validation and several scores for classifier
performance were calculated. These included the accuracy, precision, recall, F1 score,
as well as the area under the receiver operating curve for non-binary classifiers. The
average precision score describes the mean of precisions obtained every time a new positive
sample is recalled over the threshold interval of (0,1) and approximates the area under the
precision-recall curve.
5.3 Results
5.3.1 Overview over the myDrug Network
The full myDrug network contains 3,065,016 edges between 95,334 vertices (excluding genetic
variants) including 8,221 drugs, 9,304 DO diseases, and 16,306 protein domains (Supple-
mentary Tables E.2 and E.3). Furthermore, 45,746 variants that are directly linked to
diseases or drugs are also included in the myDrug HIN used for subsequent analyses.
Disease- and drug-relations in the network
2,234 of the 8,221 drugs were FDA-approved and 1,845 drug compounds were linked to 554
distinct disease DO terms (6,678 edges). 2,233 diseases had genetic data associated and
375 diseases had both drug and gene data. On average, if a compound or disease had any
information, a drug is connected to 3.6 diseases (median=2.0) and a disease is associated
with 12.0 compounds (median=3.0). The disease with the highest number of associated
drugs was acute myocardial infarction (total=258). Doxorubicin was the drug associated
with the most diseases (total=32, 88% of these are cancer types).
Protein-relations in the network
The collection of KEGG pathways contained information about 6,998 genes of which 5,053
were connected in the network. This covered 36.0% of the 19,465 protein coding genes
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included in our data set. About 60% (4,888) of the drug compounds have links to drug-
related genes, including 2,395 drug target genes and 346 PD genes. Drugs with target
information had on average 2.5 drug targets (max=144 for NADH, median=1.0) and each
gene in the network was on average targeted by 0.3 drugs. If a gene serves as a target, it
had an average of 5.1 (max=140 for CDK2, median=2.0) drugs associated with it.
Protein domains targeted by drugs
Based on co-crystallized drug-protein complexes, we also extracted associations between
compounds and the protein domains they bind to. Using this approach, we extracted
domain information for 58% of the compounds in the myDrug network. These bind on
average to 3.6 different Pfam A domains (median=1.0). 214 compounds have been co-
crystallized with ten or more domains and 13 compounds with more than 140 domains.
Each Pfam domain is associated with an average of one drug. Again, this distribution
is skewed, and those domains that have any drug association, bind 5.4 drugs on average
(median=2.0). The domains linked to the most drugs are the kinase domains (451 ligands
bind protein kinase domain, 11 of these FDA-approved, and 123 ligands bind to protein
tyrosine kinase domain, 9 of which are FDA-approved), trypsin (332 ligands, 23 FDA
approved) and the ligand-binding domain of nuclear hormone receptor (191, 25 FDA-
approved).
5.3.2 Neighborhood-Targets
We predicted indications for 2,234 FDA-approved drugs using the meta paths F2 (drug-gene-disease,
D-P-M) and F15 (drug-gene-gene-disease, D-P-P-M) where only KEGG data was used
for gene-gene edges. Drug-disease prediction returned at least one new indication for 1,457
drugs using the D-P-M meta path and for 1,204 drugs using D-P-P-M meta path. 756
of the FDA-approved drugs did not contain target annotation and thus no paths could
be constructed. For 22 drugs no instance of F2 and for 274 drugs no instance of the F15
existed despite annotated drug targets. Based on the general architecture of the algorithm,
no pairs already covered in the shorter meta path D-P-M were allowed in the D-P-P-M
set. For the 1,457 drugs with predictions using the F2 rule, an average of 38 diseases
(median=26) were predicted and for the 1,204 drugs with DPPM-based predictions 70
indications (median=43) (Figure 5.3).
Based on the included data and rational drug development concepts, we expect a sig-
nificant enrichment of known drug indications in the F2- and less so in the F15-based
predictions. Indeed, 1,258 of the 55,358 DPM-inferred pairs (2.3%) are known drug indi-
cations represented in the myDrug network. This is a four-fold enrichment over the 2,559
indications in the non-predicted set of all 513,864 possible pairs of drugs and diseases that
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Meta path F2: D - P - M Meta path F15: D - P - P - M
Figure 5.3: Distribution of disease predictions per drug based on a)
drug-gene-disease meta path and b) drug-gene-gene-disease meta path using
interactions between proteins based on KEGG pathways.
are potentially reachable in the network (29x enrichment over all 3,269,112 pairs predictable
from 2,233 diseases with genetic information). Of the 84,815 F15-based predictions, only
313 are known indications (0.4%).
External evaluation
The comparison of drug-disease predictions to known treatment options indicates that most
F15-based predictions are new. To test if these predictions have additional evidence in
clinical studies, we evaluated the overlap between the prediction set and 15,485 drug-disease
pairs in the FDA clinical trials database (covering only the drugs and diseases also present
in the prediction set): Of the 55,358 F2-inferred pairs, 1,809 drug-disease combinations were
covered by clinical trials (8x enrichment). Additionally, 1,560 of the 84,815 F15-inferred
drug-disease edges were under clinical investigation (4.5x enrichment).
Impact of hubs on prediction accuracy
We further expect that hubs in the network add noise to the predictions. Therefore we
implemented edge weights reflecting the node promiscuity as the average of the source
vertex’ outdegree and the target’s indegree. Meta path instances were then assigned a
promiscuity-score calculated as the reciprocal of the cumulative edge weights (see Methods).
These scores where then normalized by subtracting the average promiscuity score of the set
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and dividing by the standard deviation. Comparison of the promiscuity-score distribution
in the full set of predictions to those deemed correct due to their membership in either the
indication or the clinical trial set, shows that correct predictions deviate significantly from
the overall distribution with non-zero average z-scores (meanall=1.04e-13, meanindication=-
0.05, meanclinical trials=-0.14, p<0.05 for both subsets using two-sided Kolmogorov-Smirnov
tests).
5.3.3 Systematic Repurposing Using Random-Forest Classifiers
Next, we defined the drug repurposing problem as a supervised edge-prediction task (specifi-
cally, drug - disease edges). To include the full extent of information available in the myDrug
HIN, we extended the rule-set to incorporate a variety of different meta paths (Table 5.3).
These meta paths were used to construct feature vectors for drug-disease pairs which served
as input to train several RF classifiers.
Binary feature vector compared to path-instance counts
Meta paths in the network could be used in two ways to construct feature vectors as input
for the RF. While a binary feature vector only includes the information whether at least
one such meta path exists for a drug-disease pair, absolute count features harbor implicit
information about network topology and hubs.
We compared RF classifiers trained on binary feature vectors to those using absolute
feature counts to assess which yield more accurate predictions, but for RFs of 10,000 trees
hardly any difference in the performance metrics could be observed between binary and
absolute count feature vectors (average precision = 0.85, Table 5.4).
Table 5.4: Classification performance for binary and absolute count features for RFs
consisting of 10,000 unpruned classification trees.
Metric Binary Absolute Counts
F1 0.796 0.804
Accuracy 0.816 0.821
Precision 0.824 0.822
Recall 0.770 0.786
MCC 0.630 0.639
AUC 0.882 0.888
Average precision 0.851 0.854
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RF performance based on different gene interaction networks
We then compared the performance of a classifier trained on features created from a HIN
instance built from all data sources, including all three PPI network sources (KEGG, String
and PathwayCommons), to classifiers utilizing only interactions from a single PPI source for
gene-gene meta path features. Here, mean prediction accuracy ranges from 0.70 (KEGG)
to 0.80 (PathwayCommons) and AUCs from 0.76 (KEGG) to 0.87 (PathwayCommons),
which were all outperformed by the classifier built from all features (Table 5.5).
Table 5.5: Classification performance for absolute-count features across different
gene network sources for RFs consisting of 10,000 unpruned classification trees
Metric All KEGG PC STRING
F1 0.805 0.619 0.789 0.755
Accuracy 0.822 0.699 0.806 0.76
Precision 0.823 0.757 0.802 0.722
Recall 0.787 0.524 0.777 0.790
MCC 0.641 0.402 0.609 0.523
AUC 0.888 0.761 0.868 0.824
Average precision 0.854 0.752 0.841 0.805
Furthermore, the feature vectors containing a full set of features resulted in overall
increased prediction performance including higher AUCs and average precision than a
classifier trained with a reduced set of features ignoring interaction sub-types (Figure 5.4).
Here, the AUC increases from 0.87 for a classifier built on feature vectors using a single
feature per network to 0.89 when treating PPI sources and interaction sub-types separately
in the feature vector. Average precision changes from 0.84 to 0.85.
5.3.4 Relative Feature Importance
The previous subsection demonstrated that information about interaction types in the fea-
ture vector increase classifier performance and we wanted to know which of them contribute
most to prediction accuracy. We obtained the relative ranking of feature importance for the
RF classifier with highest prediction performance using the decrease in averaged weighted
Gini impurity — the measure for impurity used for splitting the decision trees in the RF
— of all trees in the forest. The features with highest impact are listed in Table 5.6 and
correspond to meta paths along the genetic neighborhood of drug targets, but also moving
out of the direct neighborhood by considering aspects such as drug similarity.
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Figure 5.4: ROC curves for different feature sets. We used absolute count features
and features built on meta paths that included gene-gene links, different data sources
could either include data from any PPI source (blue), only KEGG (green), Pathway
Commons (red) or only String (purple).
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Table 5.6: Most important features in RF classifier
Feature meta path PPI data source Importance
D-binds-R-binds-D-targets-P-catalysis_precedes→P-associates-M KEGG 0.134
D-binds-R-binds-D-targets-P-controls_expression_of→P-associates-M KEGG 0.039
D-binds-R-binds-D-targets-P-in_complex_with-P-associates-M KEGG 0.035
D-binds-R-binds-D-targets-P-interacts_with-P-associates-M KEGG 0.026
D-binds-R-binds-D-targets-P-p3-P-associates-M KEGG 0.024
D-resembles-D-binds-R-contains-P-catalysis_precedes→P-associates-M KEGG 0.023
D-resembles-D-binds-R-contains-P-controls_expression_of→P-associates-M KEGG 0.020
D-resembles-D-binds-R-contains-P-in_complex_with-P-associates-M KEGG 0.017
D-resembles-D-binds-R-contains-P-interacts_with-P-associates-M KEGG 0.014
D-resembles-D-binds-R-contains-P-p3-P-associates-M KEGG 0.013
D-resembles-D-targets-P-catalysis_precedes→P-catalysis_precedes→P-associates-M KEGG 0.012
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5.4 Discussion
In this chapter, we presented a heterogeneous information network modeling the interaction
between drugs, genes and diseases and evaluated two different methods to identify novel
drug candidates for diseases in this network. We showed that both methods result in
meaningful predictions and were able to enrich for clinical treatment candidates.
Prediction performance
We evaluated our repurposing methods using standard techniques such as cross-validation97,127,238,369,438
and comparison of prediction results to external data59,238,349. We further tested the ro-
bustness of the RF classifier through 10-fold cross-validation. With AUCs between 0.8 and
0.88, the RF approach lies in the same performance range as many other published methods
built on similar data types. The current gold standard methods for ML-based repurposing,
PREDICT and PreDR, are reported to reach AUCs between 0.85 and 0.9127,179,369,438 show-
ing that our approach is on par with these methods despite excluding gene expression data
of drug perturbations and disease states — information utilized in other approaches154.
For the rule-based approach, prediction evaluation was non-trivial because the approach
aimed to move away from conventional similarity-based methods. By calculating the
enrichment of pairs also present in clinical trials, we could compare our approach to the
GBA method proposed by Chiang and Butte59. Here, enrichment values of more than 4-
fold for clinical trials outperform those obtained with GBA59. Our prediction performance
is in line with previous studies, observing that approaches that infer edges in the drug-
gene-disease network result in predictions with higher interpretability than regression-based
predictions369, but fail to reach comparable prediction performance.
Inclusion of heterogeneous data sources
When comparing different repurposing methods, performance usually depends on two
factors: 1) the computational approach, 2) the underlying data used for model training
and edge inference127,154,179,272,369,438. Method and data are usually closely linked, which
makes independent evaluation hard.
Inclusion of more data sources seemed to generally increase prediction performance in
past studies127,154,179,369,438 even though increasing numbers of false-positive associations
add noise. Different identifier systems used by the distinct data sources of the same asso-
ciation types further complicate their seamless integration. Particularly for disease codes
the n-to-n mapping between different coding systems such as ICD and MeSH terms results
in decreasing accuracy with each mapping step. Nevertheless, our evaluation supports
this hypothesis as the inclusion of different PPI networks into the feature vector increased
classifier performance.
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A second problem arises from the automatic inclusion of heterogeneous biological data:
some relations are trivial to a medical expert but are not directly linked in the ontology154.
Especially the rule-based approach proposed in this chapter can be affected by this problem.
Important features in RF classifiers
The importance of each feature in an RF can be measured by the extent to which its
exclusion affects performance415. Features ranked highly in our RF classifiers were those
considering the genetic neighborhood of drug targets in addition to other aspects such as
compound similarity. These meta paths are to some extent more complicated than those
reported to be of high importance in a recent logistic-regression HIN-based method154.
However, our ranking is likely biased through correlated features407 in which all corre-
lated variables receive small weights as no single one dominates prediction accuracy in a
substantial subset of the RF decision trees415.
Some of the meta paths used to construct the feature vector are related in the sense
that they describe the same biological mechanism considering different data sources (e.g.,
KEGG, PC and STRING for PPIs). Furthermore, several relations included in the network
are not independent from each other in the cell, such as the association of chemically
similar drugs binding to the same protein. Thus, several clusters of correlated variables
exist in our feature set (Supplementary Figure D.2), likely affecting the ranking presented
in our analysis. However, given the random selection of features included the nodes in
each decision tree, the confounding effects of correlated features do not affect classifier
performance38. We thus chose an overall robust classifier with likely redundancy in the
included features over missing potentially important information, but acknowledge that
the listing of important features may be skewed.
Limitation of the network approach
The myDrug HIN is built on a multitude of different data sources, representing multiple
vertex and edge types (see Methods). Due to the connectedness of the network, novel
predictions for drugs or diseases do not require complete knowledge about the different
association types. However, disease and drug vertices need to be connected to other vertices
in the network to facilitate drug-disease edge prediction. It is thus not possible to make
predictions between vertices separated by multiple components in the network.
Future development
In this chapter, we demonstrated how two approaches using meta paths in a HIN — one
unsupervised and one unsupervised — can be useful to identify repurposing hypotheses.
Prediction performance is comparable to that of other repurposing approaches even though
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common data types such as gene expression data were not included in the network. The
presented RF models appear robust against false-positive associations in the training and
feature set, resulting in improved prediction performance the more data sources are included.
Due to the reported benefits of gene expression data in other studies127,154,179,272,369,438,
the inclusion of gene expression data may be capable of improving predictor performance
further.
By including knowledge about in vivo cell-type-specific gene expression landscapes, like
the Human Cell Atlas351 or GTEx135 for filtering the HIN instance, the proposed methods
could also be used for tissue-specific repurposing predictions (e.g., to adapt predictions
for neuronal diseases to genes only expressed in neurons). Personalized predictions for
treatment options could be made by adapting the myDrug HIN instance to reflect a patient’s
specific gene expression and genetic variation pattern.
We showed that low topology-based path weights in the rule-based approach enrich for
true-positive predictions. A thorough evaluation of relative association importance in the
network may thus help to prioritize predictions in both methods. Here, a logical extension of
the presented approach would be to include edge and node weights in feature computation
to downweigh highly connected or low confidence nodes. One possible weighing scheme
worth evaluation are degree-weighted paths 154.
In addition to the repurposing methods presented in this chapter and through publicly
available web server (midrug.org), the myDrug data repository that forms the basis for
the HIN can also be used to gain general insights into disease and drug mechanism in the
future. One such example will be shown in the next chapter.
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Chapter 6
Personalized Pharmacogene Analysis
6.1 Introduction
A patient’s molecular profile of their disease can be used for personalized therapy deci-
sions51,213,380. Specifically in the oncology setting, the arduous task of extracting actionable
variants from the long list of all mutations found in the affected tissue is delegated to a
specialized group of geneticists, bioinformaticians, and oncologists to make treatment deci-
sions on a patient by patient basis213,380. With the cost of genome sequencing dropping
to a level that incentivises medical insurance providers to reimburse genome sequencing in
cancer patients201, large amounts of genomics data have become available from patients.
With this influx of data, existing strategies for interpreting genomic results need to be
streamlined and automated to enable medical experts to utilize the wealth of information.
This means that tools need to be developed that allow physicians to receive an overview of
the molecular driving forces of the disease as well as be advised of actionable therapeutic
targets.
Many major medical institutions have started implementing genotyping protocols for
preemptive pharmacogenetic testing, but these usually focus on the PD and PK of drugs90.
However, as shown in Chapter 4, other drug-related genes are also relevant for a thorough
understanding of the particular disease in the patient and to guide treatment decisions.
In cancer, for example, driver gene mutations offer a selective growth advantage to the
cells in which they occur, and the identification of such genes and their interaction net-
works present a paradigm for our understanding of cancer progression and therapeutic
resistance360,433. For instance, in some instances of colorectal cancer treated with the
EGFR antibody cetuximab KRAS mutations arise, requiring secondary therapy strategies
to be implemented392.
A number of publicly available databases have been created in the past years to annotate
genetic variants in respect to their therapeutic actionability specifically for cancer109,124,133.
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These resources suffer from two major problems: 1) Manually querying them is not feasible
for all sequenced patients and, therefore, automatic mechanisms of data retrieval from
diverse resources are required. 2) Many of the genetic alterations observed in cancer have
not yet been functionally characterized and it thus remains unknown to what extent they
may influence the disease and treatment. For example, while certain variants including the
commonly seen V600E polymorphism in the serine-threonine protein kinase BRAF have
been thoroughly characterized in manually curated resources such as mycancergenome469,
PharmGKB453 and CIViC133, many less frequent variants lack data about their effect on
targeted therapeutics (e.g., in mycancergenome.com only six of the 19 variants described
in BRAF have annotated effects on targeted therapies, accessed 11/2017). Furthermore,
experimental assays such as KinomeScan, commonly employed to test protein-specific
ligand-affinities72, only incorporate few clinically established variants100, and thus currently
do not provide an sufficient data source for individualized treatment decisions.
To identify variants that may be either amenable to drug treatment or confer treatment
resistance in a patient-focused context, comprehensive probing of the drug target space and
downstream drug effects is required. Several interactive and command line analysis tools
for automated cancer genome annotation have been developed, including Drug-SNPing464,
Virtual Pharmacist57, BALL-SNP298, IntoGen360, cBioPortal49, the Broad Tumor Por-
tal233, and IMPACT156, but usually solely rely on collating existing information from the
literature.
Goals of the Project
The aim of this project was to create a computational infrastructure that can be used
to gain drug-related insights on the effects of genetic variants. This includes mining the
myDrug HIN presented in the previous chapter for pharmacologically relevant data that
may be affected by genetic variants. To increase the resolution at which the classification
of variants is performed, we developed an MM protocol to model mutations in drug targets
and to quantify the extent to which the binding affinity may be altered.
We further introduce a clinical reporting pipeline, which annotates variants with phar-
macogenomic and drug actionability information.
6.2 Materials and Methods
6.2.1 Structure-Based Modeling of Mutation Effects on Drug Binding
We developed a molecular modeling protocol for predicting the effects of a genetic variant on
protein stability and activity similar to those commonly used in the field of computational
protein design209,297.
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This protocol was implemented as a series of workflows that model the effect of one or
more single nucleotide variants in a protein on the binding affinity of a ligand given the
protein’s 3D structure:
1. Introduction of variant into structure
2. Molecular dynamics simulation
3. Extraction of representative frames using PCA
4. Virtual screening of ligand library using molecular docking
5. Pose analysis
To predict changes in binding affinity of drug-like ligands due to variation in the
protein, we extracted a representative set of frames from the MD trajectory spanning all
conformations observed during the simulation using principal component analysis (PCA)
followed by k-means and hierarchical clustering and prepared them for molecular docking.
By docking ligands into the wild-type and variant structures, we then tried to estimate
the change in binding affinity of a ligand between the native protein and its variants. We
evaluated our approach based on its ability to reproduce known conformations and changes
in binding affinities of 15 protein kinase variants.
Molecular Dynamics protocol
MD simulations of variant proteins were applied in protein design for testing the structural
integrity of designs, mapping out molecular interactions and ensuring that the protein
variant is at a potential energy minimum209,297. Extensive changes of the protein sequence,
such as those introduced by multiple variants in the active site, can result in non-native
conformations becoming thermodynamically more favorable than the native conformation.
These changes would not be observed without the modeling of protein dynamics over a
certain time209,297.
After creating a model of the altered structure by replacing the variant residues in
the wild-type input structure, we used MD simulation to simulate resulting structural
changes: To obtain the overall conformation of the modified protein at its energy minimum
we minimized the structure and then simulated the system for at least 20 ns using the
OPLS2005 force field17. This protocol was implemented in KNIME23 with the Schrödinger
extension for structure preparation and Desmond35,391 (version 38017) for system relaxation
and MD simulation. We used the Schrödinger tool multisim (version 3.8.5.11) to coordinate
the multiple stages of the Desmond simulation.
To keep the number of particles in the system small, it was solvated with TIP3P
water195 in an orthorhombic or a rhombic dodecahedron xy-hexagon box (depending on
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the protein shape). Periodic boundary conditions were satisfied using an electrostatic cutoff
of 9 Å and a box size buffer of 7 Å. The system was neutralized by adding Na+ and Cl−
counter ions to charged groups. We further simulated a cytoplasmic salt concentration of
0.15 M by adding additional explicit Na+/Cl− ions.
Preceding the 20 ns production MD simulation, each system — protein wild type and
variants — was relaxed with Desmond. Relaxation steps included two stages of minimization
(first solute-restrained, then unrestrained), followed by four stages of short equilibration
MD runs (72 ps) with gradually diminishing restraints. Here, the system was heated up
from 10 K to 310 K in four steps (12 ps at NVT conditions with restrained non-hydrogen
solute atoms restraint and 10K, then 1 step of 12 ps at NPT conditions and restrained
non-hydrogen solute atoms and 10 K and 1 atm, followed by two 24 ps runs at NPT without
restraints at 300 K and 1 atm). For the production simulation we simulated the system for
20 ns with fixed particle number, temperature, and pressure (NPT) in a Nose-Hoover chain
thermostat/Martyna-Tobias-Klein barostat, at 310 K and 1 atm. Long-range electrostatic
interactions were modeled using the particle-mesh Ewald (PME) method with a long-range
cutoff of 10 Å. We recorded energies every 1.2 ps and trajectory frames of the structure in
4.8 ps intervals for in the production MD simulation.
Docking pre-processing protocol
Representative frames were extracted from the trajectories by clustering and exporting
cluster representatives. If the variant was modeled in more than one PDB structure
for a distinct kinase conformation, we clustered those trajectories together. First, the
Desmond trajectories were converted to the CHARMM DCD trajectory format using
CatDCD (version 4.0) provided by the Visual Molecular Dynamics (VMD) tool170 to make
them compatible with BALL152 for downstream analyses. To concatenate the frames of
multiple trajectories, we further reordered the atoms in the DCD files according to the
order in one reference trajectory file. Highly flexible residues at the protein termini were
removed using a sliding window approach determining terminal residues with a sudden
change in root mean square fluctuation (RMSF)107.
Dimensionality of the data was reduced by principal component analysis (PCA) prior
to clustering. Here, we used a protocol developed by Fischer et al. using torsional space
(i.e., using backbone dihedral angles) as input to the PCA because it was shown to result in
a more diverse set of conformations extracted from the trajectory107. The dimensionality
of the complete input matrix was reduced by projecting it into the space spanned by the
first m principal components covering 95 % of the overall variance.
We extracted representative frames from the MD trajectory in a two-step process
employing k-means clustering followed by complete-linkage hierarchical clustering in R.
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During the first step we grouped the n frames in the trajectory into k clusters, following a
common rule of thumb266 of k =
√
n
2 . To account for the randomly assigned initial cluster
centroids in k-means, we repeated this process ten times and selected the run that best
represented the full trajectory by comparing the convex hulls of the covered space spanned
by the cluster representatives107.
In a second step, cluster representatives were grouped using complete-linkage hierarchi-
cal clustering to obtain a reduced set of structures for docking. This step was performed
using the RMSD on backbone Cartesian coordinates to account for positional similarity
between conformers107. The binary tree obtained in this process was cut at several levels
in the hierarchy to obtain 5, 10, 15, and 20 clusters, selecting the structure per cluster with
the overall lowest RMSD to all other members as representatives.
Docking protocol
The extracted trajectory frames were prepared for docking by converting them to the
Schrödinger-native maestro file format (.mae) and annotating them with variant- and
clustering meta-data. Then the docking grid was created for each structure using the
centroid of the co-crystallized ligand to define the inner grid box. The outer box limits
were set to 30 Å to facilitate the docking of larger ligands in the library.
We compiled a screening library from the following three data sources:
• co-crystallized ligands of kinases in PDB
• ligands with measured binding affinities by Davies et al.72
• all FDA-approved small molecule drugs from DrugBank232
These molecules were desalted and tautomerized using the Schrödinger LigPrep tool
(version 3.4), while retaining original ionization states and chirality specified in the input
structures. The ligand library was docked into the binding pocket using the Glide XP
docking protocol113 implemented in the Schödinger Glide program112,138 (version 59047).
Here, the initial number of retained poses was set to 5000 (MAXKEEP=5000) and 1000
poses were kept for energy minimization (MAXREF=1000), following previous benchmark
protocols422. Ligand poses were optimized post-docking (POSTDOCK=TRUE, POST-
DOCK_NPOSE=10).
The docking step was followed by a rescoring step using MM energy calculation combined
with the generalized Born and surface area continuum solvation (MM-GBSA) implemented
in the Prime tool (version 3.0) to obtain more accurate estimates for relative binding
affinities of the ligands132.
Initial Glide XP scores as well as MM-GBSA estimates for the free binding energy (dG)
were extracted from the Maestro poseviewer files and stored in a matrix with individual
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ligand-variant/conformation combination per row and 20 columns (one for each cluster
representative). All docking results for a conformation and variant were aggregated by
calculating the median score. For those ligands where multiple isomers/tautomers where
docked, only the conformer with the lowest score was included. The variants’ effects on
binding affinity were calculated as the difference between the predicted affinity in the
wild-type simulations and those for the variant.
6.2.2 Evaluation of the Modeling Protocols
We tested and evaluated the described protocol for several protein kinases, a protein family
of clinical interest in the field of oncology due to a large number of approved therapeutics
against these targets (Chapter 5.3.1). Protein kinases transfer phosphate groups from
adenosine triphosphate (ATP) to a residue in a protein. This step serves as an activation
signal for many cellular functions including cell cycle and cell death142. Depending on
the amino acid to which the phosphate group gets attached, one discriminates between
tyrosine and serine-threonine kinases as well as several atypical kinases which — despite
demonstrated kinase activity — do not share sequence similarity to the two other kinase
families.
The modeled proteins are summarized in Table 6.1 and contain members of both large
kinase subfamilies as well as structures representing the active and inactive conformation
of the protein depending on the “Asp-Phe-Gly” (DFG) motif. This motif is located at the
N-terminus of the activation loop and facilitates catalysis if the side chain of the aspartate
residue faces into the active site while the phenylalanine occupies a hydrophobic pocket
adjacent to the ATP-binding site (“DFG-in”)142.
Evaluation of MD protocol
We evaluated the MD protocol by comparing conformations obtained from the simulation to
known 3D structures of kinases harboring the variant. Since certain variants are known to
cause a shift from one kinase conformation to the other, we expected that if the simulation
sufficiently covered conformational space, we would observe this shift also in the frames
extracted from the trajectory. However, upon inital inspection of the results, it appeared
that a simulation length of 20 ns may be too short to cover the full conformational space of
this protein family. We thus extended the simulation duration for a single kinase, BRAF,
to 100 ns and also evaluated the conformational space coverage in this longer simulation
through PCA.
To judge the quality of individual simulations and resulting models, we devised a
workflow that computes the standard set of MD quality control (QC) measures for each
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Table 6.1: Protein kinases modeled using the proposed pipeline.
Protein Structure Catalaytic Activity Conformation Kinase Family Uniprot Accession
EGFR 2GS2, 2GS6 active DFG-in tyrosine P00533
3GT8, 3W23 inactive DFG-out tyrosine P00533
BRAF 3TV6, 3C4C active DFG-in/αC-in serine-threonine P15056
4E26, 3PRF intermediate DFG-in/αC-out serine-threonine P15056
3IDP, 4KSP inactive DFG-out/αC-out serine-threonine P15056
KIT 1PKG active DFG-in tyrosine P10721
3G0E, 1T45 inactive DFG-out tyrosine P10721
FLT3 1RJB inactive DFG-out tyrosine P36888
ROS1 3ZBF inactive DFG-out tyrosine P08922
ERBB4 2R4B, 3BCE active DFG-in tyrosine Q15303
3BBW, 3BBT inactive DFG-out tyrosine Q15303
KDR 3VHE, 3VHK inactive DFG-out tyrosine P35968
MTOR 4JSN, 4JSP inactive DFG-out atypical P42345
TTN 1TKI, 4JNW inactive DFG-out atypical Q8WZ42
EPHA3 3FY2, 4GK3 active DFG-in tyrosine P29320
2QOQ,2QO2 inactive DFG-out tyrosine P29320
EPHA5 2R2P active DFG-in tyrosine P54756
PI3K 2RD0 active DFG-in atypical P42336
simulation (energy analysis, RMSD, RMSF, radius of gyration, number of hydrogen-bonds,
solvent accessible surface area (SASA) and Ramachandran plots).
Evaluation of docking protocol
We evaluated the docking protocol by re-docking co-crystallized ligands to the cognate
structures to test if it allowed reproducing the native binding conformation. The correctness
of the docking pose was assessed by calculating the RMSD to the crystallized conformation.
For data storage and retrieval we devised a mySQL database that extents the myDrug
database introduced in the previous chapter with tables storing meta-data and modeling
results.
To quantify the extent to which predicted changes in binding affinity caused by a
mutation agree with experimental evidence, we calculated Spearman’s rank correlation
between predicted and measured differences in binding affinities (as estimated by the Glide
XP score and in vitro measurements of the dissociation constant Kd, respectively) for a
subset of 72 ligands and 15 variants in four kinases (EGFR, BRAF, KIT, FLT3 ) from
Davis et al.72.
To evaluate the changes in prediction performance after re-scoring by MM-GBSA, we
also calculated ρ between predicted ∆G differences of wild type and mutant and experi-
mental measurements. Due to the high temporal demand and license restrictions of this
process, we focused on five EGFR mutations for the this step. Experimental measurements
of Kd > 10 nM were set to null in the published data set and excluded from our analyses72.
The statistical tests were performed using the SciPy stack193 and Jupyter notebooks334.
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6.2.3 Annotation of Patient Genomes by Known Drug Effects
Overall server architecture
Due to the high computational demand of the complete protocol described above, the
prediction of variant effects based on their structural impact cannot be performed for all
possible mutations in all human genes at the moment. However, particularly in the clinical
setting, physicians and consulting experts may be interested in an aggregated collection of
mutation and gene-specific data. Such data are collacted in the myDrug database. To make
it accessible to the outside world, we developed a Flask web server, which supports different
types of queries and implements a RESTful interface to the database (code available at
https://github.com/kohlbacherlab/mydrug-server) that allow the search of the genetic
neighborhood for additional treatment candidates.
• Search by gene: query by gene symbol and retrieve list of neighboring genes, their
associated drugs and diseases
• Search by compound: query by drug name and retrieve list of diseases sharing the
drug target gene or lying in the genetic neighborhood of the drug target
• Search by disease: query by disease name, Disease Ontology ID or OMIM code and
retrieve list of drugs modulating one of the known disease target genes or affecting
neighboring genes
• Search by mutations: Annotate a set of variants, represented as a VCF file or
list of HGVS variant names, for their involvement in drug action and diseases. For
individual genes, it also allows the search for drugs targeting gene neighbors to the
mutated gene in the myDrug network. We further implemented the annotation of
specific observed variants with pharmacogenomic data from PharmGKB.
The overall structure of the service follows the model-view-controller design pattern. The
web application is modularized by individual Flask blueprints for the different use cases, as
depicted in Figure 6.3. The data model representing the data stored in the myDrug MySQL
database is shared between the individual blueprint modules using SQLAlchemy19, while
forms (forms.py) and controllers (views.py) are placed inside the individual blueprint
module directories. Jinja templates return data from the controller to build the final
view and are defined in a separate static templates directory, whose structure follows the
blueprint modularization pattern.
The RESTful API is implemented using the Flask Restplus module147 which automat-
ically builds a documentation view using Swagger410 about API usage options. Data is
returned as JSON object which allows the direct conversion in python dictionary objects
for subsequent analyses by the end user.
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Figure 6.1: Internal structure of the myDrug webservice. Each blueprint serves the
logic and view of a particular use case, including querying by drug, disease and gene.
Evaluation of approach for 198 patients with hepatocellular carcinoma (HCC)
The mutation view in the myDrug app can be used to create patient reports from VCF
files of genetic variants found in a patient. One particular use case for this pipeline is the
annotation of tumor-specific variants to explore targeted treatment options.
To evaluate the usefulness of our reporting approach, we tested the protocol on 197
freely available somatic exomes of liver cancer patients in the The Cancer Genome Atlas
(TCGA) Liver Hepatocellular Carcinoma (LIHC) study. We obtained somatic mutations
using the R/Bioconductor package TCGAbiolinks62 for the TCGA-LIHC project as a
single list with all variants observed in all samples. This list was split and converted into
individual VCF files using Python. We used the myDrug RESTful API to annotate the
individual patient exomes, running Ensembl VEP276 (release 84) to annotate the variants
based on the reference genome prior to myDrug annotation. Subsequent analyses were
performed in Python using Jupyter notebooks334, pandas274, pyVCF47 and the SciPy
stack193. Variants predicted to result in the loss of protein function by the LOFTEE VEP
plugin259 or unanimously predicted to have a deleterious effect on the protein product by
SIFT303 and PolyPhen-24 were defined as non-functional.
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6.3 Results
6.3.1 Prediction of Genetic Variant Effects on Drug Binding Affinity
We developed a protocol to predict the effects of genetic variants in drug targets consisting
of two major steps: 1) modeling the effect of a genetic variant on the protein structure
using MD, and 2) employing molecular docking to predict the change in binding affinity of
the ligand in the altered structure.
We evaluated the pipeline’s applicability in a set of clinically relevant protein kinases —
a protein family often targeted by precision cancer therapeutics.
Modeled kinases
We evaluated the protocol by modeling mutations in a set of eleven cancer-associated kinases
and comparing docking-based prediction performance to experimentally determined binding
affinities in the four most commonly affected kinases. We successfully modeled commonly
observed mutations in ten different protein kinases (Table 6.1). Simulations in PI3K failed
due to problems with the modeling software and were discarded. We obtained trajectories
for two different protein structures per kinase and conformation, where possible, to optimally
cover the known structural space. For these structures, we simulated the system for 20 ns
and extracted snapshots from the trajectory for ligand-docking.
Evaluation of the MD protocol
To test the ability of the protocol to produce stable conformations of the mutated proteins,
we compared the modeled mutant structures to known 3D structures containing the same
mutation in the PDB22 (Table 6.2). In BRAF the extracted frames of the system with
introduced mutation show lower overall RMSDs to the crystallized mutant than frames
extracted from the wild-type trajectory. Overall, structural changes in the backbone are
small for all tested examples.
Furthermore, when comparing the binding site of a modeled activating variant in an
inactive 3D structure to the crystallized active conformation, the RMSDs between modeled
structures with activating variants and the crystallized active proteins are consistently
smaller than those between active and inactive 3D structures (Table 6.3).
Based on the comparison between known mutant structures and the modeled variants,
it appears as if 20 ns are not sufficient to fully cover conformational changes introduced by
certain mutations. We therefore compared the trajectories of 20 ns to 100 ns simulations
in BRAF using the first and second principal component of dihedral space to compare
the covered conformational space (Supplementary Figure D.3). In addition to the inactive
state structure (DFG-out, αC-out, PDB: 3IDP), we modeled the intermediate conformation
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Table 6.2: Comparison between modeled mutated binding site to crystallized mutant
protein.
Protein Mutant ReferenceStructure
Modeled
Structure
Binding Site
RMSD
Backbone
RMSD
EGFR 2ITN 2GS6 0.95 1.87
2ITN 2GS6 (G719S) 0.90 1.88
2ITN 3W32 1.48 3.19
2ITN 3W32 (G719S) 1.66 3.22
EGFR 4I24 2GS6 1.50 2.86
4I24 2GS6 (T790M) 2.13 2.84
4I24 3W32 0.82 1.97
4I24 3W32 (T790M) 0.98 1.97
EGFR 4LQM 2GS6 0.85 2.11
4LQM 2GS6 (L858R) na 2.04
4LQM 3W32 1.46 2.90
4LQM 3W32 (L858R) na 2.89
BRAF 4MNF 3TV6 1.58 2.92
4MNF 3TV6 (V600E) 1.23 2.55
4MNF 3IDP 1.42 2.13
4MNF 3IDP (V600E) 1.38 1.95
KIT 3G0F 1PKG 2.49 3.98
3G0F 1PKG (D816H) 2.56 3.95
3G0F 3G0E 2.52 4.24
3G0F 3G0E (D816H) 2.81 4.29
Table 6.3: RMSD of binding site and all protein backbone residues between modeled
activation mutations and active structures
Protein ReferenceStructure
Modeled
Structure
Activating
Mutation
Representative
Frame
Binding Site
RMSD (Å)
KIT
1PKG
(active)
3G0E
(inactive) - 1.84
1PKG 3G0E D816H 3001 1.32
1PKG 3G0E D816H 57 1.82
1PKG 3G0E D816H 685 1.46
EGFR
2GS6
(active)
3W32
(inactive) - 2.62
2GS6 3W32 L858R 1448 2.23
2GS6 3W32 L858R 303 2.07
2GS6 3W32 L858R 1678 1.84
2GS6 3W32 L858R 1920 2.18
2GS6 3W32 T790M 685 1.88
2GS6 3W32 T790M 1610 1.62
2GS6 3W32 T790M 2818 1.92
2GS6 3W32 T790M 3541 1.66
2GS6 3W32 G719S 439 1.5
2GS6 3W32 G719S 1369 1.42
2GS6 3W32 G719S 2447 1.78
2GS6 3W32 G719S 4004 1.54
(DFG-in, αC-out, PDB: 4E26, 3PRF) and the active conformation (DFG-in, αC-in, PDB:
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3TV6, 3C4C). Here, the two trajectories of the intermediate state overlapped in covered
conformational space and the 4E26 trajectory further overlaps with the trajectory of the
active structure 3TV6.
Evaluation of docking results
We evaluated the ability of the docking protocol to reproduce the known binding pose of
a ligand by re-docking the native ligand back into its binding pocket. Overall, RMSDs
between co-crystallized and docked ligands are small with an average RMSD of 1.68 Å and
below 2 Å for seven out of the eight tested structures, indicating a successful reproduction
of the binding pose (Table 6.4). For FLT3 only an apo-structure existed and we could thus
not evaluate the pose reproduction accuracy for this kinase.
Table 6.4: Redocking co-crystallized ligands into native binding pocket.
Protein Structure RMSD in Å
EGFR 3W32 1.38
BRAF 3TV6 0.73
3C4C 0.59
4E26 6.69
3PRF 1.41
3IDP 1.09
4KSP 1.73
KIT 3G0E 0.71
Since the ligand binding conformation appears to be well reproduced by the proposed
docking protocol, we aimed to quantify the extent to which predicted binding affinity
changes between wildtype and variants correspond to experimentally determined changes.
We calculated the Spearman rank correlation ρ between Glide XP docking scores and
experimentally measured changes in the dissociation constant between wild-type and mutant
protein72 (Table 6.5). Given previous reports14,324,442, we did not expect to see good
correlations between Glide scores and experimental binding affinity data. This expectation
was met, with overall 15 out of 20 comparisons yielding Spearman correlation coefficients
close to random (-0.3 < ρ < 0.3).
Based on reports that this problem can be alleviated using a rescoring step14,132,327, we
tried to improve the quantitative correlation between predicted and experimental binding
affinities using MM-GBSA. This approach approximates binding free energies (∆G) and
thus predicted changes in ∆G between wild-type and mutant should correlate positively
with experimentally determined differences in the dissociation constant Kd. While the
correlation between predicted ∆∆G and experimental ∆Kd indeed increased after MM-
GBSA rescoring, these results remain statistically non-significant (Table 6.6).
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Table 6.5: Correlation of the changes in the docking scores to experimentally de-
termined changes in binding affinities from by Davis et al.72 between wild type and
variants
Protein Mutation Ligands with data active inactive
Spearman ρ p-Value Spearman ρ p-Value
EGFR T790M 27 -0.217 0.278 -0.335 0.087
L861Q 29 -0.165 0.394 0.000 0.999
G719C 27 -0.040 0.844 -0.046 0.821
G719S 27 -0.047 0.817 0.323 0.100
L858R 29 0.118 0.541 -0.224 0.244
KIT D816V 39 0.361 0.024 0.242 0.138
L576P 41 0.095 0.553 0.049 0.761
A829P 38 0.340 0.037 0.122 0.465
D816H 36 0.126 0.463 0.140 0.416
BRAF V600E 19 0.374 0.115 -0.200 0.412
BRAF intermediate: Spearman ρ=0.104, p=0.673.
Table 6.6: Correlation of MM-GBSA-predicted to experimentally determined
changes72 in binding affinity between wild type and variants
Protein Mutation Ligands with data active inactive
Spearman ρ p-Value Spearman ρ p-Value
EGFR T790M 27 -0.342 0.080 -0.495 0.009
L861Q 29 0.254 0.184 0.060 0.759
G719C 27 0.292 0.139 0.070 0.728
G719S 27 0.031 0.876 0.423 0.028
L858R 29 0.024 0.901 -0.098 0.613
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Figure 6.2: Spearman rank correlation between experimental72 and MM-GBSA
predicted binding affinities in active and inactive EGFR conformations. With the
success of kinase inhibitors in cancer therapy, multiple types of inhibitor classes have
emerged that mainly act as ATP mimetics inhibiting the active (type I, blue) or
inactive (type II, red) binding site299. Inhibitors with unspecified type can be of
either type and are colored green.
The correlation coefficients presented above could be influenced by individual outliers
due to multiple types of kinase inhibitors in the screening library. We thus also calculated
the correlation individually for all five mutations in EGFR for the inactive and active
conformation: Correlation coefficients for the presented data set varied by inhibitor, but
no clear trend was discernible for individual kinase inhibitor types (Figure 6.2).
6.3.2 Identification of Actionable Variants in Patients
Reporting outline
Automatic patient-specific reports could help support medical professionals in their therapy
decision process (Figure 6.3). Cancer, for example, is a multi-faceted disease for which it is
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now increasingly accepted that classification and treatment decisions should not be made
just based on the site of disease, but also its genetic profile49. Here, targeted therapies
developed and approved for certain genetic variants have been shown to be also effective
in other cancer types if the patients tumor also carried that variant. Vemurafenib, a
BRAF V600E inhibitor, for example, also showed clinical activity in other cancers beyond
its primary indication, melanoma174. To this end, we supply researchers and physicians
with a structured presentation, summarizing genes affected by non-functional variants,
including direct drug targets and indirect drug targets, utilizing the evidence found from
cross-referencing several public repositories.
Consultation
Sequence
tumor and 
germline
genomes
Tumor
1. Annotate variants
by eﬀect, gene &
deleteriousness
3. Find variants
with known eﬀect
on drug eﬃcacy
4. Find variants
in drug target
genes
Possible eﬀect 
on treatment
Established eﬀect
on treatment
TumorGermline
Call variants
5. Aggregate
results in a
report
Advise therapy
2. Identify 
mutated genes 
and pathways
PharmGKB
IUPHAR
HGNC
myDrug
DrugBank
Patient
presents
with
symptoms
Figure 6.3: Patient-specific reporting of genetic disease profile and actionable vari-
ants. In the case of cancer, the patient’s tumor and germline genome are sequenced
upon diagnosis to identify genetic variants that may affect treatment decisions or
treatment success. The variants are automatically annotated and compiled as a web
report that can be used by physicians or expert consultants to advise next therapy
steps.
To facilitate reporting on clinically interesting variants found in a patient, we developed
a webserver that returns information about drug targets, drugs and their primary indication
based on either a list of genes or variants (see Methods). Using this server it is possible to
create a report of variants found in a patient and further download a structured view of
this data (Figure 6.4).
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A
B
myDrug webserver query page
myDrug webserver result page
Figure 6.4: Clinical reporting using the midrug.org web server. A user can provide
variants as a list or a vcf. The variants are then annotated with their genetic impact,
affected genes and related drug information.
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Case study: Actionable variants in patients with HCC
The added benefit of a personalized reporting of actionable variants in cancer patients
can be illustrated on a case study: evaluating the reporting platform on 197 patients with
HCC. Using the annotation pipeline, we identified actionable variants for each patient. Of
all patients, 194 patients carried at least one non-functional variant in an oncogene or
tumor-suppressor gene. Furthermore, 35 carried some variant in one of the genes targeted
by the standard of care therapy, sorafenib. For 15 of these patients, the variants were
predicted to be non-functional, possibly resulting in the loss of said target in the tumor.
However, only two of the patients carried a variant with documented pharmacogenomic
effects in a sorafenib target in the external cancer database CiVIC133.
In addition to the patients with variants in any of the sorafenib targets, an additional 58
patients had non-functional variants in the canonical transcript of another gene targeted by
an approved or experimental antineoplastic agent and 22 patients presented with a variant
that was associated with altered response to cancer treatment in CiVIC. In 13 of these
cases, the variant in the target has documented effects.
6.4 Discussion
In this chapter, we developed a protocol to model protein mutation effects on ligand binding
affinity and tested it on clinically relevant protein kinases. We further developed a web
server to assess genetic variation in respect to its potential clinical effect and explore
alternative treatment options in a patient.
Limitations of Molecular Modeling Protocol
The protocol was capable of reproducing co-crystallized binding poses and, if MD simu-
lations are carried out for 100 ns, also modeled the transition between different protein
conformations, but several issues remain: even though 20 ns was shown to distinguish active
and inactive designs of cathepsin K variants208, it appears too short to reach equilibrium in
the studied protein kinases. With increasing computational capacity available through GPU
clusters and cloud computing, longer MD simulation of mutated protein-ligand complexes
for a duration required to achieve equilibrium state40 will increasingly become feasible.
We expected low correlation between Glide docking scores and experimentally deter-
mined binding energy because standard scoring functions have only limited estimates in
the gain and loss functions upon binding, omit thermodynamics and build on other sim-
plifications in the empirical function132,377. Nevertheless, we anticipated improvements
upon rescoring using MM-GBSA131,327 which were not met. In part this may be explained
by positive and negative correlations cancelling out due to inhibitors targeting the active
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or inactive conformation. In this case, type I inhibitors would correlate with the active
conformation while type II inhibitors correlate with the inactive conformation after MM-
GBSA rescoring. Unfortunately, such an effect could not be observed in the data for the
five EGFR variants (Figure 6.2).
The failure to reproduce experimentally determined changes in ligand binding affinity
due to genetic variants in the receptor in a consistent manner may be caused by multiple
reasons: 1) structure snapshots obtained from the MD trajectory do not properly represent
the protein after mutation, 2) docking does not capture the correct ligand pose, 3) binding
affinities estimated by MM-GBSA are not accurate. Additionally, due to the mathematical
relationship between binding affinities and binding constants, methods estimating binding
affinity need to be extremely accurate to not overestimate changes in binding constants363.
Given that MM methods lack terms describing charge transfer, many-body effects, and
polarization among others, they often do not offer that level of accuracy363. It remains to
be seen if quantum-mechanical approaches for rescoring could alleviate theses issues363.
Challenges with Protein Kinases as Evaluation Data Set
Kinase pharmacology further complicates structure-based prediction of variant effects. For
instance, the ATP-binding site which serves as primary binding site for type I and II
inhibitors is well conserved and common to many kinases, but the secondary binding site
and inactive state binding pockets can vary by kinase299. It is thus difficult to develop
highly specific compounds for the primary binding site and secondary pockets used for
the development of selective inhibitors299. Nevertheless, many kinases do not properly
adopt the DFG-out conformation143 hampering the computational exploration of that
conformational state. Such structural characteristics may also affect docking accuracy
when not allowing for additional flexibility during the placement steps.
Secondary variants in the so-called gatekeeper residue (T529 in BRAF ) can evolve
during treatment467. Such mutations confer drug resistance by sterically hindering the
placement of the inhibitor in the binding pocket or by increasing affinity for the primary
ligand ATP (e.g., the T790M mutation in EGFR 472)421. To observe such effects one would
need to model allosteric effects and also include ATP in the screening libary. Given the
protocol’s overall low performance, we decided against implementing these two extensions
in the current study.
Overall, the proposed variant effect prediction method succeeded in reproducing the
correct binding pose of kinase ligands, but struggled with accurately predicting the relative
effects of mutations on binding affinity. This problem was in part aggravated by the
specific properties of kinases as target family. Given this observation, our approach should
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be further tested in additional target families and with target-specific (QM-based or fitted)
rescoring methods before abandoning it in lieu of more accurate scoring functions.
Limitations of the myDrug reporting service
Despite modeling effects of new mutations, a patient can benefit from reporting existing
mutations found in their disease as well as matching potential drugs to the affected genes425.
We evaluated how many patients could benefit from automated reporting of genetic char-
acteristics in a data set of 197 HCC patients. While only one in ten patients were directly
affected with a variant altering drug-binding in the tumor, another two in ten patients had
non-functional variants of unknown pharmacogenomic effect in the primary target genes of
the standard of care therapy, sorafenib. Furthermore, an additional third of the patients
carried variants in genes modulated by antineoplastic agents aside from the standard of
care therapy. Thus for more than half of all patients clues for treatment decisions could
be found in their tumor genome. This insight is in line with real-world experiences with
genotype-directed therapy studies that reported between 40%425 and up to 95%20,151,380
of the patients carrying actionable variants. However, these real-world use cases have also
shown that, in addition to the identifying relevant variants for (off-)label or experimental
treatment options, specific requirements need to be met for a cancer patient to benefit from
genotype-based reporting: testing needs to be performed early on in the disease to be of
clinical utility151,425 and/or to match patients to suitable clinical trials164,185,424.
Given that most variants in drug targets are not yet pharmacologically characterized
(see Chapter 4), no readily available approach can be used directly in a clinical context, but
interactive tools164,372 such as the one presented here could be of value to inform expert
consortia and molecular tumor boards, by facilitating informed discussion on a patient’s
treatment plan155,164,424.
Conclusions
There exists a gap between known annotation of variant effects and those variants observed
in patients. The pipeline introduced in this chapter aimed at closing this gap, but similar
to other protocols132, the accurate prediction of binding affinities remained beyond the
capabilities of the docking protocol376. MM-GBSA rescoring sometimes overcomes short-
comings of conventional scoring functions131,327, but did not suffice here. It thus remains
to be seen if different methods, such as a protein-specific model fitted to experimental
binding affinities or the inclusion of quantum mechanics could result in an improvement.
The evaluation of such approaches in a recent review remained inconclusive363.
Our case study of genetic variants found in 197 HCC patients shows that it can be helpful
to report actionable variants. But the unknown pharmacological impact of most variants
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in drug-related genes observed in the patients underscores the importance of modeling
variant effects after overcoming the shortcomings of current scoring and rescoring methods.
Until then, an automated annotation workflow collating knowledge from databases such as
myDrug and ongoing clinical trials, can help guide physician’s therapy decisions based on a
patient’s genotype. Here, the advantage of our approach is that it is not specifically geared
towards cancer and can be used in other clinical settings.
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Conclusion and Outlook
In this thesis, we presented contributions to several challenges in the personalized medicine
value chain, ranging from early research on drug targets to point-of-care clinical reporting.
By utilizing available gene sequences across all kingdoms of life we showed that protein-
protein interactions can be modeled and insights into their binding interfaces gained from
sequence information alone — these insights can support the drug discovery process in
its target identification stage. Connected with additional data about drug and disease
mechanism, the networks formed by all PPIs in a cell can further guide the systematic
repositioning of drug molecules to additional disease areas, either during the research phase
or – hypothetically – also at the point of care if drug resistance to the original treatment
is to be expected.
We further demonstrated that the vast majority of genetic variants observed in drug-
related genes is still uncharacterized and proposed a method to alleviate this problem
using molecular modeling protocols. However, while successful in reproducing known
ligand binding poses in mutated proteins, the scoring function could not correctly rank the
changes in relative binding affinity of a variant compared to the wild type. Here, future
development will be needed to improve the approach. Nevertheless, the automatic reporting
of existing knowledge about genetic variants observed in a patient can already be beneficial
in the clinical practice.
With more drugs being approved specifically for genetic variants, such as pembrolizumab
for all mismatch repair deficient tumors regardless of site of disease, physicians will start to
rely on the support of algorithms in their decision processes. The methods presented in this
thesis are one step towards bringing such methods to the clinic — also for diseases that are
not cancer. The true power of the presented approaches lies, however, in connecting them
with other progress in the field to further improve prediction performance. We could already
show that ECs can be used to predict protein fitness of gene variants161 and the effect
of variants on protein conformation383. Predicting the consequences of genetic variants
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on drug binding affinity directly from sequencing data could be valuable as an orthogonal
approach to the presented molecular modeling protocol and help overcome some of the
weaknesses observed in traditional scoring methods. By filtering the myDrug network to
variants and gene expression profiles observed in specific patients, we could also tailor drug
repurposing predictions to individual patients.
Most of the obstacles in solving each of the presented challenges stem from an incomplete
understanding of physiological processes that could possibly be alleviated by the availability
of more data. It is, for example, estimated that a complete map of human interactome is at
least a decade away279 and network-based prediction performance will likely increase with a
more complete interaction map. Furthermore, a limited number of orthogonal data sources
describing different phenotypic and genotypic features can currently be integrated into
cellular network models471, limiting our understanding of the inter-dependencies between
genome and phenome.
Combining expert knowledge with external information can already help physicians
today find the suitable therapy for their patients202 or assign them to clinical trials match-
ing their disease (a concept commercialized by companies like FoundationMedicine). By
providing earlier and more detailed diagnoses, avoiding obvious pharmacological risks and
providing treatment suggestions, personalized medicine algorithms can improve health care
for the patient434 even with the remaining gaps in our understanding of physiological pro-
cesses202. Nevertheless, these gaps have to be accounted for and be openly addressed in the
practice. Pre-emptive pharmacogenetic testing with immediate consequences to therapy
decisions should, for example, be restricted to validated variants231, while comprehensive
strategies could be used to generate research leads in more complex cases.
Apart from gaps in our understanding of human physiology, imminent hurdles of the
healthcare system need to be overcome for the full adoption of personalized medicine in
the clinic: this includes financial aspects such as the reimbursement of genetic testing by
insurance companies or other payers434, but even more the availability of suitable and
affordable treatment options addressing patient-specific needs. Especially when solving the
latter challenge, genetic tests together with personalized treatments will have a tangible
positive impact on patient outcome345.
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Appendix A
Abbreviations
Amino acids in a general context are not abbreviated. If we refer to a particular amino
acid within a peptide or protein, standard abbreviations in 3-letter code are used with
the residue position as suffix. Thus, an arbitrary serine at position 256 is abbreviated by
Ser256. Within amino acid sequences, standard abbreviations in 1-letter code are used.
2D Two-dimensional
3D Three-dimensional
A
AC Allele count
ADME(T) Absorption, distribution, metabolism, excretion (, toxicity)
AF Allele frequency
AN Allele number
AP-MS Affinity-purification combined with mass spectrometry
APC Average Product Correction
ATP Adenosine triphosphate
B
BALL Biochemical algorithms library
BFS Breath-first search
C
CADD Computer-aided drug design
CAP Cumulative Allele Probability
CDS Coding sequence
Cmap Connectivity map
CNV Copy number variant
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A. Abbreviations
cryo-EM Cryo-electron microscopy
D
DCA Direct coupling analysis
DFG Asp-Phe-Gly motif in kinases
DNA Deoxyribonucleic acid
DO Disease Ontology
DRP Drug risk probability
E
EC Evolutionary coupling
EFO Experimental Factor Ontology
F
FDA U.S. Food and Drug Administration
FN Frobenius norm
FP False positive
G
GB Generalized Born
GBA Guilt-by-association
GEP Gene expression profile
GO Gene Ontology
GoF Gain-of-function
GWAS Genome-wide association studies
H
HCC Hepatocellular carcinoma
HGNC HUGO Gene Nomenclature
HMM Hidden Markov Model
I
i.i.d. Independently and identically distributed
ICD International Classification of Disease
indel Insertion-deletion
IP-MS Immunoprecipitation combined with mass spectrometry
L
LoF Loss-of-function
M
MD Molecular dynamics
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MeSH Medical Subject Headings
MI Mutual information
ML Machine learning
MM Molecular mechanics
MoA Mechanism of action
MS Mass spectrometry
MSA Multiple sequence alignment
N
NMFI Naive mean field inversion
NMR Nuclear magnetic resonance
NNT Number needed to treat
NPT Fixed particle number, temperature, and pressure
O
OMIM Online Mendelian Inheritance in Men
OPLS Optimized Potential for Liquid Simulations
P
PB Poisson-Boltzmann
PCA Principal component analysis
PD Pharmacodynamics
PDB Protein Data Bank
PGx Pharmacogenetics/pharmacogenomics
PharmGKB The Pharmacogenomics Knowledgebase
PK Pharmacokinetics
PLM Pseudo-likelihood maximization
PPI Protein-protein interaction
PPV Positive predictive value
Q
QC Quality control
R
RD Risk difference
RF Random Forest
RL Receptor-ligand complex
RMSD Root-mean-square deviation
RNA Ribonucleic acid
RR Risk ratio
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A. Abbreviations
S
SA Surface area
SASA Solvent-accessible surface area
SE Side effect
SMILES Simplified Molecular Input Line Entry System
SNV Single nucleotide variant
T
TCGA The Cancer Genome Atlas
TMH Transmembrane helix
TP True positive
Q
UMLS Unified Medical Language System
V
VCF variant call file
VEP Variant Effect Predictor
W
WES Whole exome sequencing
WGS Whole genome sequencing
Y
Y2H Yeast two-hybrid
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Figure D.1: Entety-Relationshio Diagram of myDrugmySQL database schema. Meta
data about the node types are stored in respective tables, information about the
relations between these nodes are stored in dedicated edge tables. Individual tables
exist for disease information from OMIM, ICD9 and Disease Ontology, but for legibility
reasons only DO tables are shown.
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F17/F18
D - D - P - [P] - [P] - M
F2/F15/F16
D - P - [P] - [P] - M
F9/19
D - R - R - P - [P] - M
F4/F13/F21/F22
D - V - P - [P] - [P] - [V] - M
Figure D.2: Correlation matrix of feature instances used in myDrug Random Forest
classifiers. See 5.3 for full list of features. Clusters of highly correlated features mainly
correspond to different instances of similar features, build from different sources and
interaction sub-types.
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Figure D.3: Conformational space covered by MD simulation trajectories for several
BRAF structures when simulated for (A) 20 ns and (B) 100 ns. Each frame is
represented as a point in 2D, projected on the first and second principal component
(PC) of dihedral space, lines connect subsequent frames in the trajectory. Starting
conformations were active (DFG-in/αC-in) for 3TV6 and 3C4C, intermediate (DFG-
in/αC-out) for 4E26 and 3PRF, and inactive (DFG-out/αC-out) for 3IDP.
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Table E.1: Existing studies of genetic variants in pharmacogenes and their effect on
different human populations.
Study Genes PGx Type Samples Origin Findings
Nelson et al.,
2012302
202 Targets 14,002 EUR,
AFR,
SAS
Abundance of rare variants (MAF
< 0.5%) across all populations, low
level of shared rare variants between
populations
Mizzi et al.,
2014287
231 ADMET 482 EUR Majority of variants in PGx genes
are rare or singletons, many would
not have been found with the most
comprehensive existing PGx geno-
typing platform
Fujikura et al.,
2015114
53 CYP450 6503 EUR,
AFR,
others
CYP genes have different genetic
variability, most variants are very
rare (MAF < 0.1%), and profiles of
genetic variants differ between in-
dividuals of European and African
origin
Kozyra et al.,
2016218
146 ADMET 6503 EUR,
AFR
Vast majority of variants is rare
(MAF < 1%) and population spe-
cific, some genes show large differ-
ences in their variation rate between
European-American and African-
American patients
Wright et al.,
2016459
120 ADMET 2504 AFR,
AMR,
EAS,
SAS,
EUR
Vast majority of variants is rare
(MAF < 0.5%); some of most con-
served pharmacogenes are those
with somatic mutations in cancer,
highly differentiated variants ob-
served between African cohort in re-
lation others, 57% of PGx genes had
high-confidence LoF variants, 97%
of individuals carried at least one
well-established PGx variant
Bush et al.,
201644
82 ADMET 5639 EUR
(85%)
96% had at least one actionable
PGx variant, between 4% (flutica-
sone) and 34.6% (simvastatin) of in-
dividuals are estimated to have a
low-frequency missense variant that
may affect its action (from Phar-
mGKB annotation)
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Table E.2: Data sources used for construction of myDrug objects.
Entity Type Source Origin Description Nodes
Compound DrugBank232 curated Most comprehensive public re-
source about drugs, their struc-
tures and other properties
8,221
Gene HGNC curated Global consortium for gene
symbols
40,967
Gene Uniprot partially cu-
rated
Information about the protein
products of genes
19,855
Domain Pfam partially cu-
rated
Protein domain data created
from hidden markov models
16,306
Disease ICD9 curated International billing codes 13,296
Disease OMIM curated Compendium of heritable dis-
eases
6,933
Disease Disease Ontol-
ogy
curated Ontology that combines differ-
ent sources, ranging fromMeSH
terms to OMIM
9,304
Variant ExAC236 automatic Gene variants found in 60,000
exomes
Variant dbSNP community con-
tributed
Database with all SNPs found
in human population so far
(subset only)
45,746
Pathway KEGG curated Compendium of functional
pathways in cells
302
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Table E.3: Data sources used for construction of relations between myDrug objects.
Relation Type Source Origin Description Links
Compound-Gene DrugBank curated ( publi-
cations)
annotates targets and ADMET
interactions
17,992
Compound-Gene IUPHAR curated (publi-
cations)
drug - target links from litera-
ture, also contains activity data
1,703
Compound-Domain PDB automatic binding sites extracted and
then region mapped to PFAM
domain
41,681
Compound-Disease MEDI text mining disease-drug relations obtained
from mining medical data
sources
4,195
Compound-Disease pharmacotherapy
DB
curated discriminates between etiology-
centered and symptom-treating
indications
1,385
Compound-Side Effect SIDER automatic side effect data from drug labels 35,770
Compound-Compound automatic Tanimoto similarity on chemi-
cal fingerprints
24,967,714
Disease-Gene OMIM curated morbidmap contains genetic ba-
sis for hereditary diseases
1,129
Disease-Gene CTD curated relationships between chemi-
cals, genes and human health
16,031
Disease-Gene Orphanet curated knowledge base dedicated to
rare diseases and their genetic
basis
32,392
Disease-Gene TTD curated (text-
books, publica-
tions)
therapeutics centered associa-
tion of diseases to genes
6,047
Disease-Disease Disease Ontol-
ogy
curated ontology relationships for direct
connections in the underlying
ontology
8,128
Gene-Domain Pfam curated protein family information
based on Hidden Markov
Models
41,681
Gene-Gene KEGG curated gene interactions in pathways
(directed)
98,000
Gene-Gene Pathway Com-
mons
automatic gene interactions from multiple
databases (some directed)
582,873
Gene-Gene STRING automatic gene interactions from different
levels of evidence (weighted &
some directed)
553,069
Gene-Gene SIMAP2 automatic Smith-Waterman alignments of
all proteins to all others
1,795,884
Pathway-Gene KEGG curated each gene listed in pathway 25,445
Pathway-Pathway KEGG curated pathway crossreferences in
pathway map
1,807
Variant-Gene myvariant.info atomatic collection of variant informa-
tion from several annotation
sources
109,081
Variant-Disease GWAS Catalog community con-
tributed
collects pubslied GWAS data
and the studied phenotypes
2,199
Variant-Disease ClinVar community con-
tributed
collects relationships among
medically important variants
and phenotypes
58,582
Variant-Compound PharmGKB curated haplotypes and variants rele-
vant for PGx
18,880
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